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ABSTRACT 
Patients who are diagnosed with pancreatic ductal adenocarcinoma (PDAC) face a 
dismal prognosis. One reason for this is the dense stroma that is a characteristic of 
PDAC, which may preclude drugs from accessing the tumour cells. Pancreatic 
stellate cells (PSCs) are the key cell responsible for desmoplasia in PDAC and it is 
becoming clear that they are a promising target for therapy. Over-expression of 
FGFs and their receptors is a feature of PDAC and correlates with poor prognosis, 
but whether their expression impacts on PSCs is unclear. The aim of my research 
was 1) to understand the role and function of nuclear FGFR1 and FGF using 2D 
based assays; 2) to use a physiologically relevant 3D organotypic model to study 
the effects of blocking nuclear FGFR1 and FGF2 in PSCs; 3) to assess whether this 
target could provide a novel therapeutic strategy in PDAC.  
 
At the invasive front of human pancreatic cancer, FGF2 and FGFR1 localised to the 
nucleus in activated PSCs but not cancer cells. Inhibiting FGFR1 and FGF2 in 
PSCs, using RNAi or chemical inhibition in vitro, resulted in significantly reduced cell 
proliferation, which was not seen in cancer cells. Cancer cells co-cultured on top of 
collagen/Matrigel gels together with PSCs showed marked invasion of both cancer 
cells and PSCs. However, FGFR inhibition blocked invasion of both PSCs and 
cancer cells. FGFR inhibition resulted in cytoplasmic localisation of FGFR1 and 
FGF2, in contrast to vehicle-treated conditions where PSCs with nuclear FGFR1 
and FGF2 led cancer cells to invade the underlying extra-cellular matrix. Strikingly, 
abrogation of nuclear FGFR1 and FGF2 in PSCs abolished cancer cell invasion. 
These findings suggest a novel therapeutic approach, where preventing nuclear 
FGF/FGFR mediated proliferation and invasion in PSCs leads to disruption of the 
tumour microenvironment, preventing pancreatic cancer cell invasion. Thus, for 
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patients with PDAC which is resistant to conventional chemotherapy, targeting the 
stroma by blocking nuclear FGFR1 and FGF2 in PSCs identifies a novel therapeutic 
approach.  
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 CHAPTER I  INTRODUCTION.  
1.1 Pancreatic cancer  
1.1.1 Epidemiology  
Pancreatic cancer has one of the highest mortality rates among malignancies, and is 
the fifth most common cause of cancer death in the western world1, 2. With a 5-year 
survival rate of 3% and median survival of less than six months3, 4, diagnosis of 
pancreatic ductal adenocarcinoma (PDAC) carries one of the bleakest prognoses in 
all of medicine. Clearly, there is an unmet need for new therapies for this disease. 
Surgery (pancreaticoduodenectomy) offers the only hope of a possible cure for 
patients; however, even of those 10% of patients eligible for curative resection, only 
21% will survive beyond five years5.. Furthermore, while treatments may be 
efficacious in other cancers, PDAC is resistant to cytotoxic agents and radiotherapy, 
which further impacts on the poor prognosis of these patients.  
 
1.1.2 Environmental risk factors 
Epidemiological and genetic studies have shown that pancreatic cancer is a disease 
of old age2, with rare incidence before age 40 and risk of developing the disease 
increasing 40-fold by 80 years6, 7. Smoking presents a significant risk factor for 
development of pancreatic cancer, doubling the risk of developing the disease8. 
Obesity, diabetes mellitus, chronic pancreatitis and heavy alcohol drinking (>six 
alcoholic drinks a day) also pose a possible risk for developing PDAC9-12. 
 
1.1.3 Hereditary /genetic risk factors 
One of the risk factors for developing pancreatic cancer is a strong familial history of 
the disease. Individuals with a first degree relative with pancreatic cancer have a 2.3 
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fold increase of developing the disease . This risk increases as the number of first 
degree relatives with the disease also increases, suggesting that inheritance of a 
rare autosomal dominant allele may be responsible for the development of this 
disease in a familial setting13. It has been observed that patients may have chronic 
pancreatitis for at least 20 years before they develop PDAC. These patients have a 
severe disease and a high rate of complications. The risk of developing PDAC is 
even higher with hereditary pancreatitis, with an estimated 70-fold increase in risk14. 
Although most of the genetic reasons for clustering of PDAC in families remain 
unclear, several genes have been identified that increase the risk of PDAC; 
summarised in Table 1. 1. 
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Table 1. 1 Genetic risk factors of PDAC  
BRCA1, breast cancer type 1 susceptibility protein; BRCA2 breast cancer type 2 
susceptibility protein; PALB2, Partner and localizer of BRCA2; STK11, Serine/threonine 
kinase 11; PRSS1, protease, serine, 1 (trypsin 1); SPINK1, serine protease inhibitor Kazal-
type 1; ATM, Ataxia telangiectasia mutated; CDKN2A, cyclin-dependent kinase inhibitor 2A; 
MLH1, MutL homologue 1; MSH2, MutS protein homologue 2; MSH6, MutS homolog 6; 
PMS2, postmeiotic segregation increased 2. 
 
Genetic syndrome Gene (s) Risk of 
PDAC 
(fold) 
Reference 
Hereditary breast and ovarian 
cancer syndrome 
BRCA1 No effect up 
to 2.26 
15 16 
 BRCA2 3.5  17 
 PALB2 Increased  18 
Peutz-Jeghers syndrome STK11 132  19 
Hereditary pancreatitis PRSS1/SPINK1 53 20 
Ataxia telangiectasia ATM Increased  21 
Familial atypical multiple mole 
melanoma 
CDKN2A 38  22 
Hereditary non-polyposis 
colorectal cancer syndrome 
MLH1, MSH2, 
MSH6, PMS2 
Increased 20 
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1.1.4 Current treatment options 
The aetiology of PDAC is multifactorial. The predominant patient population is 
elderly and shows poor health at time of diagnosis. Currently there is no simple 
reliable detection method for PDAC and the earliest symptoms are non-specific, 
which means patients present very late with their disease. Currently, complete 
resection of the pancreatic tumour offers the only hope for long-term cure of PDAC. 
However, only a minority of patients qualify for surgery23. This is due to the fact that, 
at diagnosis, tumours have either involved the major abdominal blood vessels or 
have metastasised to distant organs24. However, even following surgery, long-term 
survival is poor and tumours eventually return25. Due to the high incidence of local 
recurrence, targeted radiotherapy has been suggested; however, long-term benefits 
of adjuvant radiotherapy have proven inconclusive26. PDAC tumours are hypoxic, 
which may explain the limited impact of radiotherapy as a treatment option, since 
radiation therapy relies on the presence of oxygen27.  
 
Currently, the chemotherapeutic agent Gemcitabine (alone) and the targeted small 
molecule EGFR tryrosine kinase inhibitor Erlotinib (Tarceva, Genentech, in 
combination with Gemcitabine) remain the only two agents approved for the 
treatment of PDAC, despite their modest benefits to patient survival24. Gemcitabine 
was approved after showing clinical benefit compared to 5-Fluorouracil (5-FU) in 
patients with advanced PDAC, prolonging survival from 4.4 months to 5.6 months28, 
despite a recent large randomised phase III trial (ESPAC 3) of folinic acid 
(leucovorin) and 5-FU versus Gemcitabine showed no survival benefit between the 
two treatments26. The survival benefit of adding Erlotinib to Gemcitabine was even 
smaller (5.9 to 6.2 months), albeit clinically significant29. 
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Recently, a four chemotherapeutic drug combination of 5-FU, leucovorin, oxaliplatin 
and irinotecan (FOLFIRINOX), was administered to patients with metastatic PDAC. 
This combination chemotherapy approach has shown an increase in median overall 
survival of 11.1 versus 6.8 months compared with Gemcitabine alone30. 
Unfortunately, given the high toxicity of this regimen, FOLFIRINOX is suitable only 
for patients with a good performance status. Secondly, a phase III trial (MPCAT trial) 
for advanced PDAC, in which the nano-albumin formation of paclitaxel, nab-
paclitaxel (Abraxane), administered in combination with Gemcitabine, was 
demonstrably superior to Gemcitabine alone (median survival 8.5 months vs. 6.7 
months, respectively)31, with a more favourable toxicity profile than FOLFIRINOX.  
 
One of the possible reasons that most potential and targeted therapies fail in 
improving the prognosis of patients with PDAC may be in part explained by the 
diverse influences exerted by the microenvironment on cancer cells, which confound 
our ability to study the disease in vitro. Revealing the underlying molecular 
mechanisms of the tumour cell-microenvironment cross-talk may help to shed light 
on the huge discrepancy between relative success and effectiveness of therapies in 
preclinical assay (predominately 2D cell based assays and xenograft mouse 
models) and failure in human PDAC. Thus, the focus of my study will be to 
understand PDAC in the context of its tumour microenvironment. 
 
1.2 Pathophysiology of PDAC  
1.2.1 Development of the exocrine pancreas  
The pancreas is an endoderm-derived organ and regulates two important 
physiological functions, digestion of food and glucose (and fat and amino acid) 
metabolism (Figure 1. 1). In humans, early in embryogenesis, the pancreas 
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develops from two spatially distinct primordial buds of endoderm (dorsal and ventral) 
derived foregut tube, which grow, branch, rotate and fuse in response to signals 
produced by mesodermal tissues including the notochord, aorta and the cardiac 
mesoderm32.  
  
Golosow and Grostein first showed that growth and morphogenesis of the immature 
pancreas depended on interactions between epithelial and mesenchymal tissues33. 
The molecular basis of these interactions has since been established and, in 
particular, fibroblast growth factor (FGF) signalling from endothelial cells and 
mesenchymal cells surrounding the primitive pancreas has been shown to be crucial 
for pancreatic cell differentiation and maturation34-42. Furthermore, FGF signalling 
from the notochord early in embryogenesis is vital for the differentiation of the 
foregut endoderm towards a pancreatic fate by repressing the expression of sonic 
hedgehog (Shh) in the region of the endoderm that is destined to become the dorsal 
pancreatic bud39, 43. This inhibition of Shh signalling induces the expression of 
pancreatic genes including the homeodomain transcription factor PDX143-45. PDX1 is 
a key determinant of both exocrine and endocrine pancreatic development and, in 
mice that lack PDX1, pancreas development is arrested at an early stage46. 
 
In addition, a number of other important embryonic signalling pathways are involved 
at various stages of pancreatic development, including FGF, Notch, Wnt, Retinoid 
and TGFβ signalling, which regulate cell differentiation and maturation in a complex 
but carefully orchestrated process47-54. This information from developmental biology 
is vital in understanding PDAC pathophysiology, as a number of embryonic 
signalling cascades are hijacked by the cancer cells for their unrestrained growth. 
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Figure 1. 1  The developing pancreas. 
(A) The endodermal development of a 6 week human embryo. The pancreas is represented 
by two buds that will eventually fuse (shown in red box). (B) Pancreatic development in 
humans at 30 days, the ventral pancreas bud is close to the liver primordium. (C) By 35 days 
it begins to migrate (D) and come into contact with the dorsal pancreatic bud. 
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1.2.2 Anatomy of the mature pancreas 
The mature pancreas composes morphologically and functionally distinct endocrine 
and exocrine components. The exocrine portion makes up 95%-99% of the 
pancreas and consists of acinar and duct cells, whichsecrete enzymes into the 
intestine and promote digestion and absorption of carbohydrates, fats, and proteins 
ducts, forming a dendriform structure that eventually gives rise to the main 
pancreatic duct (Figure 1. 2)55. The small ducts are lined with cuboidal epithelium, 
while columnar epithelium lines the larger ducts. Acinar cells are pyramidal in shape 
with basal nuclei, and numerous secretory (zymogen) granules containing the 
digestive enzymes (proteases, amylases, lipases and nucleases) in the form of 
inactive precursors. These precursor enzymes become activated when they enter 
the duodenum. At the junction of the acini and ducts are cuboidal centroacinar cells, 
which are thought to secrete non-enzymatic components (such as bicarbonate). The 
endocrine cells are grouped in the islets of Langerhans, discrete cellular aggregates 
scattered in between the exocrine tissue. The islets consist of insulin producing β 
cells, glucagon producing α cells, somatastatin producing δ cells and pancreatic 
polypeptide producing PP cells56. Understanding the development, anatomy, 
histology and physiology of the normal pancreas helps us understand the 
interactions and cells of origin for PDAC and other pancreatic tumours. 
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Figure 1. 2 The exocrine pancreas 
The pancreatic ductal cell is thought to be the progenitor cell for PDAC; however, studies 
have shown that other cell types may offer an alternative route to PDAC. Mouse models in 
which K-Ras is activated specifically in some adult cell types have shown that both acini and 
insulin positive cells can give rise to PanINs and in some case PDAC. In adult pancreas, 
exocrine and endocrine components are separate secretary functional units. The exocrine 
pancreas is composed of acinar units connected to a series of increasingly large ducts that 
drain into the duodenum. The acinar cell is the major component of the pancreas, making up 
90% of its mass. The acinar cells are pyramidal in shape and secrete digestive enzymes into 
the ducts. In contrast, ductal epithelial cells make up only 10% of the pancreatic mass. 
These cells are cuboidal in shape and secrete bicarbonate and mucus into the secretary 
digestive enzyme mixture produced by the acinar cells. In the normal pancreas, quiescent 
PSCs are present in the periacinar space. These cells have long cytoplasmic processes that 
encircle the base of the acinus. Centroacinar cells have also been considered as possible 
multi-lineage pancreatic progenitors
57
 
58 
. 
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1.2.3 Classification of pancreatic neoplasms 
Most cancers of the pancreas are ductal adenocarcinomas and the terms PDAC and 
PDAC are used synonymously in error59. PDAC is characterised by an intense 
desmoplastic reaction that predominately makes up the cancer mass, with very few 
neoplastic cells60 (Figure 1. 3). Pancreatic cancers are highly infiltrative and vascular 
and perineural invasion is common, as are metastases to the regional lymph nodes 
and distant organs. Indeed, most patients present clinically with distant metastasis, 
most commonly to the liver and peritoneal cavity60.  
 
Pancreatic ductal adenocarcinoma is thought, most commonly, to develop through a 
stepwise accumulation of genetic and epigenetic changes within the pancreatic 
ductal epithelial cell, despite this representing less than 10% of the pancreatic mass. 
Broadly, the pre-neoplastic changes are morphologically defined as Pancreatic 
Intraepithelial Neoplasia (PanIN)61, representing grades of metaplasia and 
dysplasia. The lowest grade PanIN lesions are metaplastic flat (1A) or papillary (1B) 
lesions with absence of nuclear atypia and retained nuclear polarity. PanIN 2 
dysplastic lesions show evidence of nuclear atypia and infrequent mitosis, while 
PanIN 3 lesions have characteristics of carcinoma in-situ, demonstrating widespread 
loss of polarity, nuclear atypia and frequent mitosis (Figure 1. 4)62. 
 
1.2.4 Molecular genetics of PDAC. 
PDAC is a disease of somatic mutations, with a number of signature genetic 
alterations that define the disease, with a very few known germline mutations 
playing a role. Of these frequently observed somatic alterations, activating point 
mutations at codon 12 of the Kirsten Ras (K-RAS) gene are among the most 
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common genetic alterations63, although occasionally mutations are found in codons 
13 or 61. Mutations in K-RAS are found in nearly 100% of advanced pancreatic 
tumours and early PanIN lesions, suggesting that aberrant activation of this protein 
may be one of the earliest events in the malignant progression of PDAC63. In vitro 
abolition of K-RAS alone can arrest cancer cell growth64. Despite this, trials using 
pharmacological inhibitors that target K-RAS, by inhibiting post-translational 
modification, have shown no clinical efficacy65. K-RAS mutations are also found in 
patients with chronic pancreatitis who do not develop PDAC66 suggesting that K-
RAS mutations may be the initial diving force in PanIN development but, alone, are 
not sufficient to induce PDAC. Indeed, in vivo studies in which wild type K-RAS was 
overexpressed in mice showed this to be sufficient to induce chronic pancreatitis 
and cause the development of PanIN lesions. However, when combined with the 
heterozygous loss of p53 tumour suppressor gene the lesions progressed to 
PDAC.67 Inactivation of tumour suppressor genes p53, SMAD4 (DPC) and BRCA2 
are thought to occur later in pancreatic neoplastic progression68, 69. P53 serves as a 
DNA checkpoint regulator in response to mutations from reactive oxygen species 
and also telomere shortening, both of which are seen in pancreatic cancer. SMAD4 
is a part of the TGF  receptor signalling pathway, relaying signals from the 
cytoplasm to the nucleus, and loss of SMAD4 confers a growth advantage to cells.70 
BRCA2 is important for double strand break repair and, thus, important for genomic 
stability71. Loss of BRCA2 leads to a number of chromosomal aberrations in PDAC. 
Both P53 and SMAD4 are inactivated in over 50% of late stage PDAC, whereas 
BRCA2 is inactivated in 7-10% pancreatic carcinomas62. Finally, studies using a 
panel of microsatellite markers have shown that all high grade tumours exhibit loss 
of heterozygosity at more than one locus on chromosomes 3-6,8-11,13,16-18, 
underscoring the complex genetic composition of PDAC at this late stage72. Of note, 
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none of these have been effectively targeted due to a multitude of factors; one of 
which is the tumour-stroma cross-talk mediated by a number of signalling cascades. 
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Figure 1. 3 Histology of PDAC  
Haematoxylin and eosin (H&E) staining of PDAC (A) and its schematic representation (B), 
demonstrating the extensive desmoplastic stroma in PDAC. 
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Figure 1. 4 Stepwise development of PDAC 
PanINs seem to represent progressive stages of neoplastic growth that are precursors to 
PDAC. As the adenocarcinoma progresses from low grade PanIN 1A to high grade PanIN 3 
the tumour will acquire genetic mutations that seem to occur in a stepwise fashion. 
Increasing desmoplastic reaction accompanies the progression of low grade PanIN to 
PanIN3 tumour, a characteristic of PDAC. As well as histological and genetic alterations, 
PDACs frequently show over expression of a number of growth factors and cytokines. 
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1.2.4.1 Activation of developmental signalling cascades in PDAC 
Ultimately, cell differentiation and pancreas organogenesis is achieved by a subtle 
balance and well orchestrated pattern of gene expression and interaction of 
signalling pathways. Studies using genetically engineered mouse models have 
shown that many critical embryonic signal transduction pathways, quiescent in the 
adult pancreas, are re-activated during PDAC progression. Important pancreatic 
developmental signalling pathways such as Notch49, TGF 73, EGF74, Wnt75, 
Hedgehog76 and  FGF77, are all deregulated in pancreatic cancer. As the role of FGF 
signalling in PDAC is the focus of my studies, this signalling pathway will be 
discussed in detail in section Chapter IV.  
 
In vivo studies have shown that Shh signalling acts on the stromal (mesenchymal) 
compartment of PanINs and PDAC and can activate the characteristic desmoplastic 
reaction seen in PDAC78. Hh signalling occurs when the Hh ligands (Sonic 
Hedgehog, Indian Hedgehog or Desert Hedgehog in mammals) are secreted and 
bind to the Patched receptor (Ptch) on neighbouring cells. This ligand- receptor 
interaction results in Ptch inhibition and consequential release of the G protein 
coupled receptor Smoothened (Smo), leading to a cascade of events and the 
translocation of the Gli transcription factor to the nucleus79. As discussed earlier, 
suppression of Hh signalling is critical for normal pancreas development. However, 
in PDAC it appears sustained activation of this pathway enhances tumour growth, 
as shown in human tumour samples and confirmed in a genetically engineered 
‘KPC’ mouse model of PDAC76, 80. Upon treatment of mice, engineered to develop 
PDAC, with a small molecule inhibitor of Smo, the stromal architecture of their 
PDAC reorganised and the desmoplasia resolved, increasing tumour vascularity and 
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facilitating efficient delivery of the chemotherapeutic agent Gemcitabine. As a result, 
metastasis decreased and the overall survival of mice treated with the combination 
of Smo inhibitor plus Gemcitabine was significantly increased compared to control81. 
These studies suggest that targeting the stromal compartment of PDAC may 
improve delivery and efficacy of chemotherapy. In light of these results several 
clinical trials have been initiated to investigate the effects of treatment with Shh 
inhibitors in patients withPDAC. Unfortunately, disappointing Phase II clinical trial 
results, with the Smo inhibitor IPI-926 (Saridegib, Infinity Pharmaceuticals) have 
emphasised the need to fully understand this tumour micro-environment24.  
 
1.3 Pancreatic stroma  
The role of the microenvironment in tumour metastasis was first described in 1889 
by the English surgeon Stephen Paget as the so-called ‘seed and soil’ hypothesis. 
In this hypothesis, Paget described how metastasis was not a random event, but 
that certain tumour cells (‘seed’) have a specific affinity for a specific organ 
environment (‘soil’). Only when the ’seed’ and ‘soil’ were compatible, did the 
metastasis occur82. Over a century since this original hypothesis, it is now well 
appreciated that, in addition to its importance at distant metastases, the ‘soil’, or 
tumour microenvironment, at the primary tumour site also plays an important role in 
the development of the tumour.  
 
Indeed, many epithelial malignancies, including breast, prostate andPDACs, often 
exhibit a significant stromal reaction around the tumour cells83-86. The stroma not 
only functions as a mechanical barrier but also constitutes a dynamic compartment 
that is critically involved in the process of tumour formation, progression, invasion, 
and metastasis. In particular, PDAC shows the most prominent stromal reaction or 
‘desmoplasia’ (defined as proliferation of fibrotic tissue with an altered ECM which 
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contributes to tumour growth and metastasis) and destruction of the normal tissue 
architecture of all epithelial tumours87. The desmoplastic tumour environment is an 
highly heterogeneous and complex mixture of abundant ECM proteins, growth 
factors, cytokines and cells from different lineages such as fibroblasts, pancreatic 
stellate cells, smooth muscle cells, immune and inflammatory cells, endothelial 
cells88. The desmoplasia in PDAC is associated with an increased and abnormal 
expression of type I collagen, which facilitates the malignant phenotype of tumour 
cells by promoting increased proliferation and invasion of cancer cells, via activation 
of α2β1 integrin, and also promotes drug resistance89. Collagen I expression in 
PDAC can also increase the expression of snail and modulate E-cadherin, both of 
which are important in EMT and increase invasiveness of cancer cells90, 91.  
 
1.3.1 Tumour stroma interactions 
The high proportion of stromal cells in PDAC (epithelial cells frequently account for 
less than 20% of the tumour volume in PDAC92) is associated with over expression 
of growth factors such as vascular endothelial growth factor (VEGF), EGF, TGF , 
insulin-like growth factor I (IGF-I), FGF and their respective receptors, as well as 
secretion of matrix metalloproteinases (MMPs), which serve to fuel pancreatic 
cancer growth, metastasis and invasion93. In turn, PDAC cells secrete growth factors 
such as FGFs, TGF , IGF and PDGF, which are sequestered in the activated 
stroma58.  Invading cancer cells produce MMPs that are able to release these stored 
growth factors. MMPs are zinc-dependent proteinases that are frequently 
overexpressed in cancer94. Data suggest that activation of MMP-2 and MMP-9 plays 
a key role in cancer invasion and metastasis, by digesting the ECM and aiding in the 
desmoplastic reaction in PDAC95. Cancer cells also shed glypican 1 and syndecan 
1, heparan sulfate proteoglycans which can modulate paracrine growth factor 
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signalling96, 97. In addition to the changes observed in cancer cells, this interaction 
between cancer cells and stroma leads to altered transcription in stromal 
components such as fibroblasts and inflammatory cells, promoting cancer cell 
motility (via altered integrin expression patterns) and resistance to hypoxia (via 
altered expression of VEGF A and hypoxia inducible factor 1 , HIF1 )98. The net 
result is an unique micro-environment consisting of aberrant epithelial and 
mesenchymal cells, in which pancreatic cancer cells thrive92. Whilst it is clear that 
the tumour-stroma interactions are critical in development, progression and 
maintenance of PDAC, model systems to study these experimentally have only 
been available in the last decade.  Briefly there are two distinct groups: in vivo and 
in vitro model systems.  
 
1.3.2 In vivo model systems 
The development of genetically engineered mouse (GEM) models of PDAC has 
provided the most physiologically relevant model that closely mimics the situation in 
human cancer. Most of the GEM models of PDAC are based on the conditional, 
pancreas-specific, expression of the Kras oncogene (KRASG12D), present in 90% of 
human PDAC cases63. This is facilitated by expressing Cre recombinase under the 
control of the promoter of the embryonic pancreas lineage determining transcription 
factor Pdx-1 or Ptf1/p48 gene (‘KC’ mice). KC mice develop pancreatic tumours 
ranging from precursor PanINs to fully invasive and metastatic disease99, 100, albeit 
with a long latency period of up to a year. These KC mice have been crossed with 
mice harbouring several additional mutations, to investigate their contribution to the 
rapid progression to PDAC. GEM models of PDAC have been developed with 
activating mutations in TGFβ receptor and/or inactivation of tumoral suppressors 
35 
 
such as p53 (‘KPC’ mice), INK4A/ARF and Smad4, which are the most common 
PDAC drivers101. A brief summary of the various GEM available is shown in  
Table 1. 2 and there are several excellent reviews on the various GEM models that 
have been developed for studying the development of PDAC102-104. The generation 
of complex allele combinations, together with the latency period involved in the 
development of tumours, makes these models inherently expensive. Further 
criticism against GEM models of PDAC has focused on the multi-focality of their 
PDAC, involvement of whole pancreas with tumours, histological variants commonly 
observed, presence of tumours in other organs and genetic homogeneity; features 
not associated with human PDAC. In addition, the interplay of various signalling 
interactions from the diverse cell types present in the tumour makes the contribution 
from key epithelial-stromal interactions in PDAC impossible to study. The use of 
organotypic cultures using pancreatic stellate cells (PSC), the key cells driving the 
desmoplastic reaction, has been made feasible only recently105. 
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Table 1. 2 Mouse models of PDAC. 
T-Ag, SV40 large T antigen; H-RAS, Harvey RAS; Ela, elastase promoter; Mist1 a transcription factor important in acinar cell 
maturation .The expression of Mist1 is restricted to acinar cells and is not expressed in duct cells or fibroblasts within the pancreas116. 
Gene/promoter Phenotype of mouse  References 
Transgenics with predominantly acinar phenotypes   
T-Ag/Ela Acinar cell carcinoma 106 
Hras/ Ela Acinar cell carcinoma 107 
TGFα/ Ela Acinar cell carcinoma 108 
c-myc/ Ela Mixed acinar-ductal tumours 109 
KRASG12D/Mist1 Acinar cell carcinoma 110 
Activated KRAS knock in GEMs   
KRASG12DPDX1-Cre Spectrum of PanINs some mice develop PDAC after long latency 111 
KRASG12DPDX1-Cre Ink4a-/- Develop PDAC with shorter latency than KRAS mutant alone 112 
KRASG12DPDX1-Cre Ink4a/Arf -/- Develop PDAC with high penentrance and short latency. Micrometastatic 
disease 
112 
KRASG12DP48-Cre Tgfbr2-/- Accelerated PanIN and PDAC development 113 
KRASG12DPDX1-Cre p53R273H Develop PDAC with high penetrance. Metastasis 114 
KRASG12DPDX1-Cre Ink4a/Arf +/- Develop PDAC with longer latency than Ink/Arf null mice. Metastasis 115 
KRASG12DPDX1-Cre p53+/- Ink4a/Arf +/- Develop PDAC with high penetrance and shorter latency than p53-/- 115 
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1.3.3 Pancreatic Stellate Cells (PSCs) 
1.3.3.1 Isolation and characterisation of PSCs 
Hepatic stellate cells (HSCs) were first described by Karl van Kuppfer in the 19 th 
century as ‘sternzellen’, which were able to store vitamin A (retinol) as droplets in 
their cytoplasm117. A striking characteristic of stellate cells is the capability of these 
retinoid droplets to exhibit a rapidly fading blue green autofluorescence when 
excited with light at ~328nm118. Since the identification of HSCs, retinoid storing 
stellate cells have also been identified in other organs such as the kidney, intestine, 
spleen and lung119. However, it was only as recently as the 1980s, that the 
pancreatic stellate cell (PSC) was first characterised. Similar to HSCs, PSCs are 
able to store retinol in their cytoplasm and, subsequently, PSCs were identified, 
using autofluorescence of retenoids and electron microscopy, in mice that had been 
fed vitamin A58, 120. These cells have also been identified in normal rat and human 
pancreatic tissue. Studies later showed that, in patients with chronic alcoholic 
pancreatitis, lipid storing cells were abundant in the areas of fibrosis and were 
capable of secreting extracellular matrix (ECM) proteins121, 122. These studies 
suggest PSCs were a possible source of pancreatic fibrosis, similar to that has been 
observed in alcohol related liver fibrosis.  
 
In health, PSCs exist in a quiescent state123 and are a normal resident cell in the 
exocrine pancreas, where they are thought to make up 4-7% of the pancreatic cell 
types124. PSCs are present in the periacinar space and are characterised by long 
cytoplasmic processes that encircle the base of the acinus. They may also be 
present in the perivascular and periductal regions of the pancreas. PSCs express 
the marker proteins desmin and glial fibrillary acidic protein (GFAP, absent in 
fibroblasts), together with the presence of intracellular lipid droplets, which serve to 
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distinguish these cells from pancreatic fibroblasts125, present in the interlobular 
septum. 
 
Given that PSCs express many proteins that are characteristic of several cell types 
(desmin expression in monocytes, GFAP in astrocytes, nestin in neuroepithelial 
stem cells and vimentin in mesenchymal cells), the origin of stellate cells is still 
under debate. Most of the understanding of the origin of stellate cells has emerged 
from studies of HSCs, in which mesenchymal, endodermal and neuroectodermal 
origins have been suggested126-128. Recently, studies using Wilms Tumour 1 
promoter (Wt1)CreERT2 / Rosa26LacZflox mice have shown that HSCs can arise from a 
mesodermal origin129. Given that gene expression and functional studies have 
recently shown that HSCs and PSCs share many homologies (expression of genes 
related to ECM proteins, contractility, retinoid metabolism and expression of growth 
factors), but are distinctly different from normal fibroblasts126, 130, it is likely that PSCs 
and HSCs may share a common origin.  
 
The isolation and immortalisation of PSCs from human and rat pancreas has 
provided an additional tool for studies of the effect of PSC activation. PSCs have 
been immortalised by SV40 large T antigen in rat PSCs or by SV40 large T antigen 
and human telomerase in human PSCs131. The resultant immortalised PSC line is 
comparable to activated PSCs, showing expression of SMA and ECM proteins. 
Importantly, DNA microarrays used to compare primary and PSC cell lines have 
shown only a few differences, including differences in expression of ECM proteins, 
cytokines and integrins132. In addition, both immortalised and primary PSCs respond 
to TGF-ß and PDGF in a similar manner133. The use of primary and immortalised 
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PSCs, as well as co-culture systems, has given us a mechanistic insight into the 
biology of PSCs.  
 
1.3.3.2 Activation of PSCs 
During injury, PSCs have the ability to trans-differentiate from a quiescent lipid 
storing phenotype to a myofibroblastic-like activated state (with loss of lipid droplet 
storage), producing -smooth muscle actin (α SMA) and secreting excessive 
amounts of the ECM proteins, such as collagen I, that comprise fibrotic tissue (Table 
1. 3). Activation of PSCs is also associated with several morphological changes, 
including nuclear enlargement and enhanced prominence of the endoplasmic 
reticulum network, suggesting an increase in protein synthesis58.  
 
Recent studies have shown that a small proportion of activated PSCs may also be 
derived from circulating bone marrow (BM) derived cells that are attracted to the 
pancreas during injury134. In this study, irradiated female mice were injected with 
GFP expressing pluripotent BM cells isolated from male mice, followed by the 
induction of chronic pancreatitis with repeated injections of cerulein. The results 
consistently showed an induction of chronic pancreatitis, with an increase in GFP 
positive PSCs. However, the contribution of GFP positive PSCs accounted for less 
than 20% of PSCs found within the diseased pancreas. Therefore, it is likely that the 
majority of PSCs seen in response to injury are pancreatic derived. It is unknown if 
BM derived cells may be responsible for a sub-population of PSCs in human 
fibrosis.  
 
PSCs are activated when primary cells are cultured on plastic and also as a result of 
injury, including oxidative stress, toxins such as alcohol and exposure to growth 
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factors135. In vitro culture of rodent and human PSCs has highlighted numerous 
growth factors, cytokines, hormones, intracellular signalling molecules and 
transcription factors that regulate activation of PSCs. It is possible that in vivo 
paracrine factors such as cytokines (IL-1, IL-6, IL-8 and TNF ), growth factors 
(PDGF, TGF  and FGFs), angiotensin II, and reactive oxygen species from 
damaged neighbouring cells and leukocytes can lead to PSC activation105, 136-141. 
Activated PSCs can, in turn, secrete growth factors (such as PDGF, TGF ), 
cytokines (IL-1, IL-6 and TRAIL) and pro-inflammatory molecules (COX-2), which 
can all serve to fuel the activation state of PSCs in an autocrine manner138, 140, 142, 143. 
A number of key signalling pathways are able to mediate regulation of PSC state. 
The MAPK pathway serves to transduce signals from growth factors as well as 
stimulation by ethanol. PI3K, RHO kinase, JAK/STAT, NF- B and the TGFß/SMAD 
pathways can also regulate PSC activation144-146. 
 
Parenchymal necrosis and inflammation is thought to be a requisite for activation of 
PSCs. This has been confirmed using time-lapse studies with animal models, which 
have indeed shown that inflammation precedes activation147, 148. Once activated, 
PSCs show increased proliferation and migration as well as synthesis of ECM 
proteins (including collagen I and fibronectin149), leading to fibrosis or ECM 
remodelling as part of the response to injury.  PSCs play a key role in the extensive 
tissue fibrosis that accompanies chronic pancreatitis, leading to destruction of the 
normal exocrine function150.  Although the exact role of PSCs in the repair processes 
following injury remains to be elucidated, it is thought PSCs present in the pancreas 
probably contribute to the formation of a matrix that allows proliferation, migration 
and generation of new pancreatic cells147.   
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By secretion of ECM proteins and proteases such as MMPs and their inhibitors, 
PSCs can modulate the surrounding matrix151. In most studies in which PSCs are 
activated after damage to the pancreas, the inflammation processes resolves and 
activated PSCs eventually disappear after the cessation of the inflammation 
mediator58. However, repeated inflammatory damage and the failure of the 
mechanisms regulating tissue repair can lead to chronic inflammation, persistent 
PSC activation and proliferation, eventually giving rise to fibrosis. Indeed, 
continuous episodes of experimental pancreatitis produce changes that resemble 
chronic pancreatitis152 151. Furthermore, changes in the composition of the ECM 
during repair processes can modulate PSC activation. For example, activated PSCs 
can be reverted back to a quiescent state when cultured on basal membrane like 
matrix suggesting ECM composition can modulate PSC behaviour133. Fibrosis in the 
pancreas and other organs is very much a wound healing response to repeated 
damage such as chronic alcohol consumption, pancreatic duct obstruction, 
metabolic disorders, and genetic defects. This chronic injury only serves to 
exaggerate the activated PSC phenotype, thus fuelling and sustaining fibrosis153. 
Unsurprisingly then, activated PSCs are now thought to be the source of fibrosis in 
PDAC. 
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 Quiescent Activated 
Lipid droplets in 
cytoplasm 
+ Absent 
Endoplasmic reticulum + ++ 
Nucleus Basal size Enlarged 
Vimentin expression ++ ++ 
Desmin expression + + 
GFAP expression + + 
Nestin expression + ++ 
α-SMA - + 
ECM production Limited Increased 
Cell proliferation  Limited Increased 
Cell migration  Limited Increased 
 
Table 1. 3  Features of quiescent and activated PSCs 
_ Absent;  +presence; ++ abundant58 
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1.3.3.3 Role of activated PSCs in PDAC 
The link between PSCs as a source of desmoplasia and PDAC was identified 
relatively recently. PSCs were shown to be the specific cellular source of ECM 
proteins and the predominant source of collagen in the tumour stroma of PDAC 
patients121. More recent studies have shown that activated PSCs are also present in 
early PanIN lesions both in human PDAC as well as tumours that arise in the KPC 
mouse model, suggesting they may play a role in early PDAC development154.  
 
1.3.3.4 Evidence of interaction of activated PSCs and pancreatic cancers 
cells (PCCs) from in vitro studies  
In vitro studies have shown that pancreatic cancer cells (PCCs) and PSCs can exist 
in a symbiotic relationship (Figure 1. 5) PCCs stimulate proliferation and migratory 
potential of PSCs and lead to an increased production of ECM proteins122. PCCs 
secrete a number of potent mitogens such as TGF-β1, FGF, PDGF and VEGF155, all 
known to activate PSCs. It is likely that TGFβ and FGF2122 are able to mediate 
activation of PSCs to induce ECM production (this phenotype is inhibited by 
neutralising antibodies to both TGFβ1 and FGF2), whereas proliferation of PSCs is 
promoted by PDGF155. PCCs are also capable of secreting extracellular matrix 
metalloproteinase inducer (EMMPRIN), which leads to the increased secretion of 
matrix metalloproteinase 2 (MMP2) by PSCs, a factor which can induce PCC 
invasion156. Furthermore early PanIN lesions that are isolated from KPC mice are 
capable of inducing activation and proliferation of PSCs, suggesting that even early 
pre-neoplastic lesions can activate PSCs157.  
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In turn, PSCs are able to stimulate cancer cell proliferation and at the same time 
inhibit apoptosis, fuelling an increase in tumour cell population. PSCs also increase 
the migration of PCCs and induce epithelial to mesenchymal transition, as shown by 
the increased expression of the mesenchymal markers snail and vimentin, and 
reduction in the epithelial marker E-cadherin58, by yet to be determined secretory or 
other mechanisms. 
 
Moreover, the culture supernatant of PSCs isolated from PDAC has been shown to 
significantly promote proliferation and colony formation of human pancreatic duct 
epithelial cells (HPDE). Many genes involved tumourigensis were upregulated in 
HPDE cells incubated with PSC conditioned media; including FGF 2, PTEN, 
IL13RA2, ANXA2, CXCL2, KLF6, IL8, SOX8, CCR3, SP5 and MYCN, while tumour 
suppressor genes were down regulated (including CASP14, FN1, TEP1, BMP7, 
CX3CL1 and WNT10A)158. These results suggest PSCs, through paracrine factors, 
can promote the transformation of normal duct epithelium into malignant cells. 
 
The desmoplasia in PDAC is believed to have a detrimental effect on the successful 
response to chemotherapy and radiotherapy81, 156. PSCs have been shown to 
protect PCCs from radio- and chemotherapy by increasing PCC clonal survival in a 
β1 integrin dependent manner159. PSCs are also able to increase the ‘stem cell’ 
phenotype of PCCs (shown by induced expression of cancer stem cell related genes 
ABCG2, a membrane transporter protein which is highly expressed in cancer stem 
cells,160 Nestin, a marker of pancreatic progenitor cells161 and LIN28 which maintains 
embryonic stem cell functions162), a possible mechanism of resistance to therapy163. 
Therefore, PDAC cells and PSCs together establish a vicious cycle of mutually 
reinforcing mechanisms to sustain the desmoplastic reaction. 
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Figure 1. 5  Interaction of PSCs and PCCs  
There is accumulating evidence for PSC cross talk with pancreatic cancer cells, which in turn 
contributes to tumour desmoplasia in PDAC. Such cross talk can promote tumour growth 
and metastasis
121, 156, 164
,  
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1.4 Organotypic culture models of pancreatic cancer  
Many of the in vitro studies that have demonstrated the interaction of PSCs and 
PCCs have been carried out in 2D cultures, which do not give an optimal 
representation of the in vivo situation. Cells grown on 2D tissue culture plates or in 
Transwell inserts differ in their morphology, differentiation and cell-cell and cell-
matrix interactions compared to cells in vivo. For studying cell behaviour in an in 
vitro model that is easily amenable to experimental manipulation, but more relevant 
to the physiological environment of PDAC, 3D culture systems can be used165. 
 
Pancreatic cancer cell lines and normal HPDE cells previously have been cultured 
on type I glycosaminoglycan scaffolds and in Collagen type I or Matrigel. Given only 
pancreatic cancer cell lines alone were used in these models, the effect of the 
stroma on tumour cell behaviour was absent166-168. However, these studies were 
able to show that pancreatic cancer cells embedded into Matrigel formed spheroids 
with a distinct morphology and loss of apico-basal polarity compared to culturing in 
2D166. 
 
The introduction of stromal cells in PDAC 3D organotypic cultures was first 
demonstrated by our laboratory165. In these studies, activated PSCs were used to 
better simulate the tumour microenvironment seen in PDAC. Depending on the 
question that is being asked, 3D models of PDAC can be set up in various ways 
using PSCs and PCCs. In order to understand the influence of PCCs on the 
behaviour of PSCs that have invaded into the stroma, these cells can be embedded 
in an ECM gel composed of collagen and Matrigel. PCCs embedded into an ECM 
gel form spheroids that recapitulate the features of glandular epithelial cells in vivo165 
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Submerging the ECM gels, (with PCCs grown on top of the gel in which the PSCs 
are embedded) allows us to understand the early events in tumour progression. 
When PCCs are cultured on top of this model, they form luminal structures that 
resemble ducts in vivo. Using this model, our group has shown that PSCs induce 
changes in PCC cell adhesion molecules such as Ezrin and that Ezrin translocation 
from the apical to the basal compartment of the cells is an early event in PCC 
invasion169. Finally, in order to study the invasion of PCCs in the 3D model, the 
submerged culture system can be raised upon a grid (‘air-liquid’ model) and fed from 
underneath, creating a gradient that stimulates PCCs to invade. Using the air liquid 
3D model, our group has shown that the presence of PSCs leads to a significant 
increase in, and altered cellular distribution of, ß-catenin in PCCs. Interestingly, 
treating these 3D co-cultures with all trans retinoic acid (ATRA, which renders PSC 
quiescent) results in a decrease in Wnt signalling and, thereby, reduced PCC cell 
invasion170.  
 
Furthermore, 3D organotypics provide a perfect model to isolate cancer cells grown 
in these cultures and assess changes in signalling cascades and molecular targets 
due to cancer cell desmoplastic cross talk, which would not be apparent if cancer 
cells were grown on a 2D platform. In addition, using a 3D culture model reduces 
the noise from other stromal elements present in vivo and focuses on the cancer-
stromal interaction. Using this approach, we have previously isolated pancreatic 
cancer cells from organotypic models in which PSCs were embedded in the ECM 
gel and used gene expression microarrays to demonstrate that cancer cell stromal 
interactions significantly alter proliferation, cell cycle, cell movement, cell-cell 
signalling and inflammatory response in addition to changing stiffness in the ECM 
gel171. Importantly, this study also showed that changes in stiffness of ECM gels was 
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particularly prominent as the proportion of PSCs in the ECM gel increases, which is 
highly pertinent to drug delivery and perfusion in PDAC81. This study also highlights 
the possible value of multidrug targeting in PDAC in order for chemotherapy or 
radiotherapy to be effective, as many of these cancer cell pathways influenced by 
the stroma are redundant.  
 
Upregulation of Src activity has been shown to correlate with poor prognosis in 
PDAC and is a possible therapeutic target172. Despite preclinical studies showing 
promise of Src inhibitors in combination with chemotherapy, treatment only reduced 
metastasis in KPC mice by 50%, which may be explained by a failure of drug 
treatment reaching the tumour172. The accumulation of ECM component in PDAC 
distorts the normal architecture of the pancreas tissues, compressing blood vessels 
leading to reduced perfusion and delivery of therapies to tumour cells. As such, 
several groups are researching into modulating the stroma in PDAC and examining 
its potential impact on tumour perfusion. Focusing on Src kinase activity, Anderson 
and colleagues (using fluorescence lifetime imaging microscopy (FILM) to measure 
fluorescence resonance energy transfer (FRET) of PDAC cells expressing an 
ECFP-YFP Src reporter) have recently exploited the use of PDAC organotypic 
cultures in conjunction with in vivo models to investigate the tumour environment on 
dasatinib delivery in PDAC173. Using this approach (organotypic models consisted of 
PDAC cells expressing the Src biosensor cultured on top of an ECM gel with 
embedded primary human fibroblasts), they were able to show that the 3D 
environment contributes to poor drug delivery to tumour cells, dependent on 
distance of cells from the invasive edge of the tumour or location relative to 
vasculature. Furthermore, the group claim that modulating the stroma, using a 
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combination treatment approach, may facilitate a more effective tumour cell drug 
delivery.  
 
Despite their elegant approach, there are limitations to this study and results should 
be further validated. In particular, the subcutaneous in vivo models that were used in 
conjunction with the organotypic models do not simulate adequately the PDAC 
environment, making comparisons difficult to interpret. In spite of this, the study 
demonstrates the adaptability of the organotypic model as powerful tool, which can 
be easily manipulated to address specific questions.  
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1.5 Evidence of interaction of PSCs and PCCs from in vivo studies  
Animal models such as xenografts, orthotopic grafts or GEM have enabled the 
verification that cancer cells interact with PSCs in vivo. Early subcutaneous mouse 
models, in which PSCs and PCCs were injected into the flanks of 
immunocompromised mice, demonstrated that, in the presence of PSCs, PCC 
proliferation increased and tumours formed more rapidly than when PCCs were 
injected alone122. However, subcutaneous models do not recapitulate the tumour 
microenvironment that is so important for PDAC development and are not an ideal 
model to study metastasis154. The development of orthotopic and GEM models of 
PDAC have thus allowed for the study of tumours which form in a more 
physiologically relevant environment and metastasise to local and distant regions116.  
 
Studies from Apte and colleagues have been pertinent in confirming the role PSCs 
play a role in regulating PCC behaviour155. Injection of PCCs (MiaPaCa-2 and 
AsPC-1 cell lines) in combination with primary human PSC into the mouse pancreas 
was able to stimulate fibrosis, tumour growth and metastasis. Importantly, no 
tumours developed in mice injected with PCCs alone. Another group, using an 
immortalised PSC line, also reported these observed effects of PSCs on PCC 
growth in vivo174. More recently, elegant sex mismatch studies (injection of male 
PSCs and female PCCs into the pancreas of female mice) have shown that Y 
chromosome positive PSCs are able to metastasise through blood vessels, with 
cancer cells, and seed in distant sites such as liver and the diaphragm, where they 
are able to facilitate seeding, survival and growth of PCCs175. In addition to 
orthotopic mouse models, several GEM models show PDAC tumour development 
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with a prominent stroma (that contains activated PSCs) and recapitulate human 
disease. These models include: 
Kras LSl-G12D/+; Trp53LSL-R172H/+; Pdxcre/+ (KPC) mice81 
KrasLSL-G12D/+; Trp53LSL-R172H /+; R26LSL-GFP/+; Pdxcre/+ (KPGC) mice. These mice have 
the same activated K-RAS and point mutations in p53 as the KPC mice but also 
contain enhanced green fluorescent protein (EGFP) cDNA sequence flanked by 
LoxP sites knocked into the ROSA26 locus176.  
KrasLSL-G12D/+; Tgfbr2floxlox; Ptf1acre/+ mice. These mice are knockout for type II 
receptor for TGFβ (Tgfrb2) specifically in the pancreas and express activated K-
RAS in a pancreas epithelium-specific manner. Compared to the p53 inactivation 
model, PDAC in this model is largely composed of differentiated PDAC, failing to 
recapitulate the undifferentiated histology that is frequent in human PDAC177.  
 
A number of preclinical mouse model studies using therapies that target PSCs have 
shown promise. Enzymatically (PEGPH20) targeting hylauronic acid (HA, a 
prominent ECM component abundant in PDAC) in KPC mice was able to restore the 
tumour vasculature, which permitted high concentrations of Gemcitabine to reach 
the tumour. In normal tissue, HA provides excellent elasticity to connective tissue, 
but excessive HA accumulation in solid tumours raises interstitial fluid pressure and 
compresses blood vessels178. Targeting HA led to remodelling of the tumour 
microenvironment, with a significant decrease in activated PSCs, reduced 
metastasis and increased overall survival176. In addition, our laboratory 
demonstrated that treating KPC mice with ATRA significantly decreases tumour 
growth170. It is clear that more stromal-targeted therapies are needed. It is therefore 
imperative that we understand more clearly the mediators of the interactions 
between PSCs and PCC, which will allow us to identify new therapies that will inhibit 
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the synergistic effects of PCSs and PCCs. These observations from various groups 
also suggest the importance of model systems which include the key drivers of 
desmoplastic reaction is critical to study PDAC development as well as therapy. I 
aim to use these models to study the most widely known tumour-stroma signalling 
pathway in human PDAC, FGF signalling. 
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1.6 Aims  
In PDAC, a number of FGFs and FGFRs are over-expressed, correlating with poor 
patient outcome77, 179-185. For example, over-expression of the IIIC isoform of FGFR1 
in PDAC can promote tumourigenesis182, 186-188. Initial experiments exploring FGF2 
expression in PDAC described FGF2 apparent in the nuclei of many cancer cells but 
not in normal pancreatic tissue, suggesting intranuclear FGF2 may be important in 
this cancer77, 185. However, the function of nuclear FGF2 in PDAC, particularly with 
respect to PSCs, has not been explored. Thus the first aim of my project was to 
assess the localisation and expression of FGF2 and its receptor FGFR1 in PDAC 
tissue. In the second part, I aimed to understand the role and function of nuclear 
FGFR1 and FGF2 in vitro using a panel of pancreatic cancer cell lines as well as an 
immortalised pancreatic stellate cell line. Finally, I used the 3D organotypic model of 
PDAC to test assess the hypothesis that blocking nuclear FGFR1 and FGF2 in 
stellate cells could provide a novel therapeutic strategy in PDAc.  
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Chapter II  MATERIALS AND METHODS 
2.1 Cell culture 
2.1.1 Cell lines, media and culture reagents.  
2.1.1.1 Pancreatic cancer cell lines  
 
Table 2. 1. Shows the human pancreatic cancer cell lines that were used 
Cell line Origin Differentiation 
state 
Mutations Ref 
Capan-1 Male age 40 (from 
liver metastasis) 
Well KRAS, TP53, INK4A, 
SMAD3 and BRCA2 
189
 
CFPAC-1 Male 26 with cystic 
fibrosis (from liver 
metastasis) 
Well KRAS, TP53, SMAD4 
and methylated INK4A. 
190
 
Capan-2 Male age 56 (from 
primary tumour) 
Well KRAS 
189
 
818.1 Female 75 year 
old (from ascites) 
Well KRAS, TP53, INK4A 
191
  
COLO-357 From lymph node 
metastasis 
Well KRAS, SMAD4 
192
  
PaTu8898T From liver 
metastasis 
Well  
193
  
AsPc1 Female age 62 
(from ascites) 
Poor KRAS, TP53 and 
INK4A 
194, 
195
 
MIA PaCa-2 Female age 65 
(from primary 
tumour) 
Poor KRAS, TP53, INK4A 
195
 
PANC-1 56 year old female 
(from primary 
tumour) 
Poor KRAS, TP53 and 
INK4A 
196
  
PaTu8898S From liver 
metastasis 
Poor KRAS, TP53 with 
methylation of the 
5’CpG island of INK4A 
193
 
Hs766T 46 year old male 
(from lymph node 
metastasis) 
Poor KRAS, TP53, SMAD4 
197
 
SUIT-2 Male 73 (from liver 
metastasis) 
Poor KRAS, P53, INK4A 
198
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2.1.1.2 Stromal Cells 
Non-tumourgenic, primary and hTERT immortalised human pancreatic stellate cells 
were used.  Using the outgrowth method199 200, pancreatic stellate cells were 
isolated in an ethically approved manner. The resulting primary cell strains 
designated PSC1, HPSC and FS1 were verified as being of stellate cell origin based 
on the expression of characteristic stellate cell markers (expression of cytoskeletal 
proteins GFAP, Desmin, Vimentin and SMA) as previously published 122. An 
immortalised pancreatic stellate cell line, PS1, was generated previously in the lab, 
using the outgrowth method followed by immortalisation by expression of ectopic 
human telomerase reverse transcriptase (hTERT)199. 
 
2.1.1.3 Pancreatic ductal epithelial cells 
Non-tumourigenic HPV16 immortalised human pancreatic ductal epithelium (HPDE) 
and hTERT immortalised human ductal epithelium (Dec-hTERT) cell lines were 
used as control pancreatic ductal cell lines199, 201. 
 
2.1.1.4 Culture conditions and routine cell culture 
Pancreatic cancer cells were cultured as adherent monolayers in sterile tissue 
culture flasks (Corning, 431080) in a humidified atmosphere at 370C, 8% CO2 in 
either RPMI (PAA Laboratories E15-840, Capan-1, AsPc1, CFPAC-1), Dulbecco’s 
Modified Eagle’s Medium (DMEM, PAA Laboratories E15-843, HPAF, PANC-1, 
PaTu8988S, PaTu8988T, COLO-357, MIA PaCa-2, 818.1, Hs766T, SUIT-2) or 
McCoys 5A medium modified (ATTC, 30-2007, Capan-2) medium supplemented 
with 10% foetal bovine serum (FBS, PAA Laboratories A15-104). Pancreatic ductal 
epithelial cells (Dec-hTERT) were grown in DMEM supplemented with 10% FBS. 
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HPDE were cultured in keratinocyte serum free medium (Gibco, 10725) 
supplemented with 0.1mg/ml bovine pituitary extract (BPE Gibco 10450-013) and 
5ng/ml epidermal growth factor (EGF, Gibco 13028-014). PS1 and primary stellate 
cells were grown at the same humidified culture conditions as pancreatic cancer 
cells in DMEM: F12 medium (Sigma, N6658) supplemented with 10% or 20% FBS, 
respectively. Puromycin (1 g/ml Sigma, P9620) was added to the medium of PS1 
stellate cells as a selection agent.  
 
When cells reached 80-90% confluency, medium was removed and cells were 
washed with Phosphate Buffered Saline (PBS Sigma PAA17) before trypsin-EDTA  
(PAA Laboratories, L11003) was added for 1-5 minutes at 370C in order to detach 
cells from the flask surface. Once cells were detached, trypsin was inactivated with 
medium containing 10% FBS. Cell suspensions were centrifuged at 200 x g, 
followed by removal of supernatant and resuspension of cell pellet in standard 
medium. If counting of cells was required, 20 l of cell suspension was pipetted into 
a haemocytometer prior to centrifugation and cells were counted manually under a 
light microscope. Cells were subcultured at various ratios (1:2 to 1:5) depending on 
their growth rate. 
 
For storage of cells, cell pellets were resuspended at various concentrations in a 
mixture of 90% FBS with 10% dimethyl sulphoxide (DMSO), which acts as a 
cryoprotectant. One ml of cell suspension was pipetted into a cryovial and cells were 
slowly frozen first at -800C to prevent ice crystal formation and then transferred to 
liquid nitrogen for long-term storage. When recovering cells from liquid nitrogen 
stock, cells were thawed as quickly as possible in a 370C water bath. Once thawed, 
cell suspensions were transferred to a 15ml falcon tube containing prewarmed 
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standard medium. To remove DMSO, the cell suspension was centrifuged at 1200 
rpm for three minutes, the supernatant was removed and cells were resuspended in 
standard medium and plated onto a tissue culture flask. 
 
2.1.2 Collection of supernatant 
For conditioned medium to be used in Western blot analysis, cells were cultured in 
serum free medium for 12 hours (PS1 cells appeared stressed if starved for longer 
than this period of time), after which time the medium was collected, filtered and 
concentrated 20X using centrifugal filter units (Millipore UFC 800324 NMWL 3000) 
according to the manufacturer’s instructions. The membranes used in the 
centrifugation device are characterized by a nominal molecular weight limit (NMWL); 
that is, their ability to retain molecules above a specified molecular weight. The 
device used to concentrate the supernatant in these experiments had a NMWL of 
3000 Da. This enabled centrifugation solutes with molecular weights below 3 kDa to 
be excluded from the membrane and collected in the centrifuge tube while the 
concentrated supernatant was collected from the filter device sample reservoir.  
Culture medium (serum free) was used as a negative control. Sample buffer (4X, 
Invitrogen, NP0007) was added to the concentrated conditioned medium and boiled 
at 1000C for Western blotting (Section 2.4.5). Similarly conditioned medium (serum 
free) was collected and filtered from pancreatic cancer cells (COLO357) and normal 
ductal epithelial cells (Dec-hTERT) to be used in PS1 stimulation assays (Section 
2.4.2). 
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2.2 Reagents  
2.2.1 Antibodies 
All antibodies are summarised in Table 2. 2 
 
Antibody Species 
raised in 
Supplier (Cat No) Dilution 
for IF or 
IHC 
Dilution 
for WB 
HSC70 Mouse Santa Cruz (SC7298) N.A. 1:1000 
SMA Rabbit Abcam (ab5694) 1:100 NA 
SMA Mouse Dako clone 1A4 (M0851) 1:300 1:100 
Vimentin Mouse Dako clone V9 (M0725) c.s 1:2000 
FFPE 1:50 
1:250 
Ki67 Rabbit Abcam (ab15580) c.s 1:100 
FFPE 
1:100 
N.A 
FGFR1 (recognises 
intracellular epitope in 
C terminus) 
Rabbit Santa Cruz (SC121) N.A 1:1000 
FGFR1 (recognises 
extracellular epitope 
near transmembrane 
domain) 
Rabbit Abcam (10646) c.s 1:100 
FFPE 
1:500 
N.A 
FGFR1  Rabbit Cell Signalling (9740) N.A 1:1000 
Tubulin Mouse Sigma (T5168) N.A 1:2000 
Lamin A/C Goat Santa Cruz (SC6215) N.A 1.1000 
Actin  Goat Santa Cruz (SC1615)   
FGF2 Rabbit Peprotech (500-P18) N.A 1:500 
FGF2 Mouse Millipore (05-118) c.s 1:100 
FFPE 
1:100 
N.A 
pFRS2 Rabbit Cell Signalling (38645) N.A 1:1000 
pERK Rabbit Cell Signalling (91015) N.A 1:1000 
SC35 Mouse Sigma (S4045) 1:1000 NA 
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Antibody Species 
raised in 
Supplier (Cat No) Dilution 
for IF or 
IHC 
Dilution 
for WB 
HSC70 Mouse Santa Cruz (SC7298) N.A. 1:1000 
SMA Rabbit Abcam (ab5694) 1:100 NA 
Cyclin D1 Mouse Cell Signalling (2926P) N.A 1:1000 
Importin Beta Mouse Abcam 1:500 1:1000 
Cytokeratin WSS Rabbit Dako (Z0622) 1:500 N.A 
Anti-mouse HRP Goat  Dako (P0447) N.A 1:1000 
Anti-mouse HRP Rabbit Dako (P0260) N.A 1:1000 
Anti-goat HRP Rabbit Dako (P0160) N.A 1:1000 
Fluorescein-goat–anti 
rabbit 
Rabbit Invitrogen (F27 65) 1:100 N.A 
Cy3 donkey anti-
mouse 
Mouse Jackson 
Immunoresearch (715-
166-151) 
1:100 N.A 
 
Table 2. 2. Antibodies used for experiments 
 
HSC70, heat shock cognate 70 kDa protein 8; SMA, -smooth muscle actin; Cytokeratin 
WSS, wide spectrum screening, recognising a broad spectrum of human cytokeratin; 
FGFR1, Fibroblast growth factor receptor 1; FGF2, Fibroblast growth factor 2; Lamin A/C 
HRP, Horseradish peroxidase; c.s, coverslip; FFPE, formalin fixed paraffin embedded; IF, 
immunofluorescence; IHC, immunohistochemistry; WB, Western blot; N.A:  not applicable. 
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2.2.2 PD 173074 FGFR inhibitor 
 
PD 173074 or (N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5 dimethoxyphenyl)pyrido-
[2,3-d]pyrimidin-7-yl]-N’-(1,1-dimethylethyl)urea) (Sigma-Aldrich, P2499), a potent, 
cell permeable and ATP competitive inhibitor of FGFR202 was dissolved in DMSO to 
achieve a stock concentration of 20mM. Stock PD 173074 was freshly diluted in 
culture medium and used at a 2 M concentration unless otherwise stated. Medium 
was changed every two days and cells incubated in culture medium, supplemented 
with equivalent amount of vehicle (DMSO), served as controls.  
 
Figure 2. 1 PD 173074 
 
2.2.3 Small interfering RNA (siRNA) oligos 
 
Cells were transfected with a pool of siRNA oligos (Dharmacon CO), whose 
sequences are listed below in Table 2. 3. 
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On Target plus SMARTPOOL siRNA FGFR1 L-
003131 
Target Sequence 
J-003131-10  GCCACACUCUGCACCGCUA 
J-003131-11 CCACAGAAUUGGAGGCUAG 
J-003131-12 CAAAUGCCCUUCCAGUGGG 
J-003131-13 GAAAUUGCAUGCAGUGCCG 
On Target plus SMARTPOOL siRNA FGF2 L-
006695 
Target Sequence 
J-006695-05 CUAAAUGUGUUACGGAUGA 
J-006695-06 UCAAAGGAGUGUGUGCUAA 
J-006695-07 GCUAAGAGCUGAUUUUAAU 
J-006695-08 GAUGGAAGAUUACUGGCUU 
On Target plus SMARTPOOL siRNA Importin 
beta 
Target Sequence 
J-017523-06 
J-017523-07 
J-017523-08 
J-017523-09 
GAACCAAGCUUGAUCUUGU 
GCUCAAACCACUAGUUAUA 
GACGAGAAGUCAAGAACUA 
GGGCGGAGAUCGAAGACUA 
On Target plus SMARTPOOL siRNA FRS2 Target Sequence 
J-060152-05 
J-060152-06 
J-060152-07 
J-060152-08 
GGUGGGAAGUGCUCGCUUA 
GAGAAGACCUGCACUAUUA 
UGAGAGAACUGCUGCUAUG 
GUACACCGACAGUCUUUAA 
 
Table 2. 3. Sequence of siRNA oligos.  
62 
 
 
2.3 Cell transfection 
2.3.1 Introduction of siRNA into pancreatic cancer cell lines and 
pancreatic stellate cells. 
Pancreatic cancer cell lines and pancreatic stellate cells (PS1) were plated into 6 
well plates at a confluency of 5x104 cells per well (40% confluency) in standard 
medium containing FBS. The following day the medium was removed from the cell 
lines and replaced by 1 ml of fresh standard culture medium (without puromycin for 
the PS1 cells) to achieve the correct final concentration of siRNAs. The cancer and 
PS1 cells were transfected with a pool of siRNAs at a final concentration of 10 nM, 
or with a pool of non-targeting siRNA at the same concentration (sequences listed in 
Table 2.3) using INTERFERin™ (Polyplus 409-10) as a transfection reagent. 
Transfection complexes were prepared in OptiMEM (Gibco, 3165-027), to which 4 l 
INTERFERin was added, vortexed for 10 seconds and incubated for 10 minutes at 
room temperature and 105 l was added to the cells in culture medium. 
Subsequently PS1 cells treated with FGFR1 RNAi (24 hours) were harvested, 
admixed with COLO-357 cancer cells in a 2:1 ratio and cultured in a Miniorganotypic 
model for seven days (Section 2.4.3.2). Knock down was confirmed by Western blot.  
 
2.4 Functional Assays 
2.4.1 Cell growth assay 
Cancer cell lines and stellate cells were plated into 6 well pates in triplicate at a 
density of 5 x104 cells per well and the next day treated with PD 173074 inhibitor (2 
m) or DMSO as a control. At 24, 48, 72 and 120 hours following treatment, cells 
were detached with trypsin-EDTA, 500 l of cell suspension was added to 9.5 ml of 
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Isoton and cells were counted with a Casy counter (Sharfe) via electrical signals that 
are generated when cells pass through a measuring capillary. Cell counts were 
normalised to the untreated cell number, 24 hours after plating. Each experiment 
was carried out in triplicate and repeated on three separate occasions. Ki67 staining 
was also used to identify proliferating cells. Each data point plotted represents the 
percentage of cells positive for Ki67 per field. Multiple fields were taken per 
experiment. The total number of cells analysed to obtain this percentage was 
recorded in the figure. 
 
2.4.2 FGF2 stimulation assays 
For inhibitor experiments, PS1 cells were plated in 6 well plates at a density of 3x105 
cells per well, serum starved for 12 hours and then treated in serum free media for 
one hour with FGFR inhibitor PD 173074 (2 μM) before stimulation with 100 ng/ml 
recombinant FGF2 (PeproTech, 100-18C) and 300 ng/ml heparin sodium salt for 
different time points. PS1 cells were then lysed and used for Western blot analysis 
(Section 2.4.5). For quantification of nuclear FGFR1 and FGF2 following FGF2 
stimulation, PS1 cells were plated on coverslips in 12 well plates at a density of 
1x105 cells per well, serum starved for 12 hours before treating with 100 ng/ml 
recombinant FGF2 and 300 ng/ml heparin sodium salt for various time points. PS1 
cells were then fixed and stained according to Section 2.5.2. Similarly, conditioned 
medium (serum-free) from normal or cancer cells was added to serum starved PS1 
cells for 6 hours before cells were fixed and stained for quantification of nuclear 
FGFR1 and FGF2.  
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2.4.3 Organotypic culture  
2.4.3.1 Air-liquid interface organotypic model 
Figure 2. 2 shows the organotypic model used as described before165. In order to 
study the invasion of cancer cells in a 3D model, an air liquid interface model was 
used. An extracellular matrix (ECM) equivalent, composed of 75% Collagen type I 
(BD Biosciences 354236) and 25% Matrigel (BD Biosciences 354234) was prepared 
on ice by mixing one ml of a mixture of 5.25 volumes Collagen type I, 1.75 volumes 
Matrigel, 1 volume of 10X DMEM (PAA Laboratories E15-843), 1 volume of DMEM 
and 1 volume of filtered FBS, was plated into 24 well plates coated with diluted 
Collagen type I (1:100 in PBS). Gels were made in triplicate. Once the gels had 
polymerised, 1.7 x105 cancer cells mixed with 3.3 x 105 stellate cells, or 5x105 
cancer cells alone (control) were added onto the gels in 1ml of medium and left to 
adhere overnight at 370C. The next day, the gels were lifted onto a metal grid 
covered by a nylon membrane precoated with 7 volumes Collagen type I, 1 volume 
10 X DMEM, 1 volume DMEM and 1 volume FBS. 250 L of the mixture was 
pipetted onto the nylon membrane and allowed to polymerise for 15 minutes at 
370C, cross-linked with 1% glutaraldehyde /PBS and left for one hour at 40C. 
Glutaraldehyde was removed by washing the membrane three times with PBS and 
once with medium, then covering in medium and leaving overnight at 40C. The 
following day, the submerged organotypics were raised to grids and fed from below 
with medium supplemented with PD 173074 (2 M) or DMSO (control). Medium was 
changed every other day and gels were harvested at 14 days following treatment, 
fixed in 10% neutral buffered formalin, bisected and embedded in paraffin.  
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2.4.3.2 Mini organotypics 
Mini organotypics were constructed using primary PSCs (PSC1) in 0.4 µM Transwell 
inserts (Corning, 3413) in order to accommodate for the limited availability of 
primary PSC cells. Figure 2. 2 shows the construction of the mini organotypic model. 
First, the bottom of the insert was coated with Collagen type I (1:100 dilution in PBS) 
and left at 370C for one hour. Following this, 120 µl of ECM equivalent, consisting of 
5.25 collagen type I, 1.75 Matrigel, 1 volume of 10X DMEM (PAA Laboratories E15-
843), 1 volume of DMEM and 1 volume of filtered FBS, was plated into inserts and 
left to polymerase at 370C for 2 hours.  When the gels had polymerised, 200 µl of 
PSCs (0.66 x105 cells) and COLO-357 cells (0.33 x 105 cells) admixed or COLO-357 
cells alone (1x105 cells) were plated on to the gels and 600 µl of medium (DMEM) 
was added to the bottom of the well. At this point gels were left overnight at 370C for 
cells to adhere. The next day medium in the bottom of the well was replaced with 
DMEM (10% FBS) containing either PD 173074 (2 µM) or DMSO (control). Similarly, 
mini organtypics were constructed as above using PS1 cells treated with scrambled 
or FGFR1 RNAi (24 hours) and COLO-357 cells in a 2:1 ratio. For these 
organotypics, DMEM (10% FBS) medium was used in the bottom of the well. 
Medium was changed on alternate days and the organotypics were harvested at day 
seven, fixed in 10% neutral buffered formalin, bisected and embedded in paraffin. 
Twelve high power fields (HPF) were counted for each organotypic gel and an 
average of these fields were plotted and are represented by one data point. Nine 
gels were analysed from three separate experiments. Alternatively, to quantify 
invasion in the Mini organotypic model in which PS1 cells were treated with FGFR1 
RNAi, total cell number invading per gel was plotted.   
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2.4.4 Chromatin Immunoprecipitation (ChIP) 
PS1 cells were plated onto 15 cm dishes (total ~ 10x106) The next day, chromatin 
was crossed linked by adding using 1/10 volume of freshly-prepared formaldehyde 
Solution (11% formaldehyde Sigma F-8775, 0.1M NaCl, 1mM EDTA, pH 8, 50mM 
HEPES, pH 7.9) to the existing media for 15 minutes at room temperature. To stop 
the fixation 1/20 volume glycine (2.5M, Sigma G-7403) solution was added to the 
existing media in each container and left at room temperature for 5 minutes. Cells 
were scraped, using a rubber policeman, thoroughly from the culture surface and 
centrifuged to pellet the cells. Cells were washed twice using chilled PBS-NP-40 
(0.5%) and centrifuged once more to pellet the cells. Finally, the cells were 
centrifuged a third time, the supernatant was removed completely from the cell 
pellet, and cell pellets were snap frozen on dry ice and stored at –80 C, before being 
shipped to Active Motif (Carlsbad, CA). ChIP reactions were carried out using 30 ug 
of PS1 cell chromatin and anti-FGFR1 antibody from either Abcam (ab10646) or 
Cell Signaling (9740). The ChIP DNAs were processed into a standard Illumina 
ChIP-Seq library and were sequenced on MiSeq to generate >2 million reads. About 
5 million reads per sample were aligned to the human genome (hg19), and after 
removal of duplicate reads, 2.4 and 1.4 million alignments were obtained for the 
Abcam and Cell Signaling sample..  
 
2.4.5 Western blotting 
2.4.5.1 Isolation of protein 
Two methods were used to isolate protein from cell lines. To determine protein 
concentration of cell lysates, cells were grown to 80% confluency, washed with ice 
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cold PBS and lysed on ice with RIPA lysis buffer (Upstate 20-188) with freshly 
added protease inhibitor (Calbiochem 539131) and phosphatase inhibitor cocktails 
(Calbiochem 524625) at a dilution of 1:100. Cells were collected in a 1.5 ml 
Eppendorf, by scraping with a rubber policeman, and left for 20 minutes on ice with 
agitation (vortexing) every 10 minutes. Cell debris was collected by centrifugation of 
the lysates at 20,000 x g for 15 minutes at 40C. Protein concentration was 
determined with a Bio-Rad DC protein Assay (Bio-Rad Laboratories) according to 
the manufacturer’s instructions. Following determination of protein concentration, 
sample buffer (4X, Invitrogen, NP0007) was added to the lysate in order to prevent 
protein degradation and, if lysates were not to be used immediately, samples were 
stored at -800C. If the concentration of protein was not required (for example, the 
same cell line was plated at equal densities and subjected to the same treatment, or 
the treatment did not affect cell growth), cells were lysed at room temperature using 
the same amount of sample buffer and homogenised briefly by sonication.  
 
2.4.5.2 Western blot analysis 
Cell lysates were boiled at 1000C for 5 minutes to denature proteins before brief 
centrifugation to collect contents. Equal amounts of denatured protein (15-25 g) 
were loaded onto 4-12% NuPage Bis-Tris pre-cast gels (Invitrogen NP0335 or 
NP0336) and transferred to nitrocellulose membrane (GE Healthcare, PA1000). 
Transfer efficiency and protein loading was confirmed using Ponceau S (Sigma, 
P7170), a negative stain, which binds to the positively charged amino groups of 
protein on the nitrocellulose membrane. Membranes were then washed with PBS 
and non-specific binding was blocked by incubation with 5% milk, followed by 
incubation with primary antibody in 3% BSA/TBS at 40C overnight. Membranes were 
washed with 0.1% Tween20-TBS and subsequently incubated with secondary HRP-
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conjugated antibody for one hour at room temperature. Specific protein bands were 
visualised using an Amersham ECL Western Blotting Detection Kit (GE Healthcare, 
RPN2106) and photographic film (Fujifilm, 100NIF). 
 
Concentrated supernatant samples, collected from cells seeded at equal densities, 
were diluted in sample buffer, boiled at 1000C and treated as described above. 
Equal loading was determined by staining the membranes with Ponceau S before 
blocking with milk and addition of primary antibody.  
 
2.4.5.3 Stripping membranes 
Membranes were stripped using Reblot plus mild (Millipore 2502) for 10 minutes, 
washed with PBS and blocked with 5% milk/TBS before reprobing with primary 
antibody as above.  
 
2.4.5.4 Densitometry and analysis 
For Western blotting, densitometric analysis of specific bands was carried out using 
Image J software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda,   Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2005.) to obtain a semi-
quantitative measurement of the level of total protein, band densities were 
normalised to the loading control housekeeping proteins (Actin, HSC70 or Tubulin) 
on the same membrane. 
 
2.4.6  Nuclear fractionation.  
For cell fractionation, PS1 or COLO-357 cells were plated on 10 cm plates (Corning, 
430167) and experiments were performed according to manufacturer’s instructions 
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(Nuclear Extraction kit, Imgenex, 10081K). Sample buffer (4X, Invitrogen, NP0007) 
was added to the lysates and treated as above (Section 2.4.5.2). The fraction purity 
was confirmed (Lamin A/C and Tubulin antibodies for the nuclear and cytoplasmic 
fractions, respectively) 
 
2.5 Immunofluorescence 
2.5.1 Patient samples 
Ethically approved human PDAC samples were arranged in tissue micro-arrays as 
described before 169, 203. 
 
2.5.2 Cells cultured on coverslips 
Cells were seeded onto 13 mm diameter coverslips in a 12 well or 6 well plate 
(plating onto a 6 well plate allowed for isolation of protein at the same time so as to 
treat all cells equally) as a monoculture at a density dependent on planned time of 
fixation. For fixation the following day, 3 x 105 cells were plated onto 6 well plates, 
whereas for cells plated onto coverslips in a 12 well plate they were seeded at 1x105 
per well.  
 
For immunofluorescence, cells were fixed with 4% formaldehyde, permeablised with 
0.1% saponin/PBS, blocked with 6% BSA and incubated for one hour at room 
temperature with primary antibody followed by appropriate fluorescently labelled 
secondary antibody. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, 
Invitrogen, P36931). Negative controls were incubated with isotype specific 
immunogloblins at the same concentration as the primary antibody used.  
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2.5.3 Paraffin Embedded gels and patient tissue 
For immunofluorescent staining of paraffin embedded gels and patient tissue, 4 M 
sections were dewaxed and rehydrated. Unless stated, antigens were retrieved by 
boiling sections in 10mM citrate buffer (pH 6.0) for 20 minutes. Sections were 
blocked with 6% BSA/PBS and incubated with primary antibody overnight at 40C, 
washed in PBS and incubated for one hour at room temperature with the 
appropriate secondary antibody. Sections were washed in PBS and then Nuclei 
were stained with 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen, P36931). 
Negative controls were incubated with isotype specific immunoglobulins at the same 
concentration as the primary antibody used.  
 
2.5.4 Co-localisation 
Double-stained images were taken using a confocal laser scanning microscope 
(Zeiss LSM 710, Carl Zeiss, Germany) and thresholds for each channel of interest 
were set to correct for background fluorescence. Co-localisation of two proteins 
appeared as white pixels. Nuclear FGFR1 and FGF2 co-localisation in PDAC tissue 
microarrays (TMAs) was quantified by counting the total number of stromal 
fibroblasts and cancer cells per field, and then assessing the percentage of those 
cells that showed co-localisation of FGFR1, FGF2 and DAPI (white pixels) with 
constant pre-set thresholds. For patients in whom both FGFR1 and FGF2 were 
scored (36 patients) correlation between the presence of FGF2 and FGFR1 in the 
nuclei of stromal fibroblasts was assessed. The same technique was used for in 
vitro cellular co-localisation of FGFR1 and FGF2.  
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Figure 2. 2 Schematic model of a raised air liquid and Mini-organotypic culture 
model. 
 A. Submerged ECM gels were raised onto a metal grid coated with a nylon membrane and 
fed from below with medium containing either PD 173074 (2 μM) or DMSO vehicle control. 
PS1 cells were admixed with cancer cells in a 2:1 ratio and cultured on top of the ECM. 
Cultures were harvested at day 14. B. Schematic model of Mini-organotypic culture model. 
Transwell inserts (0.4 μm) were coated with Matrigel and Collagen. Cancer cells (COLO-
357) were admixed with primary PSCs or PS1 cells (treated with FGFR1 or scrambed RNAi) 
in a 1:2 ratio and cultured on top of the ECM. Cultures were fed from below with DMEM 
(10% FBS) or DMEM (10% FBS) supplemented with either PD 173074 (2 μM) or DMSO 
vehicle control. Cultures were harvested at day 7.  
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2.6 Statistical analysis 
 
All quantitative data are presented with respective statistical tests dependent on 
normality of distribution and significance was defined as p<0.05, as analysed in 
prism v 5.03 (Graphpad, USA). Unless otherwise stated, all experiments were 
performed independently a minimum of three times. 
 
2.6.1 Functional assays and western blot 
For normally distributed data, groups were compared using two tailed Student’s t- 
test. Significance was defined as p<0.05. 
 
2.6.2 Immunofluorescence 
For all experiments where pixel intensity was analysed, 3 separate experiments 
were carried out and at least four random fields were analysed (~10 cells per field 
for PS1 and ~ 30 for cancer cells). Total FGF2, nuclear FGF2 and FGFR1 levels 
were quantified with Image J software. Images were taken at x630 magnification 
and the area of red or green stain within the region of interest was determined. Initial 
thresholds were set and kept constant for all images analysed. Data were compared 
and analysed using two tailed Students t-test or ANOVA (Kruskal Wallis with Dunn’s 
multiple comparison test) and significance was defined by p<0.05. Multiple fields (at 
least 3) were taken per experiment and the total cells per field were analysed. An 
average of total, nuclear FGFR or FGF2 per field was plotted. All experiments were 
performed on three separate occasions. The total number of cells analysed is 
recorded in each figure.  
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To analyse the percentage of cells with nuclear FGFR1 and FGF2 in organotypic 
sections, multiple fields per gel were analysed. The average percentage of PS1 cells 
across these fields with nuclear FGFR1 or FGF2 were plotted and are shown by 
each graphical data point. Nine gels were analysed in total from three separate 
experiments. In order to analyse the percentage of nuclear FGFR1 and FGF2 
positive fibroblasts at the invasive front or centre of the tumour in tissue sections, 
several fields per section per patient (four patients) were analysed. Each data point 
is representative of one HPF. The total number of fibroblasts analysed for all the 
patients is recorded in the figure.  
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CHAPTER III  RESULTS - PART I 
Analysing the expression and localisation of FGFR1 and FGF2 in human 
pancreatic ductal adenocarcinoma.  
 
3.1 Introduction  
 
 Many critical embryonic signal transduction pathways, quiescent in the adult 
pancreas, are re-activated during PDAC progression. One such pathway is the FGF 
family, members of which are deregulated in pancreatic cancer. FGFs and their 
receptors drive a number of important developmental signalling pathways, so it is 
not surprising that cancer cells may hijack this pathway. Indeed, the link between 
aberrant FGFR signalling and tumorigenesis is striking. There is now evidence from 
multiple cancer types that suggests FGF signalling acts in an oncogenic context, 
driving proliferation, survival, migration, invasion and angiogenesis204. Indeed, the 
importance of FGF signalling in tumour pathogenesis was highlighted by a screen of 
more than 1000 somatic mutations found in the coding exons of 518 protein kinase 
genes from over 200 different cancers. Of the non-synonymous mutations, FGF 
signalling was one of the most commonly mutated pathways205 .  
 
Activating mutations in FGFR3 have been identified in over 50% of bladder cancers, 
as well as cervical cancers, multiple myeloma, prostate cancer and spermatocytic 
seminomas206. Mutations in FGFR2 have also been described in a small proportion 
of endometrial carcinomas, which are highly sensitive to FGFR kinase inhibitors, 
suggesting FGFR2 oncogenic addiction207. FGFR2 is amplified in around 10% of 
gastric cancers while FGFR1 amplification is commonly associated with oestrogen 
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positive breast cancer208  and to a lesser extent in oral squamous carcinoma, 
ovarian carcinoma, bladder cancer and rhabodomyosarcoma209-211. Indeed, 
amplifications of FGFR1, reported in >10 % of breast cancer patients, are 
associated with a poorer outcome212, 213. In particular, amplification and subsequent 
overexpression of FGFR1 contributes to poor prognosis in luminal-type breast 
cancers, providing a mechanism for resistance to endocrine therapy214. Furthermore 
FGFR1 amplification is the strongest independent predictor of poor outcome in 
patients with ER-positive tumours213. 
 
 FGFs are up regulated in approximately 60% of all PDAC samples. Previous 
studies have demonstrated that human PDACs express increased levels of FGF2 
and its receptor FGFR1 as compared to normal human pancreatic tissues, using 
immunohistochemical staining, northern blotting and in situ hybridisation. Other 
studies have correlated the degree of FGF2 expression with advanced tumor stage 
and shorter patient survival at the time of diagnosis77. PDAC cells express high 
levels of the mesenchymal FGFR1 c isoform, which signals through the MAP- and 
Jun-kinase pathways to affect changes in cell proliferation, adhesion, and/or 
motility182.  However, further studies are required to fully understand how FGF 
ligands, which activate different receptor isoforms on cancer cells, are orchestrated 
to induce a malignant phenotype in pancreatic cancer. Despite this, results suggest 
FGF signalling is an important mediator of PDAC and may contribute to the intense 
desmoplasia, as elevated levels of FGF2 are associated with this phenotype in 
primary tumours215. However, despite many studies, the mechanism by which FGFR 
signalling might control metastatic cell behavior and contribute to cancer 
progression in PDAC is far from clear. Initial experiments exploring FGF2 
expression in PDAC described FGF2 as being apparent in the nuclei of many 
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cancer cells but not in normal pancreatic tissue, suggesting intranuclear FGF2 may 
be important in this cancer and that FGF2 may exert differential effects in the milieu 
of the tumour microenvironment185, 216. However, the function of nuclear FGF2 in 
PDAC has not been explored. Thus my first aim was to determine the expression 
and localisation of FGF2 and FGFR1 in human PDAC.  
 
3.1.1  Nuclear FGFR1 and FGF2 in human PDAC   
The availability of in house PDAC tissue microarrays enabled me to analyse 
expression of FGFR1 and FGF2 in a number of PDAC patient samples. Cell-specific 
expression of FGF2 and FGFR1 in human PDAC was assessed by double staining 
(FGF2/cytokeratin, FGFR1/vimentin or FGFR1/αSMA) PDAC tissue microarrays. 
Analysing tissue from 46 patients demonstrated that FGF2 was expressed 
universally in PDAC tissue. In contrast to the cytoplasmic expression of FGF2 in 
cancer cells, many (~35%) myo-fibroblasts (activated PSCs105) expressed nuclear 
FGF2 (Figure 3.1). The confocal cross-hair function is a powerful tool for visualising 
comparison and quantification of colocalisation of across multiple fields (Figure 3.2). 
This method specifically defined colocalisation of FGF2 and DAPI, as depicted by 
white pixels. The same method was also used to quantify colocalisation of FGFR1 
and DAPI. Immunostaining with antibodies to FGFR1 and vimentin (to depict the 
stroma) revealed nuclear and cytoplasmic staining of FGFR1 in ~39% of cancer 
cells and ~37% of myo-fibroblasts (Figure 3.1). The specificity of FGFR1 and FGF2 
staining was shown by the lack of immunoreactivity using matched isotype 
immunoglobulins (Figure 3.1). Furthermore, taking those patients who were 
successfully scored for nuclear FGFR1 and FGF2 (36 patients), I found a positive 
correlation of nuclear FGF2 and FGFR1 in myo-fibroblasts, but not in cancer cells 
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(Figure 3.2). Thus FGFR1 and FGF2 show significant colocalisation in activated 
myofibroblasts but not in tumour cells. 
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Figure 3. 1 FGF2 and FGFR1 localise in the nucleus of activated fibroblasts in 
human PDAC tissues. 
(A) PDAC tissue showed cytokeratin positive (green, arrowhead) epithelial tumour cells with 
cytoplasmic FGF2 (red); however, cytokeratin negative stromal cells with fibroblastic 
morphology (arrow) showed nuclear FGF2 staining (red), demonstrated clearly in the side 
panel. DAPI stains the nuclei. Inset box shows IgG control. (B) FGF2 and DAPI pixel co-
localisation analysis (of 46 patients, 1 TMA core analysed per patient) performed by confocal 
microscopy confirmed the presence of nuclear FGF2 in 35% of stromal cells but not in 
tumour cells. (C) Similarly, FGFR1 (green) was present in the nuclei of fibroblasts, as 
identified by vimentin expression (red, arrow). Vimentin negative cells with epithelial, 
glandular morphology showed cytoplasmic and nuclear FGFR1 (arrow head) as shown in 
side panel consistent with A. Inset box shows IgG control. (D) FGFR1 and DAPI pixel co-
localisation analysis performed (46 patients, 1 TMA core analysed per patient) by confocal 
microscopy, as above, confirmed presence of nuclear FGFR1 in 37% of stromal cells as well 
as 39% of cancer cells. (E) Results in C and D were confirmed by independent co-staining of 
serial sections with SMA (red) and FGFR1 (green). Scale Bar: 20 μm, IgG 100 μm. 
***p<0.001, Mann-Whitney U-test (B,D). Data summary represented by median ± 
interquartile range. 
 
79 
 
 
Figure 3. 2 Nuclear signal co-localisation with confocal microscopy  
(A) Human pancreatic tissues were stained with antibodies to FGF2 (red) and cytokeratin 
(green) and counter-stained with DAPI (blue). Using the confocal cross-hair function is a 
powerful tool for visualising colocalisation of a chosen region or field, the automated method 
computes each channel pixel intensities as well as background intensities. This then leads to 
the defined distribution of all image pixels over the four cross-hair quadrants of the scatter 
plot with the background pixels sorted to the bottom left quadrant. The single channels are 
then displayed in quadrant 1 and 2 and pixels having intensity above the background in both 
channels, i.e co-localised pixels are represented in quadrant 3. The image pixels 
corresponding to quadrants 1, 2 and 3 of the scatter plot are colour coded to allow 
identification of co-localised regions. Thresholds for the crosshair are set and kept constant 
to allow comparison and quantification of colocalisation of across multiple fields. This figure 
demonstrates the specificity of this method in defining colocalisation of FGF2 and DAPI as 
depicted by white pixels. The same method was also used to quantify colocalisation of 
FGFR1 and DAPI (B) Significant correlation was found between the presence of FGF2 and 
FGFR1 in the nuclei of stromal fibroblasts from 36 patients who had been scored for both 
FGFR1 and FGF2, however there was no correlation between percentages of cancer cells 
with nuclear FGF2 and FGFR1 (C). Each data-point represents one patient.  
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3.1.2 Nuclear FGF2 and FGFR1 at the invasive front of human PDAC  
The most predominant activated fibroblasts in PDAC are PSCs, which can promote 
tumour growth and invasion121, 217. Thus it was possible that the fibroblasts in which 
FGFR1 and FGF2 co-localised in the nucleus were activated pancreatic stellate 
cells, and nuclear localisation of FGFR1 and FGF2 may regulate a more invasive 
phenotype. I therefore chose to examine whole sections from human PDAC and 
compared nuclear FGFR1 and FGF2 in fibroblasts at the invasive front of the tumour 
(invasion into tissue such as duodenum, adipose or normal pancreas) to those at 
the centre of the tumour. Independent immunostaining and analysis of FGFR1 and 
FGF2 revealed few fibroblasts with nuclear FGFR1 or FGF2 positivity (  20%) at the 
centre of the tumour. However, upon examination of areas of tumour invasion, there 
were significantly more fibroblasts with both nuclear FGFR1 and FGF2 (  45 to 
50%, respectively) (Figure 3. 3 and Figure 3. 4). This suggests a possible role for 
nuclear FGFR1 and FGF2 in driving PDAC tumour invasion in vivo.  
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Figure 3. 3 Fibroblasts with nuclear FGFR1 and FGF2 are abundant at the invasive front of the tumour 
Fibroblasts (vimentin positive, red) invading adipose tissue (invasive front demarcated in A, C and F) in PDAC sections showed increased nuclear 
FGFR1 (green) relative to those at the centre of the tumour (D) (magnification of boxed areas which represent stromal fibroblasts are shown in Ci, 
Cii, Di  and Dii). Staining of serial sections of the same tumour as in C revealed that a significantly higher number of myo-fibroblasts (αSMA positive, 
green) invading adipose tissue in PDAC sections (F) showed nuclear FGF2 (red), compared to those at the centre of the tumour (G) (magnification 
of boxed areas, which represent stromal fibroblasts, are shown in Fi, Fii, Gi and Gii). Scale Bar: 20 μm. 
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Figure 3. 4 increased proportion of fibroblasts at the invasive front display 
nuclear FGFR1 and FGF2, compared to the centre of the tumour 
Quantification of PDAC patient sections showed that a significantly higher number of 
fibroblasts at the invasive edge of the tumour (invading adipose, normal tissue or duodenum) 
had nuclear FGFR1 (A) and FGF2 (B), compared to those fibroblasts close to the centre of 
the tumour. Each data point represents the percentage of fibroblasts (vimentin or αSMA 
positive) with nuclear FGFR1 or FGF2 per field. Several fields at the invasive front or centre 
of the tumour were quantified per patient. Stromal fibroblasts were analysed in four patients 
(n=4, ~640 fibroblasts at the invasive front and central tumour were counted in total). 
*** P< 0.001. Mann Whitney U-test. Data summary represented by median ± interquartile 
range. 
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3.2 Discussion.  
 
Immunostaining and colocalisation analysis show that both FGF2 and FGFR1 
colocalise to the nucleus exclusively in PSCs in vivo (human PDAC), which 
suggests that this receptor and ligand may play an important role in regulating 
stromal fibroblast behaviour. These findings correlate with earlier studies that report 
intense FGF2 staining in the stromal fibroblasts in PDAC tissue218. Interestingly, in 
these same studies that showed patients with strong stromal FGF2, adjacent tumour 
cells were negative for FGF2. However, the importance of nuclear FGF2 staining in 
the stroma of these tumours has never been explored. The observation that FGFR1 
and FGF2 localise to the nucleus in fibroblasts in PDAC identifies a potential novel 
mechanism by which FGFR1 signalling regulates stromal cell behaviour. 
Furthermore, examination of PDAC sections revealed that a significant percentage 
of myofibroblasts at the invading tumour front displayed nuclear FGFR1 and FGF2, 
compared to myofibroblasts in the central core of the tumour, emphasising the 
possible role of nuclear FGFR1 and FGF2 in driving PDAC tumour invasion.  
 
FGF2 has been implicated in tumour angiogenesis through its ability to stimulate the 
growth of endothelial cells. In addition, FGF2 can stimulate fibroblast and epithelial 
cell growth219, 220. Classically, FGF2 mediates its effect by binding to a cell surface 
FGFR containing an intracellular tyrosine kinase domain221 (to be discussed in 
further detail in section IV), however the presence of the ligand in the nucleus of 
fibroblasts in the stroma of PDAC suggests specific nuclear functions for this 
molecule in addition to its capacity to signal at the cell surface. Given that PDAC 
tumours are hypovascular, the major role of FGF2 is unlikely to play a role in 
stimulating angiogenesis. FGF1, -2, and -3 have all been detected in the cell 
nucleus, where their presence is likely to be important for their function222. 
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Internalisation of FGF1 is essential for stimulation of cell division and a dual mode of 
action has been proposed223. FGF2 nuclear localisation is associated with 
proliferation; proliferating astrocytes show predominantly nuclear FGF2, whereas in 
contact-inhibited astrocytes FGF2 is mainly cytoplasmic224. FGFR-1 and FGFR-4 
have also been detected in the nucleus of human glial cells and  chondrocytes, and 
liver cells, where receptor accumulation appears to coincide with cell proliferation225, 
226. Furthermore, FGFR3 accumulates in the nucleus of human breast cancer cells 
but not normal breast epithelia in vivo, and this may be stimulated by stromally 
released FGF1 in breast cancer tissue227. Thus, nuclear FGFR3 may play an 
important role in the progression of breast cancer. 
 
While the clinical significance of nuclear FGFR1 and FGF2 has not been explored, 
nuclear localisation of RTKs has been implicated in poor prognosis in a variety of 
studies228-231. The EGFR family of RTKs, comprising EGFR (Erb-1/HER-1), ErbB-2 
(HER-2/neu), ErbB-3 (HER-3) and ErbB-4 (HER-4), provides the best studied 
examples of nuclear growth factor receptors that play a role in driving distinct 
biological roles. Nuclear EGFR was first observed in hepatocytes during liver 
regeneration232. In addition, EGFR ligands including EGF and pro-transforming 
growth factor α were also found in the nucleus of proliferating hepatocytes233. In 
response to stimulation, activated EGFR translocates to the nucleus and the C-
terminus of EGFR, containing a proline-rich sequence (typical feature of a 
transactivation domain for transcription factors), interacts with the AT-rich response 
sequence within the promoter of Cyclin D1234. EGFR alone can activate the Cyclin 
D1 promoter, however it interacts with transcription factors including STAT3 to 
activate a number of cancer promoting genes such as iNOS and Twist, STAT5 to 
activate Aurora and E2F1 to regulate B-Myb229, 235, 236. EGFR can interact with 
STAT3 to activate COX 2 expression in glioblastoma cells237. In breast cancer cells, 
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nuclear ErbB-3 transactivates the COX2 gene by interacting with a HER-2 
associated sequence and increasing the expression of COX2 in breast cancer 
cells238.  
 
These in vitro observations have been investigated in clinical practice, and may be 
relevant to the understanding of the role of nuclear FGFR and its ligands in the 
context of PDAC development. Indeed, an increased expression of nuclear ErbB4 
and EGFR correlates with disease progression in breast cancer patients239. Treating 
lung cancer cells with low doses of radiation can stimulate EGFR to go to the 
nucleus and, recently, it has come to light that drug resistance can correlate with an 
increase in nuclear EGFR in non-small cell lung cancer cells240. This observation 
was linked to the EGFR-dependant increases in the transcription of BCRP/ABCG2, 
a gene which encodes a multi drug resistance pump241. Furthermore, studies of 
other growth factors have shown that nuclear accumulation of the full length type 1 
insulin like growth factor 1 receptor (IGF1R) is a predictor of poor prognosis in clear 
cell renal cancer242. The presence of lymph node metastasis in patients with 
hepatocellular carcinoma is associated with a low probability of survival and the 
occurrence of regional lymph node metastasis is a prognostic factor that governs 
choice of therapy for patients243. Recently, Ziang and colleagues have shown that 
nuclear expression of CXC chemokine receptor 4 (CXCR4), a rhodopisin like G 
protein coupled receptor, is a risk factor for developing lymph node metastasis and 
correlates with poor patient outcome in hepatocellular carcinoma244. Thus, it is also 
possible that, in PDAC, the degree of nuclear accumulation of FGFR1 and FGF2 
could be used as a predictor of how a patient may be treated and may warrant 
further investigation in a larger cohort of patient samples. 
 
A hallmark of PDAC is its dense desmoplastic reaction. This desmoplsia is complex, 
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consisting of fibroblasts and proliferating stellate cells, that produce and deposit 
fibronectin and collagens I and III122. In addition, the matrix contains aberrant 
endothelial cells, pericytes, inflammatory cells and macrophages, that secrete 
chemokines and cytokines, many of which are mitogenic towards both fibroblasts 
and stellate cells245. The net result is an unique microenvironment in which 
pancreatic cancer cells thrive and readily invade and metastasise. The abundant 
connective tissue deposition in PDAC is driven by growth factors such as TGF  and 
FGF2 within the microenvironment246. These signals in turn activate autocrine and 
paracrine signalling pathways leading to a tumour growth advantage. Hence the 
tumour stroma is a vital component in the dynamic process promoting tumour 
growth and invasion and thus offers a therapeutic target. Since FGF2, a high affinity 
ligand for FGFR1, is found in abundance in the stroma, it is possible that FGF2 can 
promote nuclear accumulation of FGFR1 and FGF2, thus explaining the staining 
pattern I observed in a significant proportion of stromal fibroblasts.  
 
Another possibility for deregulation of FGF signalling in cancer is a result of 
increased availability of FGFs due to the mobilisation of FGFs from the ECM. 
Growth factors such as FGF2, TGFβ, PDGF and IGF-1 become sequestered in the 
stroma, which acts as a storage site for these factors247. Invading cancer cells 
produce MMPs that can act proteolytically to release growth factors that may be 
sequestered in the ECM95. Moreover, cancer cells also shed glypican 1 and 
syndecan 1, heparan sulfate proteoglycans that can modulate paracrine growth 
factor signalling by facilitating the interaction between growth factor and their 
cognative receptor96, 97. Studies have shown that glypican 1 expression is highly 
upregulated in PDAC stroma and can attenuate the mitogenic response of FGF2248. 
Together, these alterations result in aberrant epithelial mesenchymal interactions 
that promote cell proliferation and invasiveness, enhancing tumour spread and 
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suppressing cancer-directed immune mechanisms247. Thus, the release of growth 
factors and stimulatory cytokines by invading tumour and stromal cells may provide 
one explanation for the increase in nuclear FGFR1 and FGF2 found within 
fibroblasts at the invasive front of PDAC. 
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CHAPTER IV  RESULTS-PART II 
 
Understanding the importance of nuclear FGFR1 and FGF2 in human 
pancreatic stellate cell behaviour, using 2D cell based assays.  
 
4.1 Introduction  
Preliminary results from human PDAC tissue suggest a relationship between 
nuclear FGFR1 and FGF2 in cancer associated myofibroblasts but not within tumour 
cells. Furthermore, nuclear FGFR1 and FGF2 may play a role at the invasive front of 
PDAC. Studies have shown that the vast majority of αSMA positive fibroblasts in 
PDAC represent activated pancreatic stellate cells (PSCs)170, 217. Thus, the next step 
in my studies was to examine the expression and localization of FGFR1 and FGF2 
and understand the functional effects in vitro using immortalised PSCs, together with 
a panel of PDAC cells. Until this point I haven’t discussed in detail the molecular 
biology of FGFRs, therefore in order to interpret the results, I will first consider and 
discuss the current understanding of FGF-FGFR cellular signalling. 
 
4.2 Targeting nuclear FGFR1 and FGF2 and the effect on pancreatic 
stellate cell behaviour  
4.2.1 Background 
The first FGF was discovered as a mitogen for cultured fibroblasts over three 
decades ago249. Since then, 22 mammalian FGFs have been identified, with 
orthologues in many model organisms including Drosophila, Nematode and 
Zebrafish250. The mammalian FGF family comprises 18 secreted FGF ligands, 
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ranging from 17-34 kDa in size, that signal through four high affinity transmembrane 
FGF receptors (FGFRs). A fifth receptor, FGFR5, has no tyrosine kinase activity and 
is thought to negatively regulate signalling by dimerising with FGFRs 1-4 and 
blocking transphosphorylation251. FGFs also bind to heparan sulfate proteoglycans 
(HSPGs), low affinity receptors that do not transmit a biological signal but function 
as accessory molecules252, 253. 
 
4.2.2 FGF isoforms and mechanism of action.  
An unusual feature of FGF2 and FGF3 is that they are produced as multiple 
isoforms due to alternative translation start sites254 255. The various isoforms of FGF2 
have different sub-cellular localisation and functions and thus, can contribute to 
different cellular behaviours. Five FGF2 isoforms (18, 22, 22.5, 24 and 34 kDa) have 
been identified in humans. The various isoforms are generated by alternative 
initiation of translation of FGF2 mRNA256. Although, as with all FGF genes, FGF2 
comprises 3 exons, no splice variants have been detected in mammals. The 18kDa 
FGF2 (termed low molecular weight, LMW) is translated from a conventional Kozak 
AUG start codon257 and consists of 155 amino acids, representing the core 
sequence common to all FGF2 isoforms258. The other isoforms of FGF2 (termed 
high molecular weight, HMW) are initiated by an in frame upstream CUG site259 . 
 
It is generally thought that the HMW forms of FGF2 act within the nucleus and 
contain a nuclear localisation sequence. However, the 18 kDa LMW form of FGF2 
can also travel to the nucleus courtesy of a double arginine motif, Arg116 and 
Arg118, which is able to facilitate nuclear targeting. Mutation of these amino acids 
disrupted localisation of both the LMW and HMW of FGF2260. Furthermore, nuclear 
LMW FGF2 has been shown to stimulate cell growth in low serum concentrations261. 
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However the target genes of LMW and HMW FGF2 in the nucleus may be different 
and, therefore, theoretically capable of eliciting different biological responses262. 
 
Most FGFs are secreted. However, it is still not fully understood why FGF1, FGF2 
and FGF9, which lack leader sequences for secretion, are released from the cell. 
The lack of signal peptide in these ligands implies that they are transported to the 
extracellular space by an alternative mechanism to the classical polypeptide 
secretion pathway, dependent on the ER and Golgi apparatus255. A number of 
hypotheses have been proposed as to how these ligands are released, including 
mechanical damage263. However this theory does not explain why biologically active 
FGF2 is released during development255. It is clear further studies are required to 
fully understand how FGF1, FGF2 and FGF9 are able to exert their extracellular 
actions. 
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4.2.3 FGFR activation  
FGFRs are comprised of an extracellular ligand-binding domain linked to an 
intracellular catalytic protein kinase core, via a single pass transmembrane domain. 
Normally, the extracellular ligand binding domain of the receptor consists of three 
immunoglobulin (Ig) domains (designated D1-3,) a stretch of seven to eight acidic 
residues in the region connecting D1 to D2 (designated the ‘acid box’) and a 
conserved positively charged region, in D2, that binds heparin264 . 
 
A feature unique to the FGFR family of RTKs is the variety of isoforms that are 
generated by alternative splicing of the FGFR mRNAs265. Many splice isforms have 
been described, the principal ones being alternative splicing of the D3 domain of 
FGFR1-3, which determines the sequence of the carboxy-terminal half of the third, 
membrane-proximal, Ig domain and strongly dictates ligand-receptor binding 
specificity250 (Table 4. 1). The first half of the D3 domain is encoded by exon IIIa, 
which is spliced to either exon IIIb or IIIc, both of which splice to the exon encoding 
the transmembrane (TM) region. Other splicing events lead to inclusion or exclusion 
of the most N-terminal Ig loop, which is thought to act in an autoregulatory 
manner266, or generation of a secreted receptor when exon IIIa splices directly to the 
transmembrane region, generating a premature termination codon (Figure 4.1)267.  
 
In general, FGFRb isoforms are expressed on epithelial cells, while FGFRc isoforms 
are restricted to mesenchymal cell types, this being particularly true for FGFR2 and 
FGFR3179. This lineage specific expression of the FGFR ‘b’ and ‘c’ isoforms allows 
establishment of paracrine signalling loops between epithelial and mesenchymal 
tissues during development.  
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Figure 4. 1 Alternative splicing of FGFR. 
Ligand binding specificity is generated by alternative splicing if the Ig III domain. The first half 
of Ig III is encoded by an invariant exon (IIIa), which is spliced to either exon IIIb or IIIc, both 
of which splice to the exon that encodes the transmembrane (TM ) region
250
.  
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Table 4. 1 Specificity of ligand for FGFR isoforms 
FGFR1-3 are alternatively spliced, while FGFR4 is not. This alternative splicing event is 
regulated in a tissue specific manner and dramatically affects ligand binding. For example 
epithelial expressed FGFR2b can be activated by mesenchymal FGF7 and FGF10, however 
these ligands show no activity towards mesenchymally expressed FGFR2c
268. 
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Classically, FGFRs are activated when two FGF molecules (in concert with HSPG) 
bind to the IgII and IgIII extracellular domains, facilitating receptor dimerisation 264. 
The crystal structure of FGF in complex with the ligand binding domain of FGFR has 
given insight into the determinants that govern FGF:FGFR specificity and binding. 
Crystal structures show a 2:2 FGF:FGFR complex in which FGF interacts with IgII 
and IgIII and with the linker that connects these two domains within one receptor. 
This complex is stabilised by a secondary binding site involving interactions between 
FGF and the IgII domain of the second receptor as well as receptor: receptor 
interactions. FGF:FGFR interactions under normal physiological conditions are not 
sufficient to stabilise FGFR dimers. HPSG binding across the two IgII domains and 
adjoining the two FGF molecules is essential for dimerisation of the FGF:FGFR 
complex264, 269.  
 
4.2.4 Downstream signalling 
Ligand induced dimerisation of FGFRs leads to a conformational shift in the receptor 
structure and release of kinase auto-inhibition. This results in a 50-100 fold increase 
in kinase activity of the receptor, resulting in activation through trans-
phosphorylation of several tyrosine residues within the intracellular domain270, 271. 
This phosphorylation increases the receptor kinase activity, generating docking sites 
for downstream signalling molecules and consequent activation of multiple signal 
transduction pathways. FGFR activation leads to phosphorylation of a number of 
intracellular proteins such as FGFR substrate 2 (FRS2) and Phospholipase Cγ 
(PLCγ)272, 273 (Figure 4. 2). Binding of PLCγ at the activated tyrosine at the C 
terminus of the receptor results in hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) into two secondary messengers; diacylglycerol and inositol 1, 
4, 5-triphosphate. This in turn leads to release of intracellular calcium stores and 
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activation of the serine-threonine kinase, protein kinase C (PKC)274. Activated FRS2, 
at the juxtamembrane domain of the receptor, serves as an adaptor molecule for a 
number of signalling complexes that promote activation of RAS/mitogen-activated 
protein kinase (MAPK) and phosphoinositide-3 kinase (PI3 kinase)/Akt signalling 
pathways271 . In addition, src homology 2 domain containing transforming protein B 
(shb), Src kinase, ribosomal S6 protein kinase (RSK), signal transducers and 
activation of transcription (STATs) and Crk have all been shown to be involved in 
transducing FGF mediated signalling275.   
 
The predominant signalling pathway activated downstream of FGFRs in 
development is the MAPK signal transduction pathway276. Although, in most cellular 
contexts, FGFs will induce cellular proliferation and migration, in certain context 
FGFs may induce cell-cycle arrest277. FGF signalling can profoundly affect a number 
of basic cellular processes. How each process is affected varies according to cell 
type and maturation stage, the nature of the ligand, the nature of the receptor, and 
utilisation of distinct signalling pathways, roles of downstream effectors in different 
cell types and differential regulation of gene transcription.  
 
Several mechanisms exist to limit FGFR activation, FRS2 can form an FGFR 
inhibitory complex through the recruitment of Cbl, which leads to proteosomal 
targeted degradation of FGFRs. Similarly, signalling by FGFRs (and other RTKs) 
can induce the transcription and activity of a group of MAPK inhibitors such as 
Sprouty (SPRY), Sprouty related proteins (Spred1,2) MAPK phosphatase/dual 
specificity phosphatase (Mkp/Dusp) family members and ‘similar expression to FGF’ 
(SEF) proteins that modulate receptor signalling at several points in the FGFR 
induced signal transduction cascade278, 279. Similarly, the first Ig domain of the 
 96 
receptor may interact with the ligand binding domain of IgII and IgIII and thus 
interrupt FGF binding to the receptor. This autoinhibition would prevent activation of 
FGFRs by abundant HSPGs in the ECM or cell surface. Thus the extracellular 
domain of the FGFR can have  a role in ither an activation or inhibition of cell growth 
dependent on the context.280. 
 
Alternatively, context-specific FGF signalling can be modulated by activation or 
repression of other signalling pathways. In particular FGFs and Wnts have been 
shown to interact in a variety of developmental systems and, together, elicit cellular 
responses that are distinct from the effects of each individual factor 270. Finally, 
evidence shows that differences in signal potentiation between FGFRs may also 
affect context specific FGF signalling. Although the network of pathways through 
which FGFRs signal are similar, it has been show that signalling through FGFR1 
drives stronger downstream signal activation than through FGFR4 281.  
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 Figure 4. 2 FGFR signalling pathways  
Following ligand binding and receptor dimerisation, the kinase domains undergo trans-
phosphorylation, leading to the docking of adaptor proteins and the activation of four key 
downstream pathways, MAPK, PI3K, signal and transducer and activator of transcription 
(STAT) and phospholipase C  (PLC )
282
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The different FGFRs play an important role in both embryogenesis and the adult 
organism and embryological studies investigating the effects of loss of FGFRs 
demonstrated their importance for organ development, including that of the 
pancreas283. During development, FGFR signalling orchestrates a plethora of 
processes275. FGF signalling is key to mesenchymal-epithelial interaction and 
FGFRs are well known inducers of mesoderm. In particular, endodermal to 
mesenchymal FGF signalling plays an important role in pancreatic development.  
FGF4 serves to delineate the developing pancreatic mesenchyme early in 
development and without this molecular signal to the mesenchyme, the proper 
formation of the endoderm derived pancreas is inhibited34, 35. Later in development, 
FGF4 can induce the mesenchyme to persist, and enhance exocrine differentiation 
of the adjacent epithelium36.  
 
In addition to FGF2 signalling from the notochord, which plays a critical role in 
maintaining dorsal pancreatic development45, 284, FGFs 1, 4, 7 and 10 are all 
expressed by the pancreatic mesenchyme during development and play a vital role 
in pancreatic organogenesis37. Most of these ligands are able to bind to the 
dominant FGFR expressed in the pancreatic epithelium, FGFR2b38. FGFR2b 
appears to be the key receptor for pancreatic development and may be implicated in 
the activation and proliferation of pancreatic progenitor cells40, promoting pancreatic 
epithelial proliferation, without eliciting cellular differentiation37, 40, 41. Mouse embryos 
that lack FGFR2b display altered pancreatic development, due to a lack of early 
proliferation and branching morphogenesis of the pancreas38. Later in development, 
these FGF ligands expressed by the mesenchyme promote cells to differentiate to 
an exocrine lineage and inhibit endocrine progenitor proliferation36, 42.  Finally, FGF 
signalling from the mesenchyme to the epithelium indirectly activates Notch 
signalling. Several studies have shown that Notch signalling is critical for cell fate 
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determination within the pancreas47-49. Mouse models have shown that Notch is 
activated by FGFR2b paracrine signalling, resulting in an increase in expression of 
the Notch effector molecule hairy/enhancer of split (Hes1)35. After the appearance of 
mature pancreatic buds, FGF and Notch signalling reduces and initiation of acinar 
differentiation occurs285. 
 
In addition to the importance of FGF/FGFRs for pancreas development, FGFR 
signalling is important for formation of the nervous system, the limbs, the midbrain 
and the lungs255. FGF signalling also plays an important role in the development of 
the embryonic mammary gland286. In the adult, FGFR signalling regulates tissue 
repair, angiogenesis and inflammation255. Thus, given the role of FGF signalling in 
the developing embryo and the adult, it is not surprising that this pathway is often 
hijacked by many cancer cells including PDAC265. As such several FGFR tyrosine 
kinase inhibitors and FGFR blocking antibodies are under development by 
pharmaceutical companies and are many are in early clinical trials287.  
 
4.2.5 FGF signalling in PDAC  
FGF1, FGF2, FGF5, FGF7 and FGF10 have all been shown to be overexpressed to 
various degrees in PDAC, and over expression of FGF2 has been associated with 
shorter post-operative patient survival77, 179-181, 288, 289. A role for FGF1 and FGF2 
signalling in modulation of epithelial-to-mesenchymal transition (EMT) and motility 
has also been proposed290. One explanation for the over-expression of FGFs in 
PDAC is the frequent expression of other growth factors and cytokines that may 
drive the upregulation of these ligands in PDAC. Indeed, in vitro studies have shown 
that expression of FGF-5 and FGF-7 mRNAs is upregulated in cultured fibroblasts, 
upon stimulation with tumour necrosis factor alpha (TNF- ), EGF and platelet-
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derived growth factor (PDGF), as well as interleukin 1- . PDAC cells also over 
express the ‘c’ variant of fibroblast growth factor receptor 1 (FGFR1) which is 
normally expressed in mesenchymal cells181. 
 
The presence of the ‘c’ isoform of FGFR1 in PDAC cells of epithelial origin raises 
the possibility that malignant transformation in PDAC leads to de-differentiation and 
subsequent aberrant expression of the mesenchymal receptor isoform. Indeed, 
switching from FGFR2b to FGFR2c expression in prostate cancer cells has been 
associated with an increase in invasion, leading to a stromal independent, 
undifferentiated tumour type291. Furthermore, down-regulation of FGFR2b in 
keratinocytes resulted in malignant transformation, whereas re-expression of 
FGFR2b resulted in growth inhibition and induction of differentiation in prostate, 
bladder and human salivary adenocarcinoma cells292-294. Thus, exon-switching from 
b to c isoform in PDAC may be important for driving a more malignant phenotype. In 
addition, PDAC cells have been shown to express the 2-Ig form of FGFR1, while 
normal pancreas predominantely expresses the full-length 3-Ig receptor289. This 
raises the possibility of aberrant FGFR1 splicing in PDAC, with the ductal cells 
overexpressing the 2-Ig isoform. Indeed, overexpression of the 2-Ig splice form of 
FGFR1 occurs in astrocytomas, prostate and breast cancer, whereas the 
corresponding 3-Ig form predominates in normal breast tissue295. Consistent with a 
role for FGF signalling in supporting PDAC growth, a dominant negative FGFR1 
mutant or RNAi to glypican-1 (a membrane heparin sulphate proteoglycan that 
facilitates FGF-FGFR interactions) can inhibit growth of PDAC cell lines in vitro and 
suppress tumourgenic potential in mouse xenografts179, 248, 296, 297.  
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Moreover, FGF 10 signalling through the b isoform of FGFR2 has been shown to 
increase PDAC cell migration and invasion and is associated with increased 
expression of membrane type 1-matrix metalloproteinase (MT1-MMP) and TGFβ1 
mRNA289. However, given that FGF 10 also activates FGFR1b, and that expression 
of this isoform was not explored in this study, it is difficult to conclude that the 
metastatic phenotype of these cells was exclusive to FGFR2b signalling. Further 
studies are required to fully understand how FGF ligands, which activate different 
receptor isoforms on cancer cells, are orchestrated to induce a malignant phenotype 
in PDAC.  
 
4.2.6 Nuclear FGFRs  
As discussed above, FGFs have been shown to have nuclear functions as well as 
their role as secreted glycoproteins. There is now mounting evidence that FGFRs 
can also traffic to the nucleus, where they may carry out their function in a different 
manner to that of the classic RTK signalling pathway298. Following activation at the 
cell surface, both ligand and receptor are internalised and, in some instances, 
FGFR/FGF complexes can be translocated to the nucleus, where they regulate cell 
proliferation (however, the source of nuclear FGFR is still under debate) 128, 129. 
Much of the research that has been carried out on nuclear FGFRs has been focused 
on FGFR1. However, both FGFR2 and FGFR3 have been shown to translocate to 
the nucleus. The role of nuclear FGFR3 is not understood but has been shown in 
the nucleus of malignant and non-malignant epithelial breast tissue227, whereas 
nuclear FGFR2 has been identified in sertoli cell precursors in the testes, where it 
may play a role in regulating sertoli cell differentiation and testis development299.  
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In neuronal cells, nuclear FGFR1 (full length) has been shown to colocalise at 
nuclear speckle-like domains, which correspond to sites of RNA Pol II mediated 
transcription and co-transcriptional pre-mRNA processing, located at the edge and 
centre of the speckles, respectively300 . This suggests that nuclear FGFR1 may play 
a role in regulating gene expression. Indeed, chromatin immunoprecipitation (ChIP) 
studies have shown that nuclear FGFR1, together with CREB binding protein (CBP), 
a common transcriptional co-activator, as well as other DNA binding proteins, is able 
to bind to the promoters of the genes encoding the dopamine synthesis enzyme 
tyrosine hydroxylase (TH) and FGF2, regulating neuronal differentiation and 
proliferation226, 300-308. In addition, our laboratory has recently shown that a cleaved 
intracellular form of FGFR1 localises to the nucleus in metastatic breast cancer 
cells, where the receptor can bind to genes which regulate breast cancer cell 
migration and invasion309. This mechanism provides a novel mechanism in which 
nuclear FGFR1 may regulate breast cancer cell behaviour. Whether nuclear FGFR1 
may play a role in regulating gene transcription in other cell types is yet to be 
determined. Given that FGFR1 and FGF2 localised to the nucleus in SMA positive 
myofibroblasts in PDAC tissue, and corresponded with fibroblasts at the invasive 
front, the question arises whether FGFR1 and FGF2 may regulate stellate cell 
behaviour in PDAC and thus may offer a potential therapeutic target.   
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4.2.7 In vitro FGFR1 and FGF2 expression and localisation in human 
pancreatic cancer cells and stellate cells 
As the first step in elucidating the role of nuclear FGFR1 and FGF2, I investigated 
the localisation and expression of FGFR1 and FGF2 by screening a panel of poorly-
(Figure 4.3) and well-differentiated PDAC cell lines (Figure 4. 4), normal pancreatic 
ductal epithelial cell lines (HPDE310 and DEC-hTERT199) and immortalised (PS1170) 
(Figure 4. 5) and primary stellate cells (Figure 4. 6) (by immunostaining and Western 
blot analysis. FGFR1 immunostaining frequently revealed a low level of plasma 
membrane staining; a result of the technique used to permeabilise the cells. 
Cytoplasmic localisation of FGFR1 has been described previously311. Many well-
differentiated cancer cell lines (Capan-1, Capan-2, CFPAC-1, 818.1) exhibited 
mainly cytoplasmic or peri-nuclear localisation of FGFR1. However, in PS1 and 
some poorly-differentiated cancer cell lines (AsPc-1, MIA PaCa-2, PANC-1, 
PaTu8898S, SUIT-2,), FGFR1 was strongly nuclear and exhibited a specked 
distribution. Western blotting revealed that FGFR1 expression (full length  160 
kDa) was stronger in many of the poorly-differentiated cancer cells lines (Figure 4. 
5) than normal ductal epithelial or well-differentiated PDAC cell lines. The MCF7 
breast cancer cell line was used as a positive control as this cell line has been 
shown previously to express full length FGFR1309. 
 
Immunostaining for FGF2 showed cytoplasmic or peri-nuclear staining in cancer and 
normal ductal epithelial cell lines. In contrast, FGF2 was localised predominantly 
within the nuclei (nucleolar and diffuse nuclear staining) in PS1 cells. Western 
blotting revealed two distinct bands for FGF2, which correspond to HMW ( 24 kDa) 
and LMW ( 18 kDa) forms of the protein. Stellate cells showed strong expression of 
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both HMW and LMW FGF2 isoforms, as did many poorly-differentiated cancer cell 
lines. However, FGF2 expression was weak in many well-differentiated cancer cell 
lines and several lines showed no FGF2 expression (Figure 4. 5, 818.1 and CFPAC-
1 and Capan-2).  
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Figure 4. 3 FGFR1 and FGF2 expression in poorly differentiated pancreatic cancer lines. 
Coverslip-plated cells were stained with antibodies to FGFR1 (green) or FGF2 (red), nuclei were counter stained with DAPI (blue). Poorly- 
diffrentiated (AsPc-1, MIA PaCa-2, PANC-1, PaTu8898S, Hs766T, SUIT-2) pancreatic cancer cell lines showed cytoplasmic or peri-nuclear FGF2 
staining. Most of the poorly-differentiated cells lines showed strong nuclear FGFR1 staining also (arrow) Scale Bar: 20 μm. 
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Figure 4. 4 FGFR1 and FGF2 expression in well differentiated pancreatic cancer lines. 
Coverslip-plated cells were stained with antibodies to FGFR1 (green) or FGF2 (red), nuclei were counter stained with DAPI (blue). well-differentiated 
(B: Capan-1, Capan-2, CFPAC-1, 818.1, COLO-357, PaTu8898T) pancreatic cancer cell lines showed cytoplasmic or peri-nuclear FGF2 staining 
(arrow head). FGFR1 was mainly cytoplasmic but nuclear in PaTu8898T (arrow) and COLO-357 cells. Scale Bar: 20 μm
 107 
 
 
Figure 4. 5 FGFR1 and FGF2 expression in normal ductal and stellate cell lines. 
Coverslip-plated cells were stained with antibodies to FGFR1 (green) or FGF2 (red), nuclei were counter stained with DAPI (blue). FGFR1 and FGF2 
were absent from the nuclei of control normal epithelial cell lines HPDE and DEC-hTERT (A). Stellate cells (PS1, B) showed strong nuclear FGF2 
and FGFR1 (yellow arrow head). Immunoblot analyses  (C) were performed with lysates from poorly- and well-differentiated, normal ductal epithelial 
(HPDE and DEC-hTERT), pancreatic stellate (PS1) cell lines. MCF-7 breast cancer cell line was used as a positive control. Tubulin was used as a 
loading control. Pancreatic cancer cell lines showed moderate expression of high molecular weight (HMW, 24 kDa) and low molecular weight (LMW, 
18 kDa) forms of FGF2, however the majority of well-differentiated cell lines showed no expression of either isoform of FGF2. Weak expression of 
FGF2 was detected in control cell lines HPDE and DEC-hTERT. PS1 cells showed strong expression of both HMW (24 kDa) and LMW (18 kDa) 
forms of FGF2. Whilst FGFR1 expression was weak in normal epithelial cell lines, its expression appeared higher in many poorly-differentiated cell 
lines. Scale Bar: 20 μm. 
 108 
4.2.8 FGF2 and FGFR1 colocalise in the nucleus of pancreatic stellate 
cells 
The observed pattern of immunostaining in PSCs could be due to peri-nuclear, 
nuclear membrane or intranuclear staining. Therefore, I used confocal z-stack 
analysis to distinguish between these locations. Analysis of FGFR1 and FGF2 in 
PS1 cells revealed that FGF2 staining was only observed in those stellate cells in 
which FGFR1 was nuclear, and co-localised at distinct speckles within the nuclear 
interior (Figure 4.7, shown in yellow). Nuclear FGFR1 and FGF2 co-localised in 
around 40% of stellate cells, which was a similar distribution to myofibroblasts found 
in PDAC tissue (Figure 3. 1). I was able to confirm this observation by isolating 
cancer associated primary pancreatic stellate cells (in an ethically approved manner 
LREC 07/H0707/87) using the outgrowth method200 . Immunostaining for FGFR1 
and FGF2 in primary stellate cells confirmed the nuclear localisation of FGF2 and 
FGFR1, which I observed in the PS1 cell line (Figure 4. 6) 
 
FGF2 is a potent mitogen often secreted by many cell types255. Immunostaining of 
sections from PDAC has shown that increased expression of cytokines such as IGF 
and FGF2 maybe secreted by mesenchymal cells77, 312. FGF2 secreted by 
fibroblasts can induce proliferation and transformation of epithelia at the tumour-
stroma interface246. Furthermore, FGF2 can activate stellate cells and this activation 
can be inhibited by the presence of neutralising antibodies against FGF2122. To 
asses if the PS1 cell line was capable of secreting FGF2, I performed Western blot 
analysis for FGF2 expression using conditioned media taken from PS1 and PDAC 
cancer cell lines, MiaPaCa2 and COLO-357 (poorly- and well-differentiated PDAC 
cancer cell lines, respectively, both of which express FGF2). Stellate cells, but not 
cancer cells, secreted both HMW and LMW FGF2 (Figure 4.7). Given the close 
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proximity of stellate cells to cancer cells in vivo, this may be one way in which 
stellate cells can induce cancer cell activation in a paracrine fashion. Similarly, 
FGF2 secreted by stellate cells may lead to auto-activation via an autocrine loop.  
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Figure 4. 6 FGFR1 and FGF2 expression in primary pancreatic stellate cells. 
Pancreatic stellate cells (PSCs) isolated from resected human cancer specimens (Methods) 
were characterised by expression of SMA, GFAP, desmin and vimentin markers (A). (B) 
Primary pancreatic stellate cells (PSC1, HPSC, FS1) as well as a pancreatic stellate cell line 
(RLT-PSC) demonstrated speckled nuclear localisation of FGFR1 (arrow) as well as diffuse 
nuclear FGF2. Scale Bar: 20 μm. 
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Figure 4. 7 Nuclear FGFR1 and FGF2 colocalise in PSCs 
(A) Pancreatic stellate cells (PS1 cell line) showed punctate, nuclear speckles of FGFR1 
staining (green) and diffuse nuclear FGF2 (red), with colocalisation (yellow, indicated by 
arrow head) confirmed by optical sectioning through the Z-axis (Z-stack) and pixel co-
localisation techniques (50% of PS1 cells). Nuclear FGF2 was apparent only in those cells 
with nuclear FGFR1. (B) Serum-free conditioned media confirmed PS1, but not cancer cells, 
secrete high- and low-molecular weight (HMW 24 kDa and LMW 18 kDa, respectively) forms 
of FGF2. Whole cell lysate (untreated PS1 cells) and serum-free medium were used as 
positive and negative controls respectively. Scale Bar, 20 μm.  
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4.2.9 Relationship between nuclear FGFR1 and FGF2 in pancreatic 
stellate cells. 
The observation that FGFR1 and FGF2 colocalise in the nucleus of stellate cells 
suggests that there may be a reciprocal relationship. In glial cells, FGFR1 and FGF2 
have shown to localise to the nucleus, where the presence of FGFR1 may mediate 
the proliferative effects of FGF2226. Therefore, to assess the relationship between 
nuclear FGF2 and FGFR1 in stellate and cancer cells, PS1, Mia PaCa-2 and COLO-
357 cell lines were subjected to RNAi mediated knock-down of FGF2. Treatment of 
PS1 cells with FGF2 RNAi for 72 hours resulted in an efficient and reproducible 
knock-down of both isoforms of FGF2 protein, as shown by Western blot and also 
by confocal microscopy (Figure 4. 8). Abolition of FGF2 in PS1 cells had a profound 
effect on nuclear FGFR1, as quantified using confocal microscopy (Figure 4. 9).  
 
To confirm the sub-cellular distribution of nuclear FGFR1 and FGF2, I isolated 
nuclear and cytoplasmic fractions. The purity of the nuclear and cytoplasmic 
fractions was confirmed by using markers specific for these sub-cellular 
compartments (Lamin A/C and Tubulin, respectively). Sub-cellular fractionation 
confirmed that FGF2 (HMW and LMW) and full length FGFR1 localised to the 
nucleus in PS1 cells, and that nuclear FGFR1 was dependent on nuclear FGF2 
(Figure 4. 9). In contrast, using confocal microscopy and sub-cellular fractionation, I 
was able to demonstrate that knock-down of FGF2 had no effect on nuclear FGFR1 
in PDAC cells (Figure 4.10). Importantly, I could demonstrate this relationship 
between nuclear FGFR1 and FGF2 in PS1 cells by abolishing FGFR1 and 
observing significant reduction of nuclear FGF2 (Figure 4.11). 
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Figure 4. 8 RNAi mediated knock-down of FGF2 
(A) Cell lines (PS1, MIA PaCa-2 and COLO-357) were transfected with either FGF2 siRNA 
(FGF2) or scrambled non-targeting (Scr) siRNA for 72 hours. FGF2 expression levels were 
analysed by immunoblotting. Tubulin was used as a loading control. (B) The ratio of FGF2 
(HMW, 24kDa and LMW) to Tubulin was determined by densitometric analysis. FGF2 RNAi 
treatment achieved >90% knock-down of FGF2 protein levels in PS1, MIA- PaCa-2 and 
COLO-357 cells. *P< 0.05, **P <0.01, Student’s t-test. Data summary represented by mean 
± SEM. Images are representative of at least three independent experiments. 
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Figure 4. 9 Relationship between nuclear FGFR1 and FGF2 in stellate cells 
(A-C) RNAi mediated knock-down of FGF2 resulted in a significant reduction in nuclear 
FGFR1 in PS1 cells in comparison to scrambled RNAi (Scr), as demonstrated by 
microscopic analysis. (D) Sub-cellular fractionation and subsequent immuno-blotting 
confirmed that FGFR1 expression was dependent upon FGF2. Total lysate was used as a 
positive control. Lamin A/C and tubulin were used as markers of fraction purity and loading 
controls. Scale Bar, 20 μm. ***P<0.001. Student’s t-test. Data summary represented by 
mean ± SEM. For analysis of nuclear FGFR and FGF2, each data point shown represents 
an average of total or nuclear FGFR or FGF2 per field. Several fields were counted per 
experiment. The total number of PS1 cells analysed is recorded in the figure (n). For all data, 
images are representative of three independent experiments. 
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Figure 4. 10 Effect of FGF2 RNAi in PDAC cells 
(A-D) MIA PaCa-2 and COLO-357 cells were treated with FGF2 siRNA for 72 hours and 
stained with antibodies to FGF2 and FGFR1. Treatment with FGF2 siRNA resulted in 
significant reduction in FGF2 expression but no effect was seen on nuclear FGFR1 levels 
Scale Bar: 20 μm. (E) COLO-357 cells were treated with FGF2 RNAi for 72 hours and 
subjected to sub-cellular fractionation. No effect on FGF2 knock-down was seen on nuclear 
FGFR1 expression. *P< 0.05, **P <0.01, Student’s t-test. Data summary represented by 
mean ± SEM. Scale Bar: 20 μm. Images are representative of at least three independent 
experiments. 
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Figure 4. 11 FGFR1 knock-down results in a failure of FGF2 to translocate to 
the nucleus in stellate cells.  
(A) PS1 and COLO-357 cells were transfected with FGFR1 siRNA or scrambled non-
targeting siRNA (Scr) for 72 hours and subsequently immuno-blotted to analyse expression 
levels of FGFR1. The ratio of full length FGFR1 (160 kDa) to HSC70 was determined by 
densitometric analysis. (B-D) FGFR1 RNAi resulted in significant reduction in nuclear FGF2 
compared to scrambled RNAi (Scr) treated PS1 cells. **P<0.01 * P<0.05, Student’s t-test. 
Data summary represented by mean ± SEM. For. For analysis of nuclear FGFR and FGF2 
each data point shown represents an average of total or nuclear FGFR or FGF2 per field. 
Several fields were counted per experiment. The total number of PS1 cells analysed is 
recorded in the figure (n). For all data, images are representative of three independent 
experiments. 
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4.2.10 Effects of blocking FGFR signalling on nuclear FGFR1 and FGF2 
in pancreatic stellate cells. 
In order to test whether nuclear FGFR1 and FGF2 were dependent upon FGFR 
signalling, I treated cells with a well validated chemical inhibitor of FGFR1, PD 
173074. PD 173074 is an ATP competitive inhibitor of the FGFR family, and shows 
1000 fold more selectivity for FGFR1 than other tyrosine kinases such as PDGFR202. 
PD 173074 has been used successfully in vitro and in vivo to block FGFR signalling. 
Pardo and colleagues showed that PD 173074 can inhibit small cell lung cancer 
growth by blocking FGF2 specific FGFR activation313  
 
Preliminary results, to test the effect of different concentrations of PD 173074 
inhibitor (2nM to 2 M) on stellate cells, showed a dose dependent effect on 
inhibiting nuclear FGFR1, with the most significant effect at 2μM (Figure 4. 12). 
Treatment of stellate cells with higher doses of the inhibitor (20 M) resulted in 
substantial toxicity, with only a few viable cells remaining attached to the culture 
plate. Given that treatment with 2 M PD 173074 resulted in the most significant 
effect on nuclear FGFR1 and inhibition of FGFR signalling, and that at this 
concentration PD 173074 is ineffective at inhibiting other RTKs (such as PDGF and 
EGFR202), I chose this concentration for subsequent experiments. Confocal 
microscopy and sub-cellular fractionation showed that treatment with PD 173074 
resulted in a significant reduction in nuclear FGF2 (both LMW and HMW) and 
FGFR1 in PS1 cells (Figure 4. 12). However, no effect on nuclear FGFR1 was seen 
in COLO-357 cells (Figure 4. 12).  
 
To ensure that the PS1 cell line exhibited a standard response to FGF2 stimulation, 
serum-starved stellate cells were stimulated with 100 ng/ml FGF2 in the presence of 
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300 ng/ml heparin in serum-free media for 15, 60, and 120 min. Western blotting, 
using antibodies specific to phosphorylated FRS2 and extracellular signal–regulated 
kinase (ERK), confirmed that stimulation with FGF2 activated the FRS2 ERK 
pathway in PS1 cells (Figure 4. 13). FGF2 treatment triggered rapid FRS2-ERK 
phosphorylation, and this response was blocked by pre-treatment with PD 173074 
(2 µM) for 1 hour. Of note, abolishing FRS2 using RNAi showed a significant effect 
on both nuclear FGFR1 and FGF2, confirming that receptor activation is important 
for nuclear translocation of both receptor and ligand (Figure 4. 13).  
 
To assess whether exogenous FGF2 was able to induce nuclear FGFR1 and FGF2, 
I treated serum starved PS1 cells with recombinant FGF2 (100ng/ml) in the 
presence of 300 ng/ml heparin in serum-free media, over 2 hours. Immunostaining 
revealed that exogenous FGF2 stimulation significantly induced nuclear 
accumulation of both FGFR1 and FGF2 in stellate cells, within 15 minutes of 
treatment (Figure 4. 14). 
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Figure 4. 12 Effect of blocking FGFR signalling on nuclear FGFR1 and FGF2 in 
stellate cells 
(A) Treatment with increasing concentration of PD 173074 (2nm to 2μm) leads to a 
significant reduction in nuclear FGFR1. (B) Quantification following increasing concentrations 
of PD 173074 shows significant reduction of nuclear FGFR1 after 100nM and 2μM PD 
173074 treatment, compared to DMSO control. (C-F) FGFR inhibitor treatment (PD 173074, 
2 μM, 48 hours) resulted in significant reduction in nuclear FGF2 and FGFR1 as compared 
to vehicle control (DMSO). (G-H) COLO-357 cells were treated with PD 173074 for 48 hours 
and stained with antibodies to FGFR1. No effect was seen on nuclear FGFR1. Scale Bar: 20 
μm. *P< 0.05, **P <0.01, ***P<0.001.  Student’s t-test. Data summary represented by mean 
± SEM. Images are representative of at least three independent experiments. 
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Figure 4. 13 FGF2-driven FGFR signalling mediated by FRS2 and MEK/MAPK 
pathway. 
(A) Treatment of PS1 cells with FGF2 led to an increase in pERK and pFRS2 levels within 
15 minutes. Activation of FRS2 and ERK was completely abolished following pre-treatment 
of PS1 cells with PD174074 inhibitor for 1 hour prior to FGF2 stimulation. (B-D) PS1 cells 
were treated with FRS2 RNAi and stained with antibodies to FGFR1 and FGF2. Knock down 
of FRS2 led to a significant reduction in both nuclear FGFR1 and FGF2 (quantified in C and 
D, respectively). (E) Efficient knock-down of FRS2 after 72 hours was confirmed using 
Western blotting. Quantification of densitometry is shown in F. Scale Bar: 20 μm. *P< 0.05, 
**P <0.01, Student’s t-test. Data summary represented by mean ± SEM. Images are 
representative of at least three independent experiments 
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Figure 4. 14 FGFR stimulation induces nuclear FGFR1 and FGF2.  
(A) PS1 cells were serum starved for 12 hours and subsequently stimulated with exogenous 
recombinant FGF2 (100µg/ml) for 2 hours. (B-C) After 15 minutes of stimulation, there was a 
significant increase in both nuclear FGFR1 and FGF2 compared to serum starved cells. 
Scale Bar: 20 μm. ***P<0.001, **P<0.01, Student’s t-test. Data summary represented by 
mean ± SEM. Images are representative of at least three independent experiments 
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4.2.11  FGFR1 localises at nuclear speckles in pancreatic stellate cells.  
Immunostaining for FGFR1 in stellate cells demonstrates a distinct speckled pattern 
within the nucleus. The exact role of nuclear speckles is still controversial, however 
strong evidence suggest that these sights are centres for RNA Pol II-mediated 
transcription as well as co-transcriptional, pre-mRNA processing314. Indeed, in 
rapidly proliferating medullary cells, FGFR1 has been shown to localise to these 
domains, where FGFR1 associated with sites of active transcription and 
hyperphosphorylated RNA Polymerase II300 . Thus, I co-stained stellate cells with 
antibodies to FGFR1 and the spliceosome assembly factor SC-35, a validated 
marker of nuclear speckles315, to investigate if FGFR1 localised to these nuclear 
domains in stellate cells.  
 
As previously described, SC35 antibodies showed characteristic staining of 
speckled sites throughout the nucleus. The speckled sites of staining in the nucleus 
were also highly enriched for FGFR1, resulting in a yellow colour in the co-localised 
regions (Figure 4. 15). This is best demonstrated by an overlap of peaks within the 
nucleus of the confocal profile plot (Figure 4. 15). 
 
4.2.12 Nuclear FGFR1 and FGF2 regulate proliferation of pancreatic 
stellate cells. 
Given that nuclear FGFR1 is a characteristic of rapidly proliferating glioma cells316 
and that I confirmed FGFR1 localised at nuclear speckles in stellate cells, this 
prompted me to investigate the effect of nuclear FGFR1 and FGF2 on proliferation. 
RNAi knock-down of FGF2 or FGFR1 for 72 hours in stellate cells resulted in a 
significant reduction in the number of cells staining positive for the proliferative 
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marker Ki67, as well as a significant reduction in total cell count (Figure 4. 16). 
Furthermore, in agreement with their role in driving proliferation, there was a 
significant correlation between nuclear FGF2 or FGFR1 and stellate cells that were 
positive for FGFR1 Ki67.(Figure 4. 17). Of note, no effect was seen on the 
proliferative index (% Ki67 positive cells or cell count) in cancer cells following FGF2 
or FGFR1 knock-down (Figure 4. 18). This suggests nuclear FGFR1 is not required 
for the proliferative capacity of cancer cells, but together FGFR1 and FGF2 may 
drive cell growth specifically in stellate cells.  
 
Nuclear FGFR1 has been shown to activate expression of a number of genes, 
mediated by extracellular signals and their secondary messengers304, 306, 307. FGF2 
was one of the first genes identified as regulated by FGFR1307. It is possible that 
nuclear FGFR1 may drive proliferation by modulating FGF2 gene expression. Thus, 
I performed FGFR1 knock-down on stellate cells and cancer cells to assess the 
effect on endogenous FGF2 protein levels. Abolition of FGFR1 resulted in a 
significant reduction of FGF2 (HMW) in PSCs, but no effect was observed in cancer 
cells (Figure 4. 16 and Figure 4. 18).  
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Figure 4. 15 FGFR1 localises at nuclear speckles  
(A) FGFR1 (green) co-localised with splicing assembly factor, SC35 (red) at distinct nuclear 
speckles within the nuclei of stellate cells. Pixel intensity analysis confirmed this co-
localisation, with perfect overlap of red and green staining signals within the nucleus (blue). 
(B) This co-localisation was best visualised by the spatial coincidence of discrete peaks of 
green and red fluorescence intensity, given by a confocal profile. By taking a 20 m transect 
across the nucleus (blue line), red and green peaks overlapped, with just a few small green 
peaks that were outside of the nuclear speckles. Co-localisation was determined based on at 
least three independent experiments  
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Figure 4. 16 Stellate cell nuclear FGFR1 is associated with PSC proliferation. 
RNAi-mediated knock-down of FGF2 (A-C) and FGFR1 (D-F) in stellate cells resulted in a 
significant reduction in proliferative index (% Ki67 positive cells, B, E, each data point 
represents percentage of cells positive for Ki67 per field, multiple fields were taken per 
experiment. A total of ~216 PS1 cells were analysed.) and, consequently, total cell count (C, 
F, each data point refers to one technical repeat. Three technical repeats were carried out 
per experiment, each experiment was carried out in triplicate), relative to scrambled RNAi 
control (Scr). (G-H) RNAi-mediated knock-down of FGFR1 in stellate cells resulted in a 
significant reduction in FGF2 expression (HMW form). Scale Bar: 20 μm. ***<P, 0.001, 
**P<0.01, *P< 0.05,. Student’s t-test. Data summary is represented by mean ± SEM. For all 
data, images are representative of three independent experiments. 
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Figure 4. 17 Nuclear FGFR1 and FGF2 correlate with Ki67 positivity in PSCs  
(A) Stellate cells that were Ki67 positive (green) also showed nuclear FGF2 (red). (B) Similarly, all cells that were Ki67 positive (green) showed 
nuclear FGFR1. (C) Graphs show significant correlation between percentage of PS1 cells with nuclear FGF2 and Ki67 as well as percentage of PS1 
cells with nuclear FGFR1 and Ki67. Scale Bar: 20 μm. Data summary represented by mean ± SEM. Images are representative of at least three 
independent experiments 
.
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Figure 4. 18 Cancer cell proliferation following FGF2 and FGFR1 knock-down. 
(A-C) FGF2 RNAi in COLO-357 cells had no effect on proliferative fraction (percentage Ki67 
positive cells: green) or total cell number. (D-F) FGFR1 RNAi in COLO-357 cells had no 
effect on proliferative fraction (percentage Ki67 positive cells: green) or total cell number. (G) 
FGFR1 knock-down had no effect on expression of either HMW (24 kDa) or LMW (18 kDa) 
isoforms of FGF2 compared to Scr RNAi at 72 hours post-transfection in COLO-357 cells. 
Scale Bar: 20 μm.n.s. not significant. Data summary represented by mean ± SEM. Images 
are representative of at least three independent experiments.  
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4.2.13 Effect of PD 173074 treatment on cell cycle in pancreatic stellate 
cells 
Next, I wanted to assess the effect of PD 173074 treatment on stellate cell 
proliferation, since this inhibitor showed a significant effect on nuclear FGFR1 and 
FGF2 translocation. Treatment of stellate cells over five days with PD 173074, 
resulted in a reduced increase in cell number compared to treatment with vehicle 
control (DMSO) within 48 hours and was significantly inhibited by 72 hours of 
treatment (Figure 4. 19). This reduction in cell number increase correlated with a 
significant reduction in stellate proliferative index (percentage of Ki67 positive cells) 
after 48 hours of PD 173074 treatment. These changes in proliferation following 
treatment with PD 173074 were associated with a reduction in the major G1 cyclin, 
cyclin D1, only in stellate cells (accompanied by a significant reduction in 
percentage of cells in G2/M phase and accumulation in the G1 phase of the cell 
cycle (Figure 4. 20). Once more, PD 173074 treatment had no effect on cancer 
cells. Rather, treatment with PD 173074 seemed to lead to a small increase in 
cancer cell growth and proliferation, albeit non-significant (Figure 4. 21). 
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 Figure 4. 19 Blocking FGFR signalling results in a reduction in proliferation of 
PSCs. 
(A-C) Drug-mediated inhibition of FGFR (PD 173074, 2 μM) resulted in a significant 
reduction in proliferative index (Ki67 positive cells, B, each data point represents percentage 
of cells positive for Ki67 per field, multiple fields were taken per experiment. A total of ~216 
cells stellate cells were analysed.) and cell growth (C, each data point refers to one technical 
repeat. Three technical repeats were carried out per experiment) after 5 days treatment 
compared to vehicle (DMSO) treated cells. PD170374 treatment (PD) resulted in significant 
reduction in Cyclin D1 expression. HSC70 was used as a loading control. Scale Bar: 20 μm. 
***<P, 0.001, **P<0.01, Student’s t-test. Data summary is represented by mean ± SEM. For 
all data, images are representative of three independent experiments. 
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Figure 4. 20 Blocking FGFR signalling results in G1 arrest in PSCs 
 
(A) Cell cycle analysis after treatment with PD170374 (PD) for 48 hours revealed a G1 cell 
cycle block in stellate cells compared to vehicle-treated (DMSO) cells. Representative cell 
cycle data after propidium iodide staining and analysis by FACS (B), are shown. Cell cycle 
data are representative of two independent experiments.  
 
 
 131 
 
 
 
Figure 4. 21 Inhibition of FGFR signalling has no effect on proliferation in 
cancer cells 
(A-C) Chemical inhibition of FGFR1 signalling (PD 173074, 2 μM) in COLO-357 cells had no 
effect on proliferative fraction (percentage Ki67 positive cells: green) or cell growth after 5 
days treatment compared to vehicle (DMSO) treated cells. (D) FGFR chemical inhibition (PD 
173074, 2 μm, 48 hours), had no effect on Cyclin D1 expression in COLO-357 cells 
compared to vehicle control. Scale Bar: 20 μm. n.s. not significant. Data summary 
represented by mean ± SEM. Images are representative of at least three independent 
experiments.  
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4.3 Discussion  
4.3.1 FGFR1 and FGF2 nuclear localisation in pancreatic stellate cells  
The link between aberrant FGFR signalling and tumourigenesis is clear282. However, 
much of the work on the functional effect of FGFR signalling in PDAC has come 
from in vitro studies or xenograft models focusing solely on pancreatic cancer cells, 
despite the stroma representing up to 90% of the tumour volume in this cancer88 188, 
297. The pathophysiological mechanisms of tumour stromal progression and 
therapeutic resistance are still not well understood inPDAC. Previously I have shown 
that both FGF2 and FGFR1 co-localise to the nucleus exclusively in cancer-
associated myofibroblasts in vivo (human PDAC), which is associated with tumour 
invasion. Dissecting the role of intracrine FGFR1 and FGF2 signalling in PDAC has 
been facilitated by the isolation and creation of PSC cell lines124, 169, 199, 317 as well as 
having access to a panel of PDAC cells. Pancreatic stellate cells are thought to 
serve as key drivers in the pathobiology of PDAC stroma, where they switch from a 
quiescent to myo-fibroblastic state186, 217, 317. 
 
Confocal analysis revealed co-localisation of FGFR1 and FGF2 within the nucleus, 
with staining confined to distinct speckles306, 318. Despite observing nuclear FGFR1 
in many cancer cell lines, FGF2 remained predominantly cytoplasmic. Several 
experiments that I have carried out support the validity of my nuclear FGFR1 and 
FGF2 data. Firstly, I have used immunostaining combined with confocal microscopy 
and talking multiple Z-stacking to show that the nuclear interior contained FGFR1 
and FGF2. Secondly, using sub-cellular fractionation, I confirmed that full length 
FGFR1 (  160 kDa) and both HMW and LMW FGF2 localised inside the nucleus of 
stellate cells. This was consistent with other results, which suggest that the full 
length receptor can localise to the nucleus300. Thirdly, efficient and reproducible 
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FGFR1 and FGF2 RNAi were able to abolish reciprocal nuclear FGF2 and FGFR1 
localisation as shown by confocal microscopy and Western blot analysis. These 
observations have been supported by other studies that have shown nuclear 
FGFR1, with an array of different antibodies and with antibodies with different tags, 
when recombinant FGFR1 was examined303, 306, 309, 316. Finally, translocation of 
FGFR1 through the nuclear membrane and subsequent nuclear accumulation has 
also been demonstrated by immuno-electron microscopy303. Thus the nuclear 
interior is a major sub-cellular site of functional FGFR1 and FGF2. The observation 
that FGFR1 and FGF2 colocalise in stellate cells confirms my previous observations 
in PDAC samples and suggests this relationship may be specific to stellate cell 
behaviour.  
 
The speckled distribution of FGFR1 within the nucleus appeared strikingly similar to 
that observed with splicing factors. It is well documented that that splicing factors 
are enriched in regions of the nucleus that have been described as nuclear 
speckles, based on their staining pattern319, 320 . Several non-essential and essential 
splicing factors are targeted to these domains, including those that belong to the SR 
repeat containing family of proteins321. In double labeling experiments, I found a very 
high overlap (>90%) between sites of FGFR1 and the splicing factor SC35 at these 
speckled domains. In addition to their presumptive role as mRNA processing sites, 
several studies have established a relationship between speckled domains and sites 
of transcription322-324.   
 
In addition to storage compartments for splicing factors, several studies have 
documented the association of actively transcribed genes at the periphery and 
within nuclear speckles. RNA polymerase II and newly synthesized transcripts, 
labeled with BrUTP, have also been observed at these domains325 . Furthermore, in 
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rapidly proliferating medulloblastoma human cells, FGFR1 localised to nuclear 
speckles and associated with sites of pol II transcription but not to sites of DNA 
replication300. This suggests that sites of transcription, but not replication, associate 
with nuclear speckles. Although there was near perfect overlap between FGFR1 and 
nuclear speckles, I did observe a small proportion of FGFR1 located outside the 
speckled domains. Nuclear speckles have been proposed as storage sites, which 
could represent sites in which splicing factors and transcription factors are 
concentrated in large nuclear domains, before being recruited to areas of active 
transcription321. However, FGFR1 localises together with RNA polII at speckled 
domain at similar levels to smaller non-speckled sites suggesting transcription and 
RNA processing occur concurrently at both nuclear speckles and non-speckled 
domains300. Thus, it is possible that nuclear speckles in stellate cells may function as 
at least one of the compartments where transcription may occur via FGFR1 
mediated events. 
 
4.3.2 Relationship between nuclear FGFR1 and FGF2 
The observation that FGF2 and FGFR1 colocalise in the nucleus of stellate cells, but 
not cancer cells, suggests there may be a specific relationship between the receptor 
and ligand, which is not apparent in cancer cells. Indeed, studies have shown that 
FGFR1 translocates with intracellular FGF2 following cell stimulation318. Once in the 
nucleus, FGFR1 has been shown to activate a number of genes306, 307, 318. Moreover, 
enhancement of FGFR1 promoter activation is observed after co-transfection of 
HMW FGF2306. Nuclear accumulation of FGFR1 and FGF2 has been observed in 
developing brain, neurons, astrocytes, adrenal medullary cells and fibroblasts304. 
There could be several possible plausible mechanisms for the relationship between 
nuclear FGFR1 and FGF2 in stellate cells. Firstly, it is possible that nuclear FGFR1 
and FGF2 may be internalised as a functional unit and translocate to the nucleus 
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where they could modulate gene expression. This scenario is possible for FGFR1 
and its ligand, as studies have shown that internalised ligand/receptor tyrosine 
kinase complexes, including EGFR and insulin receptors326, can retain signalling 
capacity. Furthermore recent studies by Lin and colleagues showed that crosslinking 
EGF to EGFR on the cell surface of MDA-MB-468 cells, the ligand receptor complex 
was found in nuclear extract, and EGFR and EGF formed complexes with chromatin 
to modulate gene expression234.  
 
Secondly, it is possible that cytoplasmic FGF2 may control intranuclear FGFR1 
mobility and association with active chromatin sites. Studies by Dunham-Ems and 
colleagues, using FRAP analysis of FGFR1, have shown that there are three 
possible nuclear FGFR1 populations; a fast mobile population; a slow mobile 
population, which reflects chromatin bound FGFR1; and an immobile population, 
representing FGFR1 that is bound to the nuclear matrix and association with 
actin327. Two distinct populations of chromatin binding proteins have been described 
328. The fast moving population was proposed to represent freely diffusing proteins 
that undergo rapid non-specific intermolecular collisions, while slower populations 
represent molecules engaging in binding events and become temporarily 
immobolised on target genes. FGFR1 can effectively bind to LMW 18 kDa FGF2 
(found both extracellularly as well as N-terminally extended predominately nuclear 
HMW FGF2 (21, 22.5 and 23kDa forms). The same study showed that FGFR1 and 
HMW FGF2, linked to CFP and YFP, respectively, interact as shown by FRAP327. 
Furthermore, HMW FGF2 can decrease the mobility of nuclear FGFR1, following 
stimulation, to facilitate the interaction of the receptor with gene promoters and other 
nuclear proteins, such as CBP, thus facilitating transcription329. Both scenarios may 
be possible, as I have observed HMW and LMW FGF2 in the nucleus of stellate 
cells. Whether these isoforms correspond to newly synthesised FGF2 or internalised 
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ligand is yet to be determined. Either hypothesis requires an interaction between 
FGFR1 and FGF2 and could explain the reciprocal relationship I have seen in 
stellate cells. The concept that nuclear FGFR1 and FGF2 may have a functional 
relationship exclusively in stellate cells was strengthened by the observation that, 
upon FGF2 abolishment, FGFR1 failed to translocate to the nucleus. However, no 
effect was observed on nuclear FGFR1 in cancer cells, which do not show nuclear 
FGF2.  
 
In addition to FGF2 co-localising with FGFR1 in the nucleus, I also observed FGF2 
in the nucleolus, a major site of ribosomal synthesis. FGF2 localisation to the 
nucleolus was first identified in adult bovine aortic cells, suggesting a role in driving 
quiescent cells into a proliferative state330. Nuclear localisation of FGF2 in these 
studies correlated with transcription of ribosomal genes, during transition from G0 to 
G1 phase of the cell cycle, and increased expression of the major non-histone 
nucleolar protein, nucleolin, which has a key role in ribosomal transcription258. FGF2 
also had a direct effect on the enhancement of RNA polymerase I activity in nuclear 
extracts isolated from quiescent cells, implying a mitogenic role for nuclear FGF2224, 
306, 331. Therefore, it is possible FGF2 (possibly LMW FGF2 that is not targeted for 
secretion) may be present in different nuclear functional domains to FGFR1, or 
alternatively may bind to and engage with proteins that may prevent its interaction 
with the receptor. Thus the nuclear localisation of FGF2 within distinct regions of the 
nucleus of stellate cells may be driving distinct biological effects in concert with, or 
without FGFR1.  
 
4.3.3 Abolishing FGFR signalling and its effect on nuclear FGFR1 and 
FGF2 in pancreatic stellate cells  
Upon ligand binding, FGFRs are known to activate several downstream signalling 
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cascades, with the MAPK pathway the predominant pathway250. To assess whether 
stellate cells responded accordingly to receptor activation, I stimulated serum-
starved cells with FGF2, which activated the FRS2-MAPK signalling pathway rapidly 
upon stimulation. This pathway was abrogated by pre-treatment with a specific 
inhibitor for FGFR (PD 173074202), suggesting that FGF2 specific stimulation, via 
FGFR, is a strong inducer of MAPK signalling in stellate cells. Having confirmed that 
FGFR signalling was eliciting the anticipated functional effects in stellate cells, I 
focused specifically on FGFR1, investigating the sub-cellular trafficking of the 
receptor after ligand binding. Since the first demonstration that exogenous FGF2 
can induce nuclear FGFR1 in fibroblasts305, there have been conflicting reports as to 
the ability of FGF ligand to elicit nuclear FGFR1 accumulation in various cell types. 
Other studies have reported that nuclear FGFR1 is stimulated by other factors, such 
as angiotensin II stimulation, cell depolarization, and protein kinase C, but not 
exogenous FGF stimulation, in various neuronal cell types332.  
 
However, using recombinant FGF2 as a known ligand of FGFR1268 , I observed 
dramatic localisation of both FGFR1 and FGF2 to the nucleus, suggesting that 
FGFR activation is important for nuclear FGFR1 and FGF2 trafficking in stellate 
cells. Indeed, abolishing FRS2 in stellate cells had a profound effect on nuclear 
FGFR1 and FGF2. Whether this FGFR signalling occurs at the cell surface, or within 
the cell, remains to be determined. However, other laboratories have also observed 
nuclear accumulation of FGFR1 following FGF stimulation, suggesting that receptor 
activation is required for internalisation and translocation. FGF1, FGF2 and FGF10 
stimulation can induce rapid nuclear accumulation of FGFR1 in MCF7 breast cancer 
cells, and is abolished by pre-treatment with PD 173074 FGFR inhibitor309, 333. 
Furthermore, nuclear localisation of the the EGF receptor in epidermoid carcinoma 
cells is stimulated by incubation with EGF within 60 seconds of treatment234. Given 
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that much of the work that has been carried out on the mechanisms of nuclear 
FGFR1 is in neuronal cells, it is possible that various cell types respond to stimuli in 
a cell type specific manner and that ligand stimulation in stellate cells, as with MCF-
7 and epidermoid carcinoma cells, which are highly sensitive to stimuli, can elicit 
nuclear trafficking of its receptor. Furthermore, FGF2 is secreted by stellate cells but 
not cancer cells. Thus it may fuel an FGFR1 autocrine signalling loop in these cells, 
stimulating nuclear localisation of FGFR1 and FGF2.  
 
4.3.4 Role of nuclear FGFR1 and FGF2 in driving proliferation of 
pancreatic stellate cells 
Nuclear accumulation of FGFR1 accompanies growth of astrocytes and glioma 
cells, neurons, differentiation of neuronal progenitor cells and functional changes in 
adrenal medullary cells, which can be inhibited by transfection of a dominant 
negative nuclear FGFR1 (TK-) mutant (signal peptide replaced by a NLS)306 . 
Silencing FGF2 or FGFR1, or blocking FGFR signalling with PD 173074, in stellate 
cells resulted in significant reduction in cell proliferation. These effects were not 
apparent in PDAC cell lines, which did not display nuclear FGF2, suggesting that 
nuclear FGFR1 and FGF2 may co-activate genes involved in cellular proliferation 
exclusively in PSCs. Indeed transfection of mouse fibroblasts with a construct 
encoding full length FGFR1 with a signal peptide replaced by SV 40 large T antigen 
NLS, resulted in protein localising exclusively to the nucleus and induced expression 
of c-Jun and Cyclin D1 following FGF2 stimulation, compared to transfection of full 
length FGFR1334 . This study suggests FGFR1 stimulation initiates a set of events 
that are followed by translocation of FGFR1 to the nucleus and regulation of gene 
expression. C-Jun is a component of the heterodimeric transcription factor AP-1, 
and is required for cell proliferation335. C-Jun is also active as a homodimer and its 
role in proliferation is mediated by direct activation of the Cyclin D1 promoter336 . 
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Cyclin D1 is a cell cycle regulator essential for G1 progression, and its 
overexpression has been shown to shorten G1 and accelerate proliferation234. 
Consistent with this, blocking nuclear FGFR1 and FGF2 in PSCs, using PD 173074, 
correlated with a G1 cell-cycle block and a significant reduction in cyclin D1 
expression. Thus activation of cyclin D1 by nuclear FGFR1 and FGF2 may drive 
entry into the cell cycle, as has been shown in neuronal cells224, 226. Nuclear FGFR1 
has been shown to regulate FGF2 gene expression by activating the FGF2 
promoter307.  
 
Thus, newly synthesized FGF2 in stellate cells could be secreted or could be 
targeted to the nucleus, fuelling an autocrine signalling loop. Indeed, extracellular 
FGF2 has been shown to drive astrocyte proliferation and activates quiescent cells 
from the mature human brain to enter S phase and proliferate224. Furthermore, in 
human astrocytes, extracellular FGF2 can stimulate its own expression and drive 
the synthesis and nuclear accumulation of endogenous FGF2 protein337. I also 
observed a significant reduction in FGF2 expression following FGFR1 knock-down, 
exclusively in PSCs. Thus, modulating FGF2 expression may be another way in 
which nuclear FGFR1 may regulate proliferation in stellate cells.  
 
Of particular note was the observation that, while the cancer cells I used in my 
studies express FGFR1, which localises to the nucleus, I did not see any effect of 
2 M PD 173074 treatment on cell behaviour or nuclear translocation. Furthermore, 
abolishing FGF2 had no effect on nuclear FGFR1, while RNAi to both FGFR1 and 
FGF2 had no effect on cancer cell proliferation. Thus it is possible that nuclear 
FGFR1 is not required to drive proliferation in cancer cells and does not require 
nuclear cooperation of FGF2. Indeed, pancreatic cancer cells inherently harbour a 
plethora of genetic mutations, including mutations in KRAS and P5350 . An activating 
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mutation at codon 12 in KRAS is detected in close to 100% of all PDACs and in 
many early neoplastic lesions63. KRAS is a small GTPase and potent oncogene that 
can regulate a number of cellular functions, including survival, proliferation, and 
differentiation. These diverse activities are driven by KRAS-mediated activation of 
important signalling cascades including the RAF/ERK/MAPK pathway338 . Indeed, 
both cancer cell lines I used in my studies harboured activating KRAS mutations192, 
195, which could override the effects of blocking FGFR signalling and/or nuclear 
FGFR1. This confirms the critical role of nuclear FGFR1-driven proliferation in 
PSCs, and the importance of analysing stromal cell types in further studies of PDAC 
behaviour, a characteristic not often taken into consideration in other studies that 
have tested new drugs solely on cancer cells, demonstrating little or no therapeutic 
effect.  
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4.4 Conclusion  
Blocking nuclear FGFR1 and FGF2, inhibits proliferation in stellate cells, but not 
cancer cells. This offers a target selective for stellate cells, which may possibly lead 
to modulation of cancer cells in vivo. The distinct location of FGFR1 at nuclear 
speckles suggests a role for the receptor as a major regulator of gene expression. 
Blocking nuclear FGFR1 and FGF2 in stellate cells may influence cancer behaviour 
by inhibiting transcription of genes that control stellate cell growth and subsequently 
prevent an environment permissive for cancer cell survival. The results in this 
section come from experiments performed in 2D culture, which does not reflect the 
in vivo situation. Thus, the next step in my studies was to determine the importance 
of nuclear FGFR1 and FGF2 in stellate cells in a 3D model of PDAC. Since this 
model comprises both stellate cells and cancer cells, it allowed me to investigate the 
effects of paracrine cross talk on cell behaviour in a more relevant environment. 
 
These data suggest a specific role for nuclear FGFR1 and FGF2 in driving PSC 
proliferation. In contrast to cancer cells, PSCs are exquisitely sensitive to FGFR 
inhibition, thus opening a new selective therapeutic avenue. The role of tumour-
stroma cross-talk is increasingly recognised to play a role in PDAC progression 81, 
169, 170, 203, 217. Since my observations suggest that targeting the stroma is an 
attractive option for therapy, next I wanted to use a well-validated, pathologically-
relevant PDAC model 170 to specifically assess the interaction of cancer cells and 
stellate cells. This will be discussed in the next chapter.  
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4.5 Future challenges.  
4.5.1 Understanding the mechanism of transcriptional control of 
nuclear FGFR1 
Considering the localisation of FGFR1 and FGF2 in stellate cells at distinct nuclear 
speckles, it is likely that the receptor can transduce diverse extracellular and 
intracellular signals directly to the genome. However, whether FGFR1 is a 
transcriptional regulator in stellate cells is yet to be determined, although these 
results are the first step into elucidating the molecular mechanism of nuclear 
FGFR1. Studies have shown that FGFR1 is a potential transcriptional activator, 
which has been confirmed by chromatin immunoprecipitation experiments246, 307. 
Based on the study of nuclear FGFR1 in neuronal cells, where it has been shown to 
regulate growth and differentiation, a proposed ‘feed forward and gate’ mechanism 
has been generated for the mechanism of nuclear FGFR1 in these cells304. Diverse 
stimuli are able to transmit signals to sequence specific transcription factors via 
classical cytoplasmic nuclear signalling cascades. The nuclear accumulation of 
FGFR1, which is induced by the same stimuli, feeds the signal forward to CRE 
binding protein (CBP) to facilitate activation of CBP regulated gene programs339.  
 
FGF2 was the first gene shown to be regulated by nuclear FGFR1307 . TH, the rate-
limiting enzyme in catecholamine synthesis, has also been shown to be regulated by 
nuclear FGFR1. TH is expressed specifically in catecholamine producing cells. ChIP 
studies have shown that FGFR1, together with CBP, associates within the 
promoters of the TH and FGF2 genes306. NF-L is activated, in a cAMP response 
element (CRE) dependent manner, by nuclear FGFR1318. This was shown in 
differentiating neuronal progenitor cells by transfection of a construct which targeted 
FGFR1 to the nucleus via an NLS. This increased the expression of both 
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endogenous NF-L and a CRE containing NFL gene promoter reporter construct. C-
Jun and Cyclin D1 have also been shown to be regulated by nuclear FGFR1334. The 
promoters of both of these genes contain a CRE element, however it remains to be 
determined which cis elements mediate their regulation by FGFR1. Thus, the 
regulation of NF-L and TH genes provides a mechanism through which nuclear 
FGFR1 may stimulate differentiation of neuronal progenitor cells, while activation of 
c-Jun and Cyclin D1 may mediate nuclear FGFR1 specific proliferation, as observed 
in rapidly proliferating glial cells224, 226, 318.  
 
Since previous studies that suggest nuclear FGFR1 may associate with gene 
promoters, and given the speckled localisation of FGFR1 in stellate cells, I 
performed chromatin immunoprecipitation sequencing (ChIP-seq) experiments to 
identify the genomic regions with which FGFR1 may associate. This set of 
experiments has proved challenging, given the relative lack of knowledge regarding 
FGFR1 as a transcriptional regulator, and with much of what is known about nuclear 
FGFR1 being specific to neuronal cell gene regulation. Moreover, results obtained 
from ChIP-seq experiments, using Illumina ChIP-Seq (Mi-Seq), show that the 
FGFR1 ChIP-seq data look almost identical to the Input control (negative control), 
with no enrichment for ChIP reactions that were carried out using anti-FGFR1 
antibodies (Appendix). This raises two possibilities, either the antibodies used were 
not robust enough for ChIP-seq experiments and did not successfully pull down 
FGFR1 associated chromatin, or the role of the receptor in the nucleus may not be 
to directly associate with chromatin but may be to function in another manner to 
regulate cell behaviour (possibly as a scaffold to phosphorylate other protein on the 
nucleus). However, given the literature and accumulating evidence from other 
studies on the functional role of RTKs in regulating gene expression, I am optimistic 
that nuclear FGFR1 plays a similar role in stellate cells. Thus I am currently 
 144 
screening a panel of FGFR1 antibodies to identify a candidate that may be taken 
forward as a robust antibody for future ChIP experiments. Furthermore, identifying 
other nuclear binding proteins in stellate cells that may interact with FGFR1 may 
also shed light onto the functional role of nuclear FGFR1 and provide a route to 
understanding how nuclear FGFR1 may elicit its functional role.  
 
 If nuclear FGFR1 does not interact directly with chromatin, this begs the question 
what is the role of nuclear FGFR1 in the nucleus of stellate cells? CREB 
phosphorylation is critical for CBP, and the closely related p300, to bind to CREB, 
bridging it with RNA polymerase II complex and modifying promoter associated core 
histones340. Studies have shown that nuclear FGFR1 can activate CBP and 
stimulate CREB phosphorylation, which requires a functional receptor 
transmembrane domain306, 307. CREB can be phosphorylated directly and activated 
by a number of kinases, including 90 kDa ribosomal S6 kinase (RSK). RSK acts at 
one terminus of the MAPK signalling cascade and can phosphorylate CREB and 
histone H3341. Activated RSK phosphorylates several transcription factors, including 
cFos, CREB, I Bα, the oestrogen receptor and C/EBP. RSK also mediates H3 
phosphorylation and thus modulates chromatin remodeling342-348. Using confocal 
microscopy, FGFR1 was shown to colocalise with RSK1 in nuclear speckles, and 
FGFR1 can induce RSK1 phosphorylation and increase nuclear RSK1 kinase 
activity302. Furthermore, transfection of TE671 cells with an FGFR1 expression 
construct results in FGFR1 accumulating with FGF2 in the nucleus and undergoing 
phosphorylation302. RSK1 is phosphorylated directly by serine/threonine kinases 
such as ERK but not tyrosine kinases349. Thus, FGFR1 does not directly 
phosphorylate RSK1 but may serve as a scaffold that assembles an ERK mediated 
complex, in which the receptor could activate the RAF/RAS/MEK/ERK cascade and 
deliver the signal to FGFR1 bound RSK1302. This is a plausible scenario as all 
 145 
cascade components have been found to be present in the nuclei of stimulated 
cells350. 
 
Consistent with this model, the authors also observed that transfection of an FGFR1 
construct containing a NLS increased ERK phosphorylation in the nuclei of TE671 
medulloblastoma cells. Using a GAL4-CREB chimeric construct, the authors also 
showed that RSK1 stimulates CREB activity and RSK1 activation of CREB is 
markedly increased by nuclear FGFR1332. Thus, it is possible that FGFR1 interacts 
with RSK1, or possibly other nuclear proteins, and mediates their activation, thus 
impacting on cellular behaviour. This mechanism for indirect activation of gene 
activity has not yet been interrogated in stellate cells, however it may provide a 
plausible alternative mechanism for the role of nuclear FGFR1 in driving stellate cell 
behaviour, given that the full length receptor translocates to the nucleus with FGF2 
and is abolished by FGFR signalling inhibition.  
 
4.5.2 The origin of nuclear FGFR1 
Furthermore, one of the intriguing questions regarding nuclear FGFR is whether it is 
derived from the cell surface and how the full-length receptor may transport to the 
nucleus. There have been several conflicting reports of the origin of nuclear FGFR1. 
It has been proposed that FGFR1 enters the nucleus by retrograde transport from 
the ER lumen to the cytosol via the Sec61p channel (a protein complex that 
mediates co-translational insertion of nascent polypeptides into the ER lumen, as 
well as providing a mechanism for protein transport in the opposite direction, for 
example in the ER-associated degradation (ERAD) pathway351), before the 
endoplasmic vesicles deliver the receptor to the plasma membrane352. This process 
can be viewed as a reversal of integration of membrane proteins into the ER 
membrane. Proteins structurally similar to FGFR1 (MHC class I molecules, mutant 
 146 
insulin receptor, or T cell receptor α chain) have been shown to be retrieved from 
the ER to the cytosol in this manner353-355. The transmembrane domain of the T cell 
receptor α chain is divided into short polar regions, which are responsible for the 
release of the receptor from the ER membrane into the cytosol356. Similar to the T 
cell receptor α chain, FGFR1 consists of non-polar amino acid chains interrupted by 
polar regions, which may be critical for the mobilisation of the receptor352. The 
association of FGFR1 TM with the ER membrane is relatively unstable and the 
nucleus-destined receptor is released into the cytosol before the endoplasmic 
vesicles deliver the receptor to the plasma membrane. Furthermore, amino acid 
analysis of FGFR1-4, and predicted conformations, demonstrated that only the TM 
domain of FGFR4 displayed an uninterrupted  helical structure typical of TM 
domains. In contrast, the FGFR1 TM domain is likely to consist of a  sheet 
structure, which is untypical for membrane spanning region. FGFR2 and FGFR3 
have TM domains that are intermediate between FGFR1 and FGFR4, with both  
helix domains and  sheets352.  helix structures are required by TM domains of 
most transmembrane proteins for membrane association352. Thus, it is possible that 
the  helix structure in the TM domain of FGFR1, along with non polar amino acid 
chains, may be critical for the mobilisation of FGFR1 from the lipid bilayer and 
subsequent trafficking to the nucleus. This may also provide an explanation why 
FGFR4 does not traffic to the nucleus352 .  
 
In this model, following protein translation, the FGFR1 polypeptide elongates and 
translocates into the ER lumen. If an atypical transmembrane domain is reached the 
receptor is released from the ER membrane and FGFR1 is transported into the 
cytoplasm, otherwise the receptor anchors into the lipid bilayer. Cytosolic FGFR1 
may be then degraded by the 26S proteasome, or rapidly transported into the 
nucleus352. This model was supported by an increase of cytosolic FGFR1 upon 
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proteosome inhibition. However, studies that propose this mechanism of nuclear 
entry have not addressed the mechanism for movement of FGFR1 out of the ER 
membrane into the cytosol, or the impact of stimuli that cause nuclear trafficking of 
the receptor.  
 
Contrary to this, others have shown that the receptor may originate from the cell 
surface. This presents a continuing conundrum as to how a membrane receptor can 
escape the lipid bilayer and traffic to the nucleus. However, studies on EGFR 
demonstrate that this receptor following ligand stimulation is internalized, targeted 
for degradation and down regulation of signalling, or other trafficking fates. In some 
instances, ligand/receptor complexes can initiate signalling from within the 
endosome326. Understanding of endocytic trafficking of growth factors is now 
extending to the nucleus357. Bryant and colleagues, using biotinylation experiments, 
showed that at least some of the nuclear FGFR1 derives from the cell surface and 
multiple isoforms of the receptor could be recovered in cell following cell surface 
biotinylation333. Furthermore, the same group has shown that surface FGFR1 is 
internalised and traffics to the nucleus via the endosomal pathway. Interestingly, 
inhibition of clathrin dependent endocytosis was not sufficient to block nuclear 
FGFR1, suggesting another endocytic pathway may be involved333. Other studies 
have suggested a caveolin dependent mechanism for internalisation and nuclear 
translocation358.  
 
As I have observed that FGFR1 and FGF2 can translocate to the nucleus following 
ligand stimulation, it is possible to speculate that these proteins will be internalised 
and jointly translocated to the nucleus. Indeed, studies of EGF family signalling has 
shown that pairing of EGFR and EGF ligands can act as a functional transcriptional 
unit within the nucleus itself234. Once in the cytoplasm, FGFR1 is free to interact with 
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nuclear import machinery and it may enter the nucleus via importin 334 . Importin  
is soluble nuclear import protein that shuttles between the cytoplasm and nucleus 
and can carry cargo into the nucleus either directly or with in conjunction with an 
adaptor protein359.  
 
Recent results from stellate cells suggest that nuclear FGFR1 is mediated by 
importin . Co-imunostaining with FGFR1 and importin  showed that importin  is 
nuclear in stellate cells in which FGFR1 also localises to the nucleus, but remains 
cytoplasmic when FGFR1 is not nuclear (Figure 4. 22). Furthermore, treatment of 
stellate cells with importin  RNAi abolishes nuclear FGFR1 (Figure 4. 23). Although 
these results are preliminary, they suggest that FGFR1 in stellate cells is 
transported into the nucleus via importin . Further work is required to understand 
the origin of nuclear FGFR1 and explain the disparities reported in the literature. 
Despite the origin of nuclear FGFR1, several questions still remain regarding the 
role of FGF2 in aiding nuclear entry of FGFR1. Preliminary data from other groups 
suggest that FGFR1 does not interact directly with importin 334, indicating an 
adaptor molecule is required to mediate the interaction. Most adaptor proteins 
interact with the NLS of proteins destined for the nucleus. Since FGFR1 lacks a 
typical NLS304, it is possible that the receptor is co-transported with another 
molecule containing a NLS. Thus, HMW FGF2, which contains a NLS, may 
chaperone FGFR1 into the nucleus with importin . This idea would compliment 
earlier observations where I observed FGF2 in the nucleus of stellate cells alongside 
FGFR1 in all experiments.  
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Figure 4. 22  Nuclear FGFR1 and importin  localisation in stellate cells 
Immunostaining stellate cells with antibodies to FGFR1 (green) and importin  (red) showed 
that, in cells in which FGFR1 is nuclear, importin  also localises to the nucleus. In cells in 
which FGFR1 is mainly cytoplasmic, importin  is not found within the nucleus .  
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Figure 4. 23 Abolishing importin , leads to a reduction in nuclear FGFR1 
(A) Immunostaining shows that, following treatment of stellate cells with importin  RNAi for 
72 hours, there is a significant decrease in importin  expression (green) as well as a failure 
of FGFR1 (red) to enter the nucleus. (B) Western blotting demonstrates efficient knock-down 
of importin  after 72 hours treatment with importin  RNAi. Densitometry normalised to Beta 
actin. Scale Bar: 20 μm. ***<P, 0.001, **P<0.01, Student’s t-test. Data summary is 
represented by mean ± SEM. For all data, images are representative of three independent 
experiments. 
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CHAPTER V  RESULTS-PART III 
 
A physiologically relevant three-dimensional model of PDAC to study the 
impact of nuclear FGFR1 and FGF2 on pancreatic stellate cell and cancer cell 
behaviour.  
 
5.1 Introduction.  
PDAC is characterised by an intense stroma, which can make up to 90% of the 
tumour volume. Studies have shown that the tumour stroma cross talk in PDAC can 
influence chemotherapy response rate and patient prognosis360, 361. Furthermore, 
pancreatic stellate cells have been the found to be the key cell driving the 
desmoplastic reaction in PDAC105. PSCs and cancer cells can interact in a 
bidirectional relationship, activating each other and fueling cell survival, migration 
and invasion. Therefore, targeting the desmoplastic stromal compartment is of 
particular interest in PDAC as PSCs are tumour specific, in contrast to circulating 
immune cells. 
 
I have shown that FGF2 and FGFR1 localise to the nucleus in stromal fibroblasts at 
the invasive front of human PDAC (Chapter III). Furthermore, results from 2D 
assays show FGFR1 and FGF2 colocalise to the nucleus in PSCs but not in cancer, 
or normal ductal epithelial, cell lines. Abolishing FGFR1 and FGF2 functions in 
stellate cells, using either RNAi or an FGFR inhibitor, results in a significant 
reduction in cell proliferation and is associated with G1 cell-cycle block (Chapter IV). 
Therefore, I hypothesised that targeting nuclear FGFR1 and FGF2 in stellate cells 
may have an anti-tumour effect and offer a novel therapeutic strategy for PDAC.  
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In cancer research, there has been an abundance of evidence suggesting that 3D 
models are superior to the conventional 2D culture in plastic flasks. However, 
current preclinical research still relies heavily on the latter362. From the simplest 
form: the ‘monotypic’ cell model, comprising just one epithelial cell type, 3D co-
cultures have evolved progressively to contain multiple cell types, thus enabling 
study of their respective contributions363. An early example was the ‘skin equivalent,’ 
achieved by culturing keratinocytes either on de-epidermalised dermis or on 
collagen gels embedded with dermal fibroblasts364 365.  
 
The success of pioneering studies with breast epithelial cells cultured in, or on, a 
reconstituted basement membrane undergoing glandular differentiation, developing 
apico-basal polarity and forming a central, hollow lumen366, have led to similar 
experiments for the liver, salivary gland, bone, lung, skin, intestine, kidney and 
thyroid gland364, 367-371. The choice of cell source and ECM is critical in developing a 
representative model. For example, human luminal breast epithelial cells grown in 
laminin-rich basement membrane analogue (Matrigel) form acini372; however when 
grown in collagen I, these same cells show an altered integrin profile and abnormal 
polarity373.  
 
These 3D models have increased our understanding of how cells perceive 
biochemical and physical cues from the surrounding microenvironment374. For 
example, ß1 integrin is expressed in normal breast epithelial cells but is lost when 
cells transform into a malignant phenotype. Re-expression of ß1 integrin in 3D 
models induces the reversion of the tumour phenotype by allowing the malignant 
cells to differentiate into glands375. 
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The incorporation of tissue specific stromal cells is critical for approximation to the in 
vivo condition. Thus, the isolation and availability of human stellate cells has been 
critical to the development of PDAC organotypic cultures376. The expertise in our 
laboratory in developing these models has given me the opportunity to understand 
the role of nuclear translocation of FGFR1 and FGF2 on stellate cell behaviour, and 
how this may impact on stroma-cancer cell cross talk in a more physiologically 
relevant system.  
 
5.1.1 Morphological and proliferative response of tumour cells 
cultured with pancreatic stellate cells on organotypic gels treated 
with PD 173074.  
The introduction of stromal cells in PDAC 3D organotypic cultures was first 
demonstrated by our laboratory165. Depending on the hypothesis being explored, the 
flexible 3D models of PDAC can be set up distinctly.  In order to study the invasion 
of pancreatic cancer cells in the 3D model, I used the ‘air-liquid’ model, in which 
cancer cells and stellate cells are cultured on top of an ECM gel (Methods), raised 
upon a grid and fed from underneath with 2μM PD 173074 or vehicle control 
(DMSO) for 14 days, creating a gradient that stimulates pancreatic cancer cells to 
invade. Previous studies by our laboratory have shown that the composition and 
stiffness of the ECM gel can have a profound effect on pancreatic cancer cell 
behaviour171.  When cancer cells and PSCs are co-cultured in ECM gels composed 
of 75% collagen, 25% Matrigel, cancer cells form multicellular spheroids and 
recapitulate important features of glandular epithelial cells in vivo165. Thus, all 3D 
culture experiments were carried out using this matrix composition. 
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I chose to culture stellate and cancer cells in a 2:1 ratio on top of the gel, as studies 
by our laboratory have demonstrated that this ratio is optimal for cancer invasion377 
and also mimics the in vivo situation of PDAC, in which stellate cells often 
outnumber cancer cells. In order to distinguish between the direct effect of PD 
173074 on cancer cells, or an indirect effect via changes in stellate cells, I also 
plated cancer cells alone on top of the organotypic gels, to compare results with 
those models in which stellate and cancer cells were admixed.  
 
Haematoxylin and eosin (H & E) staining revealed that when cancer cells were 
grown alone in organotypic cultures they formed a thin cell layer on top of the ECM 
gel and failed to invade into the underlying stroma. Furthermore, when cancer cells 
were plated as a monoculture they showed no significant changes in cell 
proliferation or invasion upon FGFR blockade (PD 173074, Figure 5. 1). However, 
when cancer cells were admixed with PS1 cells or primary PSCs, there was a 
significant increase both in cancer cell number and in invasion of cancer and stellate 
cells into the matrix. This invasion was abrogated by FGFR blockade (Figure 5. 1), 
suggesting a pivotal role for PSCs in mediating pancreatic cancer cell invasion. 
Immunostaining for Ki67, a marker of proliferation, revealed that there was no 
significant difference in cellular proliferation when organotypic cultures were treated 
with PD 173074 or DMSO control, neither when they comprised cancer cells 
cultured alone, or when cancer cells were admixed with PS1 cells (Figure 5. 1)  
 155 
 
5.1.2 Invasion of pancreatic cancer cells and stellate cells and the 
morphological effects of PD 173074 treatment.  
When cancer cells and stellate cells were cultured on top of the ECM gel, dual 
staining of the vehicle treated organotypic cultures, with pan cytokeratin (cancer 
cells) and vimentin (pancreatic stellate cells), demonstrated that both cancer cells 
and stellate cells invaded into the ECM gel. Interestingly, stellate cells appeared to 
invade as either single cells or in collective clusters of cells within one organotypic 
gel (Figure 5. 2). However, it appeared that cancer cells invaded most commonly as 
collective cohorts (two or more cancer cells). It also appeared that stellate cell 
invasion preceded cancer cell invasion and generated tracks for cancer cell invasion 
to follow, with PSCs exhibiting a spindle fibroblast like morphology (Figure 5. 2). In 
contrast, in the PD 173074 treated gels, cytokeratin and vimentin staining revealed 
that stellate cells were ‘trapped’ within the cancer cell layer on top of the ECM gel 
and cancer cell invasion was significantly decreased (Figure 5. 2). Interestingly, 
‘trapped’ stellate cells showed a more rounded, ‘quiescent like’ morphology than the 
invading stellate cells in vehicle treated gels.  
 
In order to confirm my observations, and not limit them to one cell line, I also used 
primary pancreatic stellate cells, isolated from cancer-associated tissue, in the 3D 
culture models. However, the relative paucity of primary stellate cells to conduct all 
the experiments in sufficient replicates restricted me to using a mini organotypic 
model (Methods), which has been shown to give comparable results to the 
conventional ‘air liquid’ co-culture model171. Using fewer cells per organotypic gel, 
stellate cells and cancer cells, in a 2:1 ratio, were plated on top of an ECM gel 
constructed in a Transwell insert, fed from below with medium containing either 
vehicle control or PD 173074, for 7 days. Confirming earlier observations, H & E 
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staining revealed that PD 173074 treatment abolished invasion. Again, these 
observed changes were due to the effects of PD 173074 on stellate cells, as 
treatment of cancer cells alone in the 3D cultures did not result in any changes in 
invasion (Figure 5. 3). Dual staining with cytokeratin and vimentin again showed 
stellate cells failed to invade into the ECM when treated with the FGFR inhibitor. 
Interestingly, it appeared that, rather than remaining trapped within the cell layer 
with cancer cells, less invasive primary stellate cells appeared to form a wall at the 
tumour - gel interface (Figure 5. 3). Thus, the prevention of stellate cell invasion 
following PD 173074 treatment inhibited cancer cell invasion, possibly due to the 
decrease in invasion promoting tracts that are formed by stellate cells. 
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Figure 5. 1 FGFR inhibition in stellate cells leads to reduced cancer cell 
invasion.   
(A-B) A 2x2 experimental design, with COLO-357 cells alone or PS1 and COLO-357 cells 
co-cultured in the presence or absence of PD 173074 (2 μM) for 14 days, was used to detect 
consequences of inhibition of FGFR1 signalling (See Methods). H&E images showed that 
(A) COLO-357 cells alone formed a thin monolayer on top of the extra-cellular matrix (ECM), 
and were not affected by FGFR inhibition (PD 173074). (B) In the presence of stellate cells 
(PS1), there was a marked increase in cancer cell (COLO-357) number as well as invasion 
(arrow head) into the ECM. This invasion was abrogated by FGFR inhibition (PD 173074). 
(C-D) There was no significant change in proliferative index (Ki67 staining) in organotypic 
cultures treated with PD 173074 when PS1 and cancer cells were admixed, relative to when 
cancer cells were cultured alone. Scale Bar: 100 μm.*** P< 0.001. Student’s t-test. Data 
summary represented by mean ± SEM or median ± interquartile range. Images are 
representative of at least nine organotypic gels for each condition. 
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Figure 5. 2 PD 173074 treatment of organotypic culture: changes in stellate 
cell morphology and invasion. 
(A-B) Cytokeratin (green) and vimentin (red) staining to delineate tumour and PS1 cells, 
respectively, confirmed a significant decrease in cancer cell invasion into the ECM upon 
FGFR inhibition (PD 173074), compared to vehicle-treated (DMSO) cultures. (C) Graph 
shows the reduction in cancer cell invasion into the ECM when cultures were treated with PD 
173074. Invading cohorts were analysed over twelve fields per organotypic gel. Each data 
point represents an average of invading cohorts across these 12 fields. (D)Arrow shows 
stellate cells at the leading edge of invading cancer cohorts, magnified from A. Arrow head 
shows stellate cells has a more spindle like morphology when invading compared to stellate 
cells that were trapped in the cell layer. Stellate cells appeared trapped within the overlying 
cell layer following PD 173074 treatment and failed to migrate into the underlying ECM, 
magnified in E.. Scale Bar: 100 μm. *** P< 0.001. Student’s t-test. Data summary 
represented by mean ± SEM or median ± interquartile range. Images are representative of at 
least nine organotypic gels for each condition. 
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Figure 5. 3 Invasion of primary stellate and cancer cells in a mini-organotypic 
3D model. 
(A) COLO–357 cells only (or primary PSCs and COLO-357 cells) were cultured in the 
presence or absence of PD 173074 for 7 days. H&E staining of gel sections showed that 
COLO-357 cells alone formed a thin monolayer on top of the ECM and were not affected by 
treatment with PD 173074. When primary PSCs and COLO-357 cells were cultured together 
there was a marked increase in cell number and invasion into the ECM, which was 
abrogated by treatment with PD 173074 (B). Vimentin (red) and cytokeratin (green) staining 
showed that both cancer cells (cytokeratin positive) and primary PSCs (vimentin positive) 
invaded into the ECM) and this was blocked by PD 173074 treatment. Scale bar 100 μm. 
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5.1.3 Blocking stellate cell nuclear FGFR1 and FGF2 abolishes cancer 
cell invasion in an organotypic model of PDAC. 
FGFR1 and FGF2 localise to the nucleus in fibroblasts at the invasive front of 
PDAC, but not at the centre of the tumour. Furthermore, 2D cell culture based 
assays have shown that treating stellate cells with 2µM PD 173074 leads to a 
significant reduction in nuclear FGFR1 and FGF2. Thus, I wanted to interrogate the 
organotypic culture model for localisation of FGFR1 and FGF2 in specific cellular 
compartments (within both cancer and stromal cells), upon PD 173074 treatment. 
Immunostaining with FGFR1 and vimentin, to mark stellate cells, showed FGFR1 
was localised mainly to the nucleus in invading stellate cells. In contrast, in those 
stellate cells remaining juxtaposed to cancer cells, it was mainly in the plasma 
membrane and cytoplasm (Figure 5. 4) 
 
Upon PD173074 treatment. FGFR1 localised to the nucleus in the stellate cells 
invading into the matrix, whereas those stellate cells remaining juxtaposed to cancer 
cells showed less frequent nuclear FGFR1 (Figure 5. 4.). Similar results were also 
demonstrated in organotypic cultures constructed with cancer-associated primary 
stellate cells obtained from patients (Figure 5. 5). I also confirmed that PS1 cells that 
were able to invade into the matrix showed significantly more nuclear FGFR1 than 
trapped cells, using digital quantification to give a more unbiased approach (Figure 
5. 5).  
 
A huge advantage of the organotypic system is that any component of the model 
can be readily modulated in a short time frame. Therapeutic agents such as 
chemotherapy, small molecules or RNAi can be tested in these organotypic cultures. 
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PD 173074 is an highly selective FGFR1 inhibitor at nM concentrations, however 
studies have shown that this molecule can also inhibit phosphorylation and 
activation of FGFR2, FGFR3 and FGFR4 as well as VEGFR2202, 378. Thus, to 
confirm specific abolition of FGFR1 could prevent invasion of stellate cells and 
indirectly affect cancer cell invasion, I admixed PS1 cells, that had been treated with 
FGFR1 RNAi for 24 hours, and COLO-357 in a 2:1 ratio and cultured them on top of 
a mini-organotypic gel for 7 days. Compared to cultures generated using stellate 
cells treated with scrambled control RNAi, knock-down of FGFR1 in stellate cells 
resulted in a significant reduction in cell invasion (Figure 5. 6). Western blotting over 
7 days confirmed that FGFR protein levels were abolished in stellate cells for the 
duration of the experiment. These results confirm previous observations in 
organotypic cultures, as well as observations in PDAC tissue, that nuclear FGFR1 
and FGF2 can promote stellate cell invasion, and show for the first time that this 
invasion promoting effect can be inhibited by targeting stellate cells with PD 173074. 
 
In addition, immunostaining for FGF2 and SMA (to mark stellate cells) revealed 
there was a significant increase in the percentage of invading stellate cells with 
nuclear FGF2, compared to non-invading stellate cells. When treated with PD 
173074, PS1 cells were unable to invade into the extra-cellular matrix and FGF2 
remained cytoplasmic (Figure 5. 7and Figure 5. 8). 
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Figure 5. 4 Differential FGFR1 localisation in stellate cells upon FGFR 
inhibition in 3D cultures. 
The percentage of stellate cells (identified by vimentin stain: red) demonstrating nuclear 
FGFR1 (green) was significantly less in the stellate cells that failed to invade into the extra-
cellular matrix) as compared to those invading (arrow in A) in vehicle-treated organotypic 
cultures. Upon FGFR inhibition (PD 173074), stellate cells failed to localise FGFR1 to the 
nucleus and did not invade into the matrix (arrow in B, quantified in C). A total of four fields 
were counted per organotypic gel. Each data point represents an average of the percentage 
of stellate cells with nuclear FGFR1 over these four fields (total ~540 cells counted in total). 
Scale Bar: 100 μm. ** P< 0.01, *P<0.05, n.s: not significant. Student’s t-test.  Data summary 
represented by mean ± SEM or median ± interquartile range. Images are representative of at 
least nine organotypic gels for each condition.  
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Figure 5. 5 Digital quantification of FGFR1 localisation in stellate cells upon 
FGFR inhibition in 3D cultures. 
Nuclear FGFR was also analysed in vimentin positive invading and ‘trapped’ stellate cells 
following PD 173074 treatment (A) using Image J digital quantification (B, see methods). 
Those cells that were able to invade (vehicle treated) showed significantly more nuclear 
FGFR1 than those cells that remained trapped in the cell layer following PD 173074 
treatment. Each data point represents the average nuclear FGFR1 per field. Several fields 
were counted from three separate gels (a total of ~120 stellate cells per condition were 
analysed). (C) FGFR1 (green) appears nuclear in invading stellate cells (vimentin positive) 
when treated with vehicle control compared to stellate cells that failed to invade following 
treatment with PD 173074. These images are zoomed in to demonstrate the invading stellate 
cells in the ECM for the DMSO control and stellate cells next to cancer cells in the PD 
173074 treated mini-organotypics. Scale Bar: 100 μm. ** P< 0.01. Student’s t-test.  Data 
summary represented by mean ± SEM or median ± interquartile range. Images are 
representative of at least nine organotypic gels for each condition.  
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Figure 5. 6 Abolishing FGFR1 in stellate cells prevents cell invasion. 
(A) Western blotting confirms that FGFR1 was abolished for 7 days following FGFR1 RNAi 
treatment compared to scrambled RNAi treated stellate cells. (B) Stellate cells were treated 
with FGFR1 or scrambled RNAi for 24 hours before harvesting and subsequent culture in a 
mini-organotypic model admixed with COLO-357 cells in a 2:1 ratio. Gels were cultured for 7 
days. H & E images show a significant reduction in total cell invasion when PS1 cells were 
depleted for FGFR1 compared to scrambled RNAi treated PS1 cells. Number of invading 
cells is quantified in C., ** P< 0.01,. Student’s t-test.  Data summary represented by mean ± 
SEM or median ± interquartile range. Images are representative of at least nine organotypic 
gels for each condition.  
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Figure 5. 7 Differential FGF2 localisation in stellate cells upon FGFR inhibition 
in 3D cultures. 
In vehicle-treated organotypic cultures, FGF2 (red) was nuclear in a significant percentage of 
stellate cells (identified by αSMA stain: green, arrow in A) that invaded into the extra-cellular 
matrix, compared to those that remained within the admixed cell layer on top of the gel 
(arrow head in A). Upon FGFR inhibition (PD 173074, 2 M, 14 days), stellate cells failed to 
invade into the ECM. FGF2 was mainly cytoplasmic in these non-invading stellate cells 
(arrow in B). Scale Bar: 100 μm. 
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Figure 5. 8 Quantification of FGF2 localisation in stellate cells upon FGFR 
inhibition in 3D cultures. 
Upon FGFR inhibition (PD 173074, 2 M, 14 days), stellate cells failed to invade into the 
ECM. FGF2 was mainly cytoplasmic in these non-invading stellate cells (arrow in B). A total 
of four fields were counted per organotypic gel and each data point represents an average of 
percentage of stellate cells with nuclear FGF2 over these four fields (total ~60 cells counted 
per data point). ***P<0.001. Student’s t-test.  Data summary represented by mean ± SEM. 
Images are representative of at least nine organotypic gels for each condition.  
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5.1.4 Cancer cells secrete factors that regulate FGF signalling in 
stellate cells 
In a diseased state, under the influence of growth factors, cytokines and oxidative 
stress, PSCs transform into a myofibroblast like phenotype, secreting excess 
amounts of ECM, as well as matrix degrading enzymes. Growth factors such as 
TGF- 1, PDGF and VEGF, which are secreted by pancreatic cancer cells, are 
known to induce PSC activation121, 122. These observations support the concept that 
pancreatic cancer cells recruit stromal cells to produce a growth permissive 
environment that facilitates cancer progression155. To determine whether an 
interaction exists between pancreatic cancer cells and stellate cells, which may 
influence the FGF pathway, I examined the influence of conditioned medium from 
the pancreatic cancer cell line COLO-357 on the nuclear translocation of FGFR1 
and FGF2 in stellate cells. Incubation of stellate cells with conditioned medium from 
COLO-357 cancer cells, but not normal pancreatic ductal epithelial cells (Dec-h 
TERT), led to a significant increase in nuclear translocation of FGFR1 and FGF2 
(Figure 5. 9). Thus, nuclear translocation of FGF2 and FGFR1 in stellate cells is 
regulated by factors secreted by cancer cells.  
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 Figure 5. 9 Nuclear FGFR1 and FGF2 translocation in stellate cells following treatment with cancer cell conditioned medium 
(A) Shows an increase in nuclear FGFR1 (green) and FGF2 (red) following culture of PS1 cells with conditioned media (serum-free) from COLO-357 
cancer cells and complete media (10% FBS) compared to conditioned media from Dec-hTERT normal epithelial cells or PS1 cells cultured in serum-
free media (control). Quantified in B and C (normalised to PS1 cells cultured in serum-free media). Scale bar 20 μm. ***P<0.001, ** P< 0.01. 
Kruskal-Wallis test with Dunn’s post-test comparison. Data summary represented by median ± interquartile range. Images are representative of at 
least three independent experiments. 
 169 
5.2 Discussion. 
5.2.1 Three dimensional modelling reveals changes evoked in 
pancreatic cancer cells by stellate cells treated with PD 173074  
 
Using a 3D co-culture model of PDAC demonstrated the importance of the presence 
of stellate cells on pancreatic cancer cell invasion. In the absence of stellate cells, 
pancreatic cancer cells formed a thin layer on top of the ECM gel and failed to 
invade into the matrix. Thus, pancreatic stellate cells are required for cancer cells to 
invade. Indeed it appeared, upon immunostaining of gels with markers to distinguish 
cancer cells from stellate cells, stellate cells often preceded cancer cell invasion, 
suggesting that stellate cells form tracts in which cancer cells can follow. Indeed, 
this observation has also been observed by others in our laboratory, where it 
appears the extent of invasion is dependent on the ratio of stellate cell to cancer 
cells171. 
 
Furthermore, it appears that cancer cells require direct cell-cell contact with 
fibroblasts, as previous studies have shown that, when stellate cells are embedded 
into the matrigel, cancer cells fail to invade165. Indeed, co-culture of squamous cell 
carcinoma cells and cancer associated fibroblasts has demonstrated that, via Rho-
mediated regulation of myosin light chain (MLC) activity and force-mediated matrix 
remodeling by fibroblasts, tumour cells cells move collectively within tracks laid 
down by the fibroblasts379. These results also highlight the importance of 
establishing a relevant 3D environment when generating organotypic models in 
order to establish a physiomimetic system. Our laboratory, as well as other groups 
generating 3D models that recapitulate various in vivo systems, have demonstrated 
this. Recently, Tian and colleagues have shown that FGF2 secreted by PSCs can 
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induce expression of the c isoform of FGFR1 in cancer cells when cultured in 
stellate cell conditioned media186. This is of particular interest, as I have 
demonstrated that PS1 cells readily secrete FGF2 in vitro, and could represent one 
way in which stellate cells induce an invasive phenotype in pancreatic cancer cells 
in the organotypic model. Indeed, studies have shown that FGFR1 IIIc expression in 
spontaneously immortalised pancreatic ductal cells results in malignant 
transformation188. Furthermore, FGF2 secreted by stellate cells is able to induce a 
down regulation of the FGFR1 IIIb isoform in cancer cells, which is associated with 
potent inhibition of the malignant phenotype380. This gives rise to an important 
paracrine signalling loop involving FGF2 derived from stellate cells that is able to 
induce the expression of FGFR1 IIIc in cancer cells. Furthermore, neutralising the 
effects of FGFs by heparin sepharose precipitation completely abolished these 
effects186. This mechanism may contribute to the invasive phenotype of 
humanPDAC, which is based on tumour stroma interactions involving stellate cells. 
Furthermore, N-cadherin and FGF2 have been shown to act synergistically in breast 
cancer cells, to increase cell invasion and migration and to enhance the expression 
of matrix metalloproteinase 9381. N cadherin prevents ligand mediated down 
regulation of FGFR1, leading to increased receptor signalling, sustained ERK 
activation382 and could possibly provide a mechanism whereby FGF2 paracrine 
signalling from stellate cells may establish, and participate in, a more invasive 
pancreatic cancer cell phenotype.  
 
Blocking FGFR signalling in our organotypic model resulted in striking effects on 
cancer cell and PSC invasion. Following treatment with PD 173074, there was a 
significant block of invasion of cancer cells into the ECM, and it was apparent that 
PSCs were ‘trapped’ within the overlying cell layer and exhibited a more rounded 
shape, distinct from the spindle myofibroblast like morphology shown by invading 
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stellate cells. This phenotype is indicative of a more quiescent stellate cell. Indeed, 
treating activated stellate cells with ATRA renders stellate cells quiescent170, which 
has significant anti tumour effects on cancer cells, and cells change from a spindle 
shape to a more rounded form. It is yet to be determined if the stellate cells treated 
with PD 173074 are indeed rendered quiescent. However, results from cell cycle 
experiments suggest that stellate cells, following treatment with PD 173074, are not 
apoptotic, but are arrested in the G1 phase of the cell cycle. Studies by our group 
have shown that, for PDAC, the maximal effect on increasing cancer cell invasion as 
well as decreasing cancer cell apoptosis, occurs when stellate cells constitute the 
majority of the cellular population (maximal stellate cell proportion at 0.66-0.83) and 
accompanies changes in expression of key molecules such as E-cadherin and  
catenin171. 
 
An additional way by which signalling molecules can elicit distinct responses in 
different cell types is through activation or repression of other signalling pathways. 
This cross talk between signalling pathways results from specific interactions 
between signal transducing molecules, and the convergence or divergence of the 
programs of gene expression activated by each pathway. Combinations of signals 
may alter the effect of an individual pathway or one pathway may confer 
competence to a second signal. Recent results from our group suggest that 
pancreatic cancer cells show active Wnt signalling170. Like FGF pathways, Wnt 
signalling is important in the embryological development of the pancreas and is 
reactivated or deregulated in PDAC383. Importantly, FGFs have been shown to 
interact with Wnts in a variety of developmental systems and in some cases the 
simultaneous activation of Wnt and FGF pathways leads to effects that are distinct 
from the individual effects of each factor384. A key event in the canonical Wnt 
pathway is the activation of  catenin, which subsequently regulates transcription of 
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specific target genes that modulate cell proliferation and apoptosis385.  catenin also 
functions at the cell membrane where, as a component of the adherens junction, it 
links cadherins to the cytoskeleton386. In certain contexts, studies have shown that  
catenin can modulate the effects FGF signalling. For example, FGF2 treatment 
promotes translocation of  catenin to the nucleus and maintains the proliferation of 
multipotent neural stem cells387. Thus, FGF2 secreted by stellate cells in this 
coculture model may modulate the effect of Wnt signalling in cancer cells and fuel 
an increase in tumour cell growth. It would be of interest to assess the cross talk 
with Wnts and other known signalling pathways that interact with FGF signalling, 
such as TGF, IGF and Notch, that are known to be deregulated in pancreatic cancer 
cells50. It is possible that targeting stellate cells by blocking nuclear FGFR1 and 
FGF2, which I have shown has a significant effect on stellate cell proliferation, may 
be sufficient to modulate the tumour microenvironment in such a way that is no 
longer permissive for cancer cell invasion. Interestingly, I did not see a significant 
effect on overall cell proliferation when organotypics were treated with PD 173074, 
however this is likely due to the dilution of the number in stellate cells in the 
organotypic cultures and the proliferation is representative of the cancer cell 
population, which is not effected by PD 173074 treatment.  
 
Over the last decade, several therapeutics have been developed for the treatment of 
PDAC. While many show promise in simple 2D preclinical assays or xenograft 
mouse models, many fail when they are tested clinically including Gemcitabine, the 
current approved treatment for PDAC patients28. This may be due to the oversight of 
the tumour microenvironment as a major factor impacting on cancer cell drug 
resistance, and many therapies have not been tested in a relevant system. Indeed, 
when I treated pancreatic cancer cells alone with PD 173074 in organotypic models 
or in 2D cell based assays, this had no effect on cells, confirming the importance of 
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the role of the tumour microenvironment and stellate cells on cancer cell behaviour. 
Importantly, the generation of genetically engineered mouse models (GEM) for 
PDAC that faithfully recapitulate the human disease, including resistance to 
Gemcitabine, has enabled new approaches to understand the importance of the 
tumour microenvironment in disease pathogenesis and therapeutic response. 
However, given the long latency and cost of the GEMMs, 3D organotypic models 
that mimic the morphological and functional features of their in vivo parental tissues 
are an attractive option for bridging the gap between cell-based discovery research 
and complex animal models388, 389. 
 
5.2.2 Nuclear FGFR and FGF2 mediate invasion of pancreatic stellate 
cells.  
In vehicle-treated organotypic cultures, there was a significant increase in the 
number of PSCs with nuclear FGFR1 and FGF2 that were able to invade into the 
ECM. Following FGFR blockade, PSCs remaining in the cancer cell layer displayed 
mainly cytoplasmic staining for both FGFR1 and FGF2. These results suggest that 
nuclear FGFR1 and FGF2 may have a profound effect on PSC invasion, which in 
turn mediates cancer cell invasion.  
 
Similar observations in isolated cancer associated primary stellate cells strengthens 
the idea that nuclear FGFR1 and FGF2 are important for stellate cell invasion and 
cancer cell behaviour, by not limiting studies to one stellate cell line. When I isolated 
and cultured primary stellate cells (after ethical permission was obtained), after a 
few passages the cells became quiescent, preventing their use in the original air-
liquid interface model. However, the mini-organotypic model gave me robust 
comparable results to the original model. As more pancreatic tissue is becoming 
available, the expertise in isolating and culturing primary stellate cells, as well as 
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other stromal cell types (endothelial cells) to be used in co-culture with cancer cells 
in the laboratory, is increasing.  
 
Despite the specificity of PD 173074 for FGFR1 inhibition, it can inhibit activity of 
other FGFRs as well as VEGFR2 activity202 . Given that VEGF is often secreted by 
cancer cells and can promote stellate cell activation155, it was necessary to 
demonstrate the FGFR1 specific effects on stellate cell behaviour. Thus, the 
flexibility of the organotypic system allowed me to use PSCs that had been treated 
with FGFR1 RNAi to further confirm and demonstrate the specificity of FGFR1 on 
regulating stellate cell invasion and modulation of cancer cell behaviour.  
 
Once in the nucleus, the role of FGFs in signalling and transcription has been 
extensively documented. In fact in some instances, the nuclear targeting of FGFs is 
required to elicit their full mitogenic response, which can be inhibited by mutation of 
the ligands NLS223, 390. The nuclear roles of FGFs include regulating cell proliferation 
and DNA transcription and FGFs have been detected in rapidly proliferation tissues 
such as sights of injury and in cells of metastatic origin224. However, the functional 
role of nuclear FGFR1 is only beginning to emerge, despite the extensive literature 
on other RTKs, such as EGFR, being directed and convincingly located to the 
nucleus230, 234, 391. However, the oncogenic significance of nuclear FGFR1 and FGF2 
in an in vivo setting has not yet been established. Given the role of FGFR1 and 
other RTKS in driving proliferation, and by implication cell cycle progression, and the 
correlation with poor patent outcome, it not surprising that that the nuclear 
accumulation of this receptor and ligand could be oncogenic.  
 175 
 
5.2.3 Signals from cancer cells can influence nuclear FGFR1 and FGF2 
Culturing stellate cells in cancer cell conditioned media led to a significant increase 
in nuclear FGFR1 and FGF2. This is not surprising, as nuclear accumulation of 
endogenous FGFR1 is induced by changes in growth factors (such as FGF2, BMP7, 
EGF and angiotensin II304). PDAC cancer cells secrete a number of growth factors 
and cytokines that can activate PSCs, such as TGF 1 and PDGF58. How these 
factors may increase nuclear FGFR1 and FGF2 is yet to be examined. However, 
studies have shown TGF  can upregulate FGF2 expression via a TGFRII/Smad-3 
dependent pathway392. It is likely that other factors, not yet identified, are secreted 
by cancer cells and may induce nuclear activation. Nuclear FGFR1 can also be 
induced by changes in cell-cell contact and depolarisation331, thus it may be possible 
that in a 3D co-culture environment, cancer-stromal interaction could also induce 
nuclear FGFR1 and FGF2 in PSCs. Further studies are required to investigate 
changes in PSC gene expression in appropriate physiologically relevant 3D culture 
conditions, in the presence of cancer cells, to define the exact role of paracrine and 
autocrine signalling.   
 
Examination of PDAC sections revealed that a significant percentage of 
myofibroblasts at the invading tumour front had nuclear FGFR1 and FGF2, 
compared to myofibroblasts in the central core of the tumour. These results, coming 
from our 3D PDAC model, further emphasise the possible role of nuclear FGFR1 
and FGF2 in driving PDAC tumour invasion. In PDAC, it appears the nuclear 
localisation of FGFR1 and FGF2 is critical in mediating the invasion of PSCs and, 
consequently, cancer cells. Although these results warrant further investigation, 
these data may provide a rationale for further targeting of this novel stromal pathway 
in clinical trials, in conjunction with conventional chemotherapy. 
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5.3 Conclusion  
Taken together, I can conclude that the striking anti-invasive effect, seen when 
organotypic cultures were treated with PD 173074, is a consequence of a change in 
the cellular microenvironment provided by PSCs. In vivo, the stroma is appreciated 
as a major driver in promoting the aggressiveness of PDAC and makes up 80% of 
the tumour volume170. The presence of PSCs in orthotopic models of PDAC 
increases distant spread of the tumour217, with PSCs co-migrating with cancer cells 
to distant sites, likely aiding in the translocation of the tumour to the new 
microenvironment. It is possible that preventing nuclear FGF/FGFR mediated 
proliferation in PSCs leads to disruption of the tumour microenvironment, preventing 
pancreatic cancer cell invasion, thus identifying a novel therapeutic approach, 
targeting within the stroma of PDAC. A proposed model of possible mechanisms of 
nuclear FGFR1 and FGF2 in stellate cells is shown, based on the results found 
during my studies (Figure 5. 10). Furthermore, blocking nuclear FGFR1 and FGF2 in 
stellate cells, and the indirect effect this has on cancer cell behaviour, may have a 
wider impact than just in PDAC alone. The stellate system has been found in other 
organs such as the liver, kidney, intestine, spleen and lung119. Given that gene 
expression and functional studies have recently shown that hepatic stellate cells and 
PSCs share many homologies (expression of genes related to ECM proteins, 
contractility, retinoid metabolism and expression of growth factors)126, it is possible 
that stellate cells from other organs may be targeted in a similar manner and this 
strategy may be extended to other disease types.  
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Figure 5. 10 Proposed possible models for the relationship between nuclear 
FGFR1 and FGF2 in stellate cells 
Based on the results I have obtained from my studies I can hypothesise that there are three 
possible mechanisms for the relationship between nuclear FGFR1 and FGF2 in stellate cells. 
1. FGF2, secreted by stellate cells, may bind and activate membrane bound FGFR1, 
resulting in receptor activation and internalisation. FGFR1 could then be translocated to the 
nucleus (possibly via endocytic pathway) where the receptor carries out its function 
regulating stellate cell proliferation by modulating FGF2 gene expression. Newly synthesised 
FGF2 could be released and carry out its function in an autocrine loop, driving stellate cell 
proliferation. 2. HMW FGF2, which contains a NLS, may be required to chaperone FGFR1 to 
the nucleus, possibly in a complex with the nuclear import receptor, importin . 3. FGF2 may 
associate with FGFR1 in the nucleus, possibly regulating receptor mobilisation and nuclear 
entry, in order for FGFR1 to carry out its function in regulating gene expression. In all three 
scenarios a relationship between nuclear FGFR1 and FGF2 exists, specifically driving 
proliferation in stellate cells.  
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5.4 Future challenges 
3D cell culture models are valuable tools for studying the mechanisms ofPDAC, 
providing an easily manipulated system in which specific questions can be 
addressed, thus facilitating the translation of basic science to clinic. Although no 
single in vitro model could entirely replicate the ecosystem ofPDAC, or provide a 
complete understanding of the fundamental mechanisms governing pathogenesis, 
organotypic models have advanced our understanding of the molecular and cellular 
mechanisms of PDAC. By providing an environment in which cell behaviour and 
novel treatment options can be investigated in an easily reproducible and controlled 
manner, these models more precisely mimic PDAC, thus providing a major 
contribution to preclinical drug and therapeutic discovery. A huge advantage of the 
organotypic system is that any component of the model can be readily modulated in 
a short time frame. For example, the matrix composition can be altered to reflect the 
in vivo situation. The increase in ECM stiffness exerts elevated force on transformed 
cells increasing cellular response and resulting in increased tumour growth, survival 
and motility171, 393. Additional cell types, such as or endothelial cells, can be titrated 
in. This is being tested in our laboratory by Dr Francesco DiMaggio and shows 
promising results. In oesophageal cancer, to assess the role of stroma on 
angiogenesis, endothelial cells on a 2D monolayer have been cultured with 
fibroblast and cancer cells embedded in a collagen gel layered on top394. Another 
example includes investigation of the role of macrophages in malignant growth of 
human squamous cell carcinoma 395. Immune response and inflammation play an 
important role in the desmoplastic reaction and inflammation is thought to activate 
pancreatic stellate cells 139, 396. Thus this model would be particularly pertinent to 
PDAC.  
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In addition pancreatic tumours are characteristically hypoxic. This hypoxia is 
exasperated because of hypovasularity with profuse stroma which provides an 
environment in which PCCs thrive. 397. Hypoxia is a driving force in PDAC 
progression, contributing to resistance to chemo- and radiotherapy as well as 
increasing tumour metastasis and contributing to poor patient survival398, 399. It has 
been shown that under hypoxic conditions (1% oxygen)400, PSCs may influence 
PCC invasion more strongly than those in normoxia, thus it may be more reflective 
of the in vivo situation to culture organotypics in a hypoxic environment and treat 
with PD 173074 to assess the effect on cancer cell invasion.  
 
Finally, many PDAC patients present very late with their disease when metastases 
have already occurred. Thus, treating PDAC cells in a 3D environment when they 
are first assembled does not reflect the true clinical setting as tumours are already 
established at the time of patient treatment. Currently Miss Elisabeta Carapuca is 
investigating the effect of treatment of organotypic models once they are established 
and invasion of PDAC and/or stromal cells has begun. It is likely this would give a 
better understanding of the treatment regimen that is required when new novel 
therapies emerge into a preclinical setting. It would be particularly important to 
assess the effect of blocking nuclear FGFR1 and FGF2 in stellate cells once the 
organotypics are established and assess the effect on cancer cell invasion. In 
addition it would be interesting to assess any potential benefit of blocking nuclear 
FGFR1 and FGF2 in PSCs using PD 173074, in combination with standard cytotoxic 
agents and assess the effects of cancer stroma cross talk using the organotypic 
model. Preclinical studies have shown that histone deacetylase (HDAC) inhibitors 
may down regulate FGF2 expression401, thus it would be of interest to assess if 
treating 3D organotypics with PD 173074 and an HDAC inhibitor would have 
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synergistic effects in modulating the tumour microenvironment and offer a new 
treatment modality in PDAC.  
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CHAPTER VI CONCLUDING REMARKS 
 
FGF signalling has been heavily implicated in the molecular pathology of pancreatic 
cancer. PSCs have been identified as the key cells responsible for the stromal 
reaction in PDAC and chronic pancreatitis and have been identified as a major 
contributor to aberrant FGF signalling in PDAC121, 402. Thus targeting FGF signalling 
in PDAC offers an attractive target. The availability of the hTERT immortalised 
pancreatic stellate cell, PS1 has enabled me to investigate the effects nuclear 
FGFR1 and FGF2 in an organotypic model that recapitulates the PDAC situation in 
a physiologically relevant manner. Other groups have used immortalised PSCs, 
however these lines did not express key stellate cell markers including desmin and 
GFAP174, 403. Moreover, the use of SV 40 to immortalise these cells can induce 
genetic changes and could possibly generate a cell line that does not correctly 
represent characteristics of ‘normal’ stellate cells (non tumour associated)404. The 
PSC line in our laboratory (PS1) is sourced from human pancreas and immortalised 
using hTERT and, after more than 5 years of continuous culturing, these cells still 
express stellate cell markers including desmin, GFAP, vimentin and SMA170.  
 
The strength of my experiments lies with use of a range of pancreatic cancer cell 
lines, ranging from well to poorly differentiated, as well as primary stellate cells 
(cancer associated) isolated from different patients, as well as PS1 (taken from 
normal pancreas), to thoroughly scrutinise the role of nuclear FGFR1 and FGF2. I 
have shown that these cancer associated stellate cells demonstrate the true 
characteristics of PSCs. Studies by Apte and colleagues have shown that stellate 
cells isolated from normal pancreas and PDAC tissue can stimulate tumour growth 
similarly in vivo, suggesting that ‘normal’pancreatic stellate cells are rapidly 
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activated when exposed to cancer cells175. When I isolated primary pancreatic 
sellate cells, I was only able to passage the cells for a limited number of times 
before the cells became senescent. It would have been ideal to use primary stellate 
cells isolated from different patients in all of my models to investigate the effect of 
nuclear FGFR1 and FGF2 on cell behaviour, however the expertise in our laboratory 
at culturing these cells is increasing and it may be possible to generate sufficient 
quantities of primary PSCs in the future. Nevertheless, given the similar results of 
nuclear FGFR1 and FGF2 obtained from using the primary isolated stellate cells and 
PS1 cell line, both 2D cell culture assays and in the modified 3D mini organotypic 
co-culture model, the relevance of the results using the PS1 cell line can be 
confidently interpreted. Furthermore, the effects of nuclear FGFR1 and FGF2 
observed in vitro on the behaviour of stellate cells could be recapitulated in human 
PDAC tissue. Examination of PDAC sections revealed that a significant percentage 
of myofibroblasts at the invading tumour front had nuclear FGFR1 and FGF2, 
compared to myofibroblasts in the central core of the tumour. This further 
emphasises the possible role of nuclear FGFR1 and FGF2 in driving PDAC tumour 
invasion.   
 
Developing new therapeutics has been a challenge for PDAC131. PDAC still carries 
one of the bleakest prognoses in all of medicine and there is an urgent need for 
therapies. One of the possible reasons that targeted therapies fail to improve the 
prognosis of patients with PDAC may, in part, be explained by the diverse influences 
exerted by the tumour microenvironment. Delineating the signalling networks within 
the tumour microenvironment, may help to explain the huge discrepancy between 
relative success and effectiveness of therapies in preclinical assay (predominately 
2D cell based assays and xenograft mouse models) and their abject failure in 
human PDAC, in which the stroma is not well represented. Furthermore, PDACs 
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harbour a plethora of heterogeneous genetic abnormalities. Performing a 
comprehensive genetic analysis of 24 cancers, Jones and colleagues showed that 
PDACscontain on average 63 genetic alterations, the majority of which are point 
mutations. These alterations defined a core set of 12 cellular signalling pathways 
and processes that were genetically altered in 67-100% of the tumours. However, 
the pathway components that are altered in the in any individual tumour differ 
greatly and would thus entail combinations of agents such as chemotherapy and 
targeted therapy that broadly target downstream mediators or key pathways73. Until 
a more tailored approach is feasible to treat PDAC on an individual basis, targeting 
the stroma is an attractive approach. I have shown that using an FGFR inhibitor can 
specifically target nuclear FGFR1 and FGF2 in stellate cells and ultimately modulate 
the tumour environment into one that is not permissive for cancer cell invasion. The 
advantage of this system is a possible prevention of the escape or adaptation of 
cancer cells, which may lead to tumour resistance.  
 
Although the organotypic model provides a physiologically relevant means to study 
the tumour stroma interactions and the use of new therapies to target this cross talk, 
it still remains a simplified representation of the complex in vivo situation. However, 
the use of the organotypic model as a preclinical tool is becoming increasingly 
important and our laboratory, as well as others, are modulating the 3D cultures to 
recapture other important aspects of the tumour microenvironment that can 
influence cancer cell behaviour including vascularity and inflammation. Thus, 3D 
organotypic models have potential for bridging the gap between cell-based 
discovery research and complex animal models[388, 389] The next step will be to test 
the therapeutic potential of blocking nuclear FGFR1 and FGF2 in stellate cells by 
treating a mouse model with an FGFR inhibitor, or an FGFR inhibitor combined with 
the current standard of care, Gemcitabine. One appropriate model is the KPC 
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mouse which express mutant KRAS and TP53 alleles in pancreatic cells and 
develop tumours that strongly recapitulate human PDAC, including a strong 
desmoplastic reaction114. This is likely to give a reliable prediction of the effect of 
FGFR inhibitors as a new therapy for patients withPDAC.  
 
Several pharmaceutical companies have developed FGFR tyrosine kinase inhibitors 
that are in early phases of clinical trials265, 405, however preclinical development of 
potent FGFR TK inhibitors has been complicated by some side effects. For 
example, FGF23 is involved in phosphate homeostasis and, in preclinical models, 
highly potent FGFR tyrosine kinase inhibitors have caused hyperphosphatemia- 
mediated tissue calcification by blocking FGF23 signalling14. It is not known if this 
will be a problem in human trials. Thus, it is even more critical that the targets with 
which nuclear FGFR1 and FGF2 may specifically regulate stellate cell behaviour are 
identified in order to develop new targeting strategies and reduce toxicity. 
 
Finally I propose that preventing nuclear FGF/FGFR mediated proliferation in PSCs 
leads to disruption of the tumour microenvironment, preventing pancreatic cancer 
cell invasion, thus identifying a novel therapeutic approach targeting within the 
stroma of PDAC and may lead to a better outlook for patients with this deadly 
disease.  
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Two ChIP reactions were carried out using 30 µg of PS1 cell chromatin and anti-FGFR1 
antibodies from either Abcam (ab10646) or Cell Signaling (9740). The ChIP DNA was 
processed into a standard Illumina ChIP-Seq library and MiSeq sequenced to generate >2 
million reads. Approximately 5 million reads per sample were aligned to the human genome 
(hg19 assembly) and, after removal of duplicate reads, 2.4 and 1.4 million alignments were 
obtained for the Abcam and Cell Signaling immunoprecipitated samples, respectively. A 
signal map showing fragment densities along the genome was generated and visualised in 
the Integrated Genome Browser (IGB). In addition, MACS peak finding was performed to 
identify the most significant peaks. Using default settings (without control file), 189 and 127 
peaks were identified.  
 
These peak numbers are essentially at the background level, as 100-250 peaks are typically 
also obtained with Input DNA. Images show the four IGB screenshots of different 
chromosomes (A) Chr 14, (B) Chr 7, (C) Chr 8, (D) Chr 1. Each one shows the FGFR1 data 
in the top 2 tracks. The 3rd to 6th data tracks of the screenshots (turquoise color) show 2 
negative and 2 positive controls for comparison. These controls were also generated with 
2.0-2.5 million tags. Two controls each are shown to illustrate the variation in background 
noise seen in the negative control (tracks 3 and 4), and the range of peak signals seen in 
successful antibody test validation assays (tracks 5and 6). The 2 tracks at the very bottom 
with the green boxes show the RefSeq genes in the plus and minus strand. The results show 
that the FGFR1 ChIP-Seq data look almost identical to the Input control (negative control), 
thus there are no significant peaks. In conclusion, the antibodies did not identify significant 
binding between FGFR1 and any specific regions of the genome in ChIP Seq. This may be 
due to lack of antibody specificity for ChIP, or may reflect an absence of FGFR1 binding. 
These possibilities are now the subject of further investigation in the lab 
